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RESUMO 
      O Capítulo 1 apresenta os principais desafios clínicos em idosos com diabetes tipo 2 e enfatiza a 
lacuna de conhecimento a respeito de duas das síndromes geriátricas mais importantes, a polifarmácia e 
o tratamento excessivo em ensaios clínicos randomizados e diretrizes de prática clínica. Para preencher 
essa lacuna de conhecimento na prática clínica de rotina, uma revisão sistemática e metanálise de 
estudos observacionais, de coorte e de desenho transversal, seguido por três estudos de desenho 
observacional e transversal, com os critérios de inclusão de ser idosos com tipo 2 diabetes e com 65 
anos ou mais foram todos conduzidos e implementados no Capítulo 2. Uma breve descrição dos 
métodos de pesquisa foi apresentada no Capítulo 2.1. Os resultados da revisão sistemática e da meta-
análise (Capítulo 2.2) mostraram que a polifarmácia em idosos com diabetes tipo 2 foi associada de 
62%, 96%, 33% e 72% de probabilidade de mortalidade, enfarte do miocárdio, acidente vascular 
cerebral e hospitalização, respectivamente. A análise de dados baseados em farmácia (Capítulo 2.3) 
revela que a polifarmácia, interações medicamentosas potencialmente graves e clinicamente relevantes 
e medicamentos potencialmente inadequados foram associados a 80%, 34% e 57% de chances de 
menor qualidade de vida relacionada à saúde em idosos adultos com diabetes tipo 2, respectivamente. 
A análise de uma base de dados administrativa (Capítulo 2.4) mostrou que a polifarmácia e 
medicamentos potencialmente inadequados foram associados a probabilidades 2 a 2.5 vezes maiores de 
alteração do controle glicêmico, e os medicamentos potencialmente inadequados também podem estar 
associados a 5.5 vezes maior probabilidade de alterações da função renal graves em adultos idosos com 
diabetes tipo 2. Além disso, a análise de dados administrativos de instituições especializadas em 
tratamento de diabetes (Capítulo 2.5) também conclui que mais de 60% dos adultos mais velhos com 
diabetes tipo 2 foram potencialmente supertratados e mais de 12% foram potencialmente subtratados. 
Os doentes com sobretratamento, mostraram ser mais homens, pré-obesos, têm maior compromisso 
macrovascular, neuropatia e pé diabético, e associados estão a uma maior prevalência de doença renal 
crônica grave. Os doentes, e potencialmente subtratados eram maioritariamente do sexo feminino, 
obesos, com uma maior prevalência de dislipidemia , doenças vasculares periféricas, infecções e pé 
diabético, e usavam mais insulina em comparação com aqueles que cumpriam os objectivos 
terapêuticos. No capítulo (Capítulo 3), apresenta-se uma discussão compreensiva dos resultados. Os 
estudos realizados mostraram que a polifarmácia e o sobretratamento em idosos com diabetes tipo 2 
podem estar associados a vários resultados relacionados com a saúde na prática clínica do mundo real, 
onde estes conceitos são subestimados em ensaios clínicos randomizados e diretrizes de prática clínica, 
que podem induzir mais danos do que benefícios. A terapia individualizada dos doentes e a otimização 
da medicação podem ser a maneira de reduzir o risco dessas importantes síndromes geriátricas. 
Palavras-chave: Polifarmácia, Sobretratamento e subtratamento, Mortalidade, Doenças 
cardiovasculares, Hospitalização, Qualidade de Vida, Controle Glicêmico de Idosos, Função Renal, 
Diabetes tipo 2 
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ABSTRACT  
      Chapter 1 introduces the major clinical challenges in older adults with type 2 diabetes and 
emphasizes the knowledge gap of the two important geriatric syndromes: the polypharmacy, and the 
overtreatment in randomized controlled trials and clinical practice guidelines. To bridge this knowledge 
gap in routine clinical practice, Chapter 2 conducts a systematic review and meta-analysis of 
observational, cohort and cross-sectional design studies, and then followed by three observational, 
cross-sectional design studies. The latter implements data which include the criteria of being older 
adults (aged 65 years old or more) with type 2 diabetes. A brief description of research methods is 
presented in Chapter 2.1. The results of the systematic review and meta-analysis (Chapter 2.2) show 
that polypharmacy in older adults with type 2 diabetes has been associated with 62%, 96%, 33%, and 
72% of having odds of mortality, myocardial infarction, stroke, and hospitalization, respectively. The 
analysis of pharmacy-based data (Chapter 2.3) reveals that polypharmacy, potentially serious clinically 
relevant drug-drug interactions and potentially inappropriate medicines were associated with 80%, 34% 
and 57% of odds of lower health-related quality of life in older adults with type 2 diabetes, respectively. 
The analysis of administrative-based data of specialized diabetes care institution (Chapter 2.4) 
concludes that polypharmacy and potentially inappropriate medicines were associated with 2 to 2.5 
greater odds of alteration of glycemic control, and that potentially inappropriate medicines can be also 
associated with 5.5 greater odds of severe kidney function in older adults with type 2 diabetes. Further,  
the analysis of specialized diabetes care institution administrative-based data (Chapter 2.5) also 
concludes that more than 60% of older adults with type 2 diabetes have found to be potentially 
overtreated, and more than 12% were found potentially undertreated. The former tends to be 
composed mostly of males, pre-obese, who have higher macrovascular, neuropathy, and diabetic foot, 
as well as being associated with a higher prevalence of severe chronic kidney disease; whereas the latter 
tend to be females, obese, with a higher prevalence of dyslipidemia, peripheral vascular disease, 
infections, and diabetic foot, along with using more insulin compared to those appropriately on target. 
Chapter 3 then discusses these results. Overall, the conducted research shows that polypharmacy and 
overtreatment in older adults with type 2 diabetes can be associated with several health-related 
outcomes in real-world clinical practice. These two concepts are underestimated in randomized 
controlled trials and clinical practice guidelines, possibly inducing more harm than benefits. The 
individualized therapy of patients and the optimization of medication could be the way to reduce the 
risk of these important geriatric syndromes.  
Keywords: Polypharmacy, Overtreatment, Undertreatment, Mortality, Cardiovascular diseases, 
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      In the recent decades, the worldwide prevalence of diabetes has especially risen among the 
older population aging 65 years or more. The aging of the population is thought to be one of 
the most important contributors to the prevalence of diabetes, since the increase in age is itself 
a substantial risk factor for the development of type 2 diabetes (T2D) (1)(2), along with obesity 
and physical inactivity (3). T2D is a major and costly health concern worldwide, often resulting in 
high morbidity, disability, mortality, and impaired quality of life (4). 
1.1.1 Pathophysiology of T2D in elderly people 
      T2D is a progressive disease, and glucose levels are known to increase with age. However, 
there is evidence for differences in the pathophysiology of T2D in the elderly when compared 
with younger adults. It is unclear whether the degree of T2D in older adults primarily results 
from an age-related deterioration in β-cell function (5). Since it was suggested that impaired 
insulin secretion, rather than insulin resistance, commonly led to T2D in elderly adults 
compared with young adults (5,6). The divergence in body composition related to aging includes 
the reduction of the fat-free mass (muscle, bone, water) and the relative increase of fat mass, 
with visceral obesity leading to alterations in insulin sensitivity (8,9). 
      Other studies found that most cases regarding older adults with T2D are due to a 
combination of increased insulin resistance and impaired insulin secretion. Insulin resistance 
which is associated with advanced age is believed to be due to a combination of adiposity, 
sarcopenia, and physical inactivity. Impaired pancreatic β-cell adaptation to insulin resistance 
appears to be an important contributing factor to age-related glucose intolerance and risk of 
T2D (10,11). 
1.1.2 Prevalence of T2D in elderly people  
      Around 20-25% of the elderly population is diagnosed with diabetes and the vast majority of 
those elderly (more than 90%) have T2D (7,12,13). Predictably, the incidence of diabetes could 
reach two-fold in the next decades; accordingly, the prevalence of diabetes is to be more than 
two times higher among the elderly compared to middle age or young adults (14,15). A major 
shift in the epidemiology of diabetes has been to those aged 60–79 years old (16). Those who 
are more likely to remain undiagnosed, that is, 45.6% of the total elderly population with 
diabetes, tend to be men with a more stable rate of  health status (15,17). In Europe, the 
prevalence data shown an average of 20% (18). Nevertheless, there are some differences across 
the European countries, where it ranges 14%–16% in Denmark, 15%–18% in the UK, 19%–31% 
in Greece, 15%–26% in Italy, and 25.5%-27.1% in Portugal (19–23). 
 
 
Page | 23  
 
      A very high prevalence of T2D in older adults is not only seen in the western globe, where 
the economic standards are high, but also in developing countries, such as Brazil and China. In 
Brazil, almost 3 million of the 12 million people with T2D are aged over 65 years old, whereas in 
China, 35 million of the 92 million adults with diabetes are aged over 60 years old, and 20 
million are aged over 70 years old (24,25). It was estimated that the incidence of diabetes 
mellitus increases with age nearly until the age of 65, which means that elderly adults with 
diabetes may either be diagnosed at or after the age of 65, or the onset of the disease 
happened in their middle or earlier age (26).  
1.1.3 Diabetes complications 
      The elderly people with T2D represent a diverse population with varied cultural, health, and 
social care needs. Although many elderly people with T2D will continue to live well and 
independently, with a good quality of life and high life expectancy, self-managing their diabetes 
without undue difficulty; others may suffer progressive physical or mental health, frailty, 
cognitive decline or disability, which increases dependency and vulnerability, and poses  ground 
for added social isolation and loneliness (27). In general, the objective of T2D treatment in older 
adults is to maintain functional abilities and quality of life, as well as to prevent diabetic 
complications. However, older adults must endure not only problems related to the treatment 
of T2D, but also the additional burden related to aging and associated co-morbidities (28). 
      One of the biggest clinical challenges of managing elderly people with T2D is that the 
disease rarely occurs in isolation. Many chronic conditions can be associated with it, such as 
hypertension, dyslipidemia, arthritis, and kidney disease. Chronic conditions are very common 
among the elderly with diabetes for nearly 60% of older adults with T2D have at least one 
coexisting chronic illness, and almost 40% of them have four or more (29–31). Compared to 
young adults, elderly people with T2D are at a higher risk of having a wide range of severe long-
standing T2D complications, which are usually divided into macrovascular and microvascular 
ones (32). With a greater proportion of diabetes cases present in the older population, who are 
mostly vulnerable, it is not judicious to consider how this population compares to younger 
patients regarding the development of diabetes complications due to the potentially longer 
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1.1.3.1 Macrovascular complications  
      Cardiovascular diseases (CVDs) are a common complication in people with T2D and its 
prevalence has been growing overtime (34). CVDs represent the principal cause of death and 
morbidity among older people with diabetes, especially in those with T2D. It can be associated 
with a 75% increase in mortality rate in older adults and accounts for a large part of the excess 
mortality (35). It was estimated that 77% of hospitalizations for chronic complications of 
diabetes were attributable to CVDs (36), with substantial global impact on direct medical costs of 
T2D, both at patient and population levels (37). 
      Between 2007 and 2017, a global systematic literature review estimated the prevalence of 
CVDs among elderly people with T2D found that out of 4,549,481 individuals with T2D, 52% 
were male, 47% were obese, aged 63.6 ± 6.9 years old, with T2D duration of 10.4 ± 3.7 years. 
CVDs affected 32.2% of the population overall; 29.1% had atherosclerosis, 21.2% had coronary 
heart disease (CHD), 14.9% heart failure, 14.6% angina, 10% myocardial infarction (MI) and 
7.6% stroke. CVDs were the cause of death in 9.9% of T2D individuals (representing 50.3% of all 
deaths) (38). 
      Elderly people with T2D and CVDs have a 4-fold higher incidence rate of cardiovascular 
events (CVEs) and an 8-fold higher incidence rate of vascular interventions compared to high-
risk elderly people without T2D and CVDs (39). However, most elderly patients with T2D are 
unaware they have CVDs. In a population-based autopsy study including 293 elderly patients 
with diabetes without clinically known coronary heart problems, nearly 75% had high-grade 
coronary disease and more than half had the multivessel disease (40). Silent myocardial ischemia 
(SMI) is another serious problem among elderly patients with T2D. A French study found that 
SMI with significant lesions occurs in 20.9% of T2D elderly male adults who are asymptomatic 
for coronary artery disease (41). 
      Elderly people with T2D are also at higher risk of morbidity and mortality from 
cerebrovascular diseases (CBVs). Nearly 20% to 40% of patients with T2D suffer from cerebral 
blood vessel diseases, which can be induced by T2D with sugar, fat and a series of nutrient 
substance metabolic disorders, resulting in intracranial large and small vessel diseases (42).  
Another Italian study found the prevalence of CBVs in elderly patients with a history of T2D was 
10.6% (43). However, the pathophysiological reasons for this association between CBVs and T2D 
are not fully elucidated, particularly in elderly people (44). In CBVs, the presence of T2D 
increases the risk of ischemic cerebral infarction, which accounts for more than three-quarters 
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of all strokes, but is not the risk of cerebral haemorrhage (45). A prospective cohort study of 375 
elderly people with T2D with a mean age of 75 demonstrated that lower scores on the Geriatric 
Morale scale and Elderly Diabetes Burden scale were predictors for CBVs (HR 2.6  95%CI 1.1–
6.5). This suggests psychosocial factors may be associated with stroke events among elderly 
patients with diabetes (46). 
      Comparisons of epidemiological data on diabetic and nondiabetic subjects in the general 
population have clearly demonstrated that T2D is an independent risk factor for ischemic stroke 
(47), as seen in a prospective cohort study of 14,432 individuals with T2D, for which the average 
age was ≥ 65 years old, with and without a history of cardiovascular disease, and  during a 4-
year follow-up, 296 incident stroke events were recorded. In persons with no history of 
cardiovascular disease, the age-standardized incidence of stroke (per 1000 person-years) was 
5.5 (95%CI 4.2 to 6.8) in men, and 6.3 (95%CI 4.5 to 8.2) in women. In people with a history of 
cardiovascular disease, it was 13.7 (95%CI 7.5 to 19.8) in men and 10.8 (95%CI 7.3 to 14.4) in 
women (48). 
      The peripheral arterial disease (PAD) is another of the most common macrovascular 
complications in elderly patients with T2D. It presents broad clinical characteristics and various 
consequences and is known as one of the major macrovascular complications of T2D. Although 
the global prevalence of the latter is knowingly rising (49). the prevalence of PAD in the T2D 
elderly population is still unclear. However, in the Framingham heart study, 20% of 
symptomatic PAD patients were associated with diabetes disease (50). Moreover, a German 
study including people with T2D aged ≥ 65, found that the prevalence of PAD by low ankle-
brachial index in those elderly adults with diabetes was 15.3% (51). 
      Among U.S. elderly people aged 60 years and more the prevalence of PAD for people with 
diabetes was almost twice as high compared to those without diabetes (52). A multicenter study 
estimated the prevalence of PAD to be 60.6% among a cohort of 1,430 diabetes people aged 70 
years and older (53). Another Indonesian study has shown that elderly adults with T2D aged 
between 70 and 80 years old were 7.4 times more likely to develop PAD compared to adults 
with T2D aged between 60 and 69 years old (54). The elevation of PAD prevalence is related to 
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1.1.3.2 Microvascular complications  
      Retinopathy is considered the most common microvascular complication and the leading 
cause of blindness in elderly people with T2D (57). According to the World Health Organization 
(WHO), diabetic retinopathy is responsible for 4.8% of the number of cases of blindness (37 
million) worldwide (58). The overall prevalence of retinopathy in T2D is estimated to be 25.2% 
(59). The prevalence of retinopathy is considered slightly higher in elderly adults with T2D 
compared to those younger than 65 years old (29.5% vs. 28%) in the U.S. (33). In Japan, the 
prevalence of retinopathy reached 43% in elderly people with T2D aged 65 or more (60). A 
Swedish study has shown that the prevalence reached 34.6% in the T2D population with a 
mean age of 70.3 years, compared with those without diabetes (8.8%) with a mean age of 75 
years (61). 
      Nephropathy is another critical microvascular complication with elderly people with T2D 
and is considered the most common cause of chronic kidney disease (CKD) and end-stage renal 
disease (ESRD) (62). Nearly 25% to 30% of T2D patients exhibit a renal disease, usually expressing 
as typical diabetic glomerulosclerosis, but sometimes as prominent vascular nephropathy. 
These two forms of renal lesions are usually intricate. Chronic pyelonephritis, which is 
particularly frequent in elderly people with T2D with recurrent urinary tract infections, can also 
contribute to decreased renal function (63). 
      An Italian study investigating the association of clinical variables and quality of care 
measures in 157,595 T2D individuals (more than 63% of them aged ≥ 65 years old) found that 
the prevalence of both estimated glomerular filtration rate (eGFR) and Albuminuria increase 
with age. Diabetic kidney disease is associated with the poor cardiovascular risk profile and a 
lower quality of care, although these associations are influenced by the type of renal 
abnormality and by aging (64). The impact of T2D on renal impairment changes with increasing 
age. Serum markers of glomerular filtration rate and microalbuminuria identify a renal decline 
in different segments of the diabetic population (65). 
      The prevalence of nephropathy in elderly people with T2D is higher than in those with type 
1 diabetes (T1D) (63). In the U.S., comparing the elderly people with diabetes with those without 
diabetes, the prevalence of CKD was higher in individuals older than 65 diagnosed with 
diabetes. The analysis was conducted through three data sources: the Kidney Early Evaluation 
Program (KEEP), the National Health and Nutrition Examination Survey (NHANES), and the 
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billing codes in the Medicare (KEEP 48.2% vs. 40.4%, NHANES 58.3% vs. 41.4%, Medicare 14.2% 
vs. 4.4%) (66). 
      The increase in diabetes-related to end-stage kidney disease correlates with the increased 
burden of diabetes. The elderly population with diabetes remains a large group of those 
receiving dialysis for diabetic nephropathy (67). The European Renal Association—European 
Dialysis and Transplant Association Registry Annual Report (2014) showed that 70,953 
individuals commenced kidney Replacement Therapy (KRT) in 2014, equating to an overall 
unadjusted incidence rate of 133 per million population. Of the patients commencing KRT, 
almost two‐thirds were men, more than half aged ≥ 65, and a quarter had diabetes as their 
primary kidney diagnosis (68). The proportion of ESRD in people with T2D who are considered 
elderly is currently the fastest-growing segment of incident ESRD population. Despite the fast 
growth of this group, it is poorly characterized in current literature (69). ESRD with diabetes can 
be associated with an increased risk of dementia (70).   
      Moreover, this older population may be more likely to have arteriovenous fistula 
complications. Among a cohort of elderly adults with T2D aged 65 years and older, 28.6% of 
patients with diabetes had fistula failure compared to only 10.3% of patients without diabetes 
(71). Diabetic neuropathy affects both peripheral and autonomic nervous systems and causes 
considerable morbidity and mortality in T2D patients. Diabetic neuropathy is the most common 
form of neuropathy, accounting for more hospitalizations and resulting in 50% to 75% of non-
traumatic amputations (72,73). 
      In elderly people with T2D, peripheral neuropathies are especially troublesome due to their 
detrimental effects on stability, sensorimotor function, gait, and activities of daily living. As the 
severity of neuropathy increases, the functional impairment worsens and the quality of life of 
elderly adults with T2D can be affected (74–76). The clinical diagnosis of diabetic neuropathy is 
often difficult in elderly adults with T2D. The relationship between symptoms and neuropathy 
and that between neuropathy and diabetes are more difficult to ascertain in elderly patients, 
due to age changes in the peripheral and autonomic nervous system and associated diseases 
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      Identification of diabetic neuropathy signals a high risk of foot complications, such as ulcers 
and gangrene, often resulting in amputation, whereas cardiovascular autonomic neuropathy is 
associated with an increased risk of postural hypotension and coronary events. All these risks 
increase markedly with elderly people with T2D (78–80). Therapeutic clinical trials in elderly 
people with T2D with diabetic neuropathy are insufficient, and clinical complications of diabetic 
neuropathy in the elderly population are frequently severe. Moreover, there is a lack of 
treatment options targeting the neuropathic disease state (81,82). The causal pathways leading 
to diabetic foot ulceration include several components causes, the most important of which is 
peripheral neuropathy. Foot ulcers have been estimated to affect 1–4% and may be as high as 
6%, affecting as many as 25% of the individuals with diabetes over their lifetimes (83,84), This is 
present to some degree in more than 50% of diabetic persons older than 60 years (85). Once a 
foot ulcer has developed, there is an increased risk of wound progression that may ultimately 
lead to amputation; for diabetic ulceration has been shown to precede amputation in up to 
85% of cases (86).  
1.1.4 Co-morbidities and geriatric syndromes   
      In addition to the macrovascular and microvascular complications associated with T2D, 
there is also an increased risk of multiple coexisting medical conditions in older adults, as well 
as other critical problems which can develop, usually referred to as the geriatric syndromes. 
This emphasizes that ‘one size fits all’ treatment strategies are not convenient for this 
population (87) and can impact the ability of patients to self-manage as well as affect their  
health-related quality of life, in addition to other health outcomes (88). 
      The geriatric syndrome can be defined as “clinical condition taken in a very broad sense 
(personal history and complaints of the patient, clinical examination, and results of 
complementary examinations) that does not fit into a discrete disease category”(89). 
Notwithstanding, the concept of geriatric syndrome remains poorly defined. Despite the 
heterogeneity of elderly T2D population, geriatric syndromes share many common features. 
They are highly prevalent in older adults with T2D, especially those with a frailer health. Their 
impact on the quality of life and disability is fundamental (90,91). Some researchers suggest that 
geriatric syndromes can be considered “medical errors” for reasons which can be associated 
with an increased risk of mortality. The literature also has declared that geriatric syndromes can 
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1.1.4.1 Cognitive dysfunction  
      Cognitive dysfunction is a common and often underdiagnosed syndrome in older people 
with T2D (94). Alzheimer’s disease and vascular dementia are proportionally twice as likely to 
occur in elderly people with T2D compared with the non-diabetic elderly. The cognitive 
impairment can vary from one patient to another, from subtle executive dysfunction to clear 
dementia and memory loss (95), as the prevalence of cognitive impairment and dementia 
increases with age. The presence of comorbidities in diabetes can contribute to this association. 
Dementia affects up to 16% of the elderly with diabetes aged >65 and 24% of those aged >75  
(96). Additionally, it was found that insulin resistance is a critical risk factor for cognitive 
impairment in older people with T2D (97). 
      Mild to moderate cognitive impairment and dementia can be observed more often in elderly 
people with diabetes (98,99), and it was estimated that at least half of older people with T2D will 
become cognitively impaired and functionally disabled (100). Furthermore, several studies have 
shown an association between hyperglycemia and cognitive dysfunction. Hypoglycemia is 
highly connected to cognitive dysfunction in a way that cognitive impairment may increase the 
additional risk of hypoglycemia, and the presence of a history of severe hypoglycemia is also 
linked to the incidence of dementia (101–103). 
      Since cognitive dysfunction affects treatment adherence and diabetes self-management, the 
resulting poor glycaemic control and an increased rate of severe hypoglycemia contribute to a 
vicious cycle. Overall, individuals with cognitive dysfunction have difficulty performing self-care 
(such as patients not being able to recognize or treat hypoglycemia, or to remember and 
administer their insulin regime correctly), leading to a significantly reduced quality of life (104). 
Furthermore, a study of 1,617 elderly people with T2D in the U.S. evaluated the association of 
diabetes with the incidence of dementia and cognitive impairment without dementia, while 
accounting for competing risk from death. The study found that in models adjusted for 
competing risk of death, those with treated and untreated T2D had an increased risk of 
dementia/cognitive impairment without dementia (HR 2.05 95%CI 1.41-2.97) and (HR 1.55 
95%CI 0.93-2.58) compared with those without diabetes (105). Additionally, the presence of 
retinopathy (a microvascular complication) and stroke (a macrovascular complication) in older 
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1.1.4.2 Functional impairment 
      A functional situation involves the ability to undergo simple daily tasks required for routine 
living. Advanced age and diabetes itself can be recognized as risk factors for functional 
impairment (108).  Functional decline and physical disabilities are an important clinical and public 
health problem in older adults because they are associated with the  loss of independence (109). 
Generally, diabetes patients have two-to-three times greater difficulty in performing tasks of 
daily living when compared to patients without diabetes (52). A study in Hong-Kong including 
elderly people with T2D examined the relationship between diabetes and impairments in 
functional and cognitive status, as well as depression, and found that the elderly with T2D may 
be less capable of managing the disease than younger patients as a result of increased risk of 
both physical (odds ratio (OR) 1.65 95%CI 1.51-1.80) and cognitive impairment (OR 1.28  95%CI 
1.11-1.48) (110). 
      The causes of functional impairment in elderly people with T2D can include the interaction 
between coexisting comorbid conditions namely, peripheral neuropathy, vision, and hearing 
difficulties, as well as  gait and balance problems. The presence of peripheral neuropathy in 
almost (50-70%) of elderly people with T2D can lead to postural instability, balance problems, 
and muscle atrophy (111–113). A long duration of diabetes increases the loss of muscle function in 
elderly people with T2D and this may contribute to the underlying pathophysiological changes 
in frailty, disability, and sarcopenia. There is also a gradient effect of functional decline on 
mortality in the elderly with diabetes, and among those with other chronic conditions, as 
functional decline was associated with a greater burden of mortality (114–116). 
1.1.4.3 Fall and fall risk  
      Fall is also a common geriatric syndrome in elderly people with T2D and contributes to 
morbidity, mortality, and the loss of independence. Elderly people with T2D are at higher risk of 
falling than those without diabetes (117). Falls are a critical concern for elderly adults with T2D 
(118,119). The annual incidence of falls in the elderly with T2D reached up to 39% (120). A 
longitudinal study found that this demographic has an increased risk of recurrent falls (30.6%) 
compared to those without diabetes (19.4%) (121). Elderly people with diabetic peripheral 
neuropathy are at a high-risk of falling and of declines in sensory function, which is not only 
caused by neuropathy but also in presence of retinopathy, possibly leading to increased risk of 
falls in the elderly with T2D (74,122). In addition, intensive glycemic control associated with 
hypoglycemia may be associated with risk falls (123,124). 
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      A systematic review and meta-analysis evaluated the impact of diabetes mellitus on the risk 
of falls in older adults found that in subgroup analysis, the risk of falls seemed more 
pronounced among both gender groups (relative risk (RR) 1.81 95%CI 1.19–2.76) than among 
women (RR 1.52 95%CI 1.04–2.21). Risk of fall increased 94% (RR 1.94 95%CI 1.42–2.63) in 
insulin-treated patients and 27% (RR 1.27 95%CI 1.06–1.52) in non-insulin treated patients (125). 
Another longitudinal study found that, in elderly people with T2D, reducing diabetes-related 
complications may help prevent falls. Achieving lower HbA1C levels with oral hypoglycemic 
agents was not associated with more frequent falls, but among those using insulin, HbA1C ≤ 6% 
increased the risk of falls (126). Other potential factors which could be related to the increased 
frequency of falls in the elderly with T2D include polypharmacy, pain, lower physical activity, 
functional limitations, and cognitive impairments (127). 
1.1.4.4 Vision and hearing impairment 
      The decline of vision and hearing may be associated with an increase of the risk of fall in 
elderly people with T2D, leading to functional disabilities and potentially resulting in older 
patients feeling isolated and more vulnerable to depression (128). Elderly people with T2D have a 
higher prevalence of vision impairment than those without diabetes. Among patients aged 60 
years and older, the prevalence of self-reported vision impairment was 34.2% for those 
diagnosed with diabetes compared to 21.4% for those without diabetes (128). The epidemiology 
of Hearing Loss Study found that T2D was associated with a 41% increased prevalence of 
age‐related hearing loss after controlling for potential confounders (129). Other studies also 
reported that there is a small but statistically significant association of cardiovascular disease 
and hearing status in the elderly with T2D that is greater for women than men (130), and those 
who are not on insulin (131).   
1.1.4.5 Depression  
      Diabetes is associated with a high prevalence of depression. Undiagnosed depression can 
lead to limitations in self-care activities and implementing a healthy lifestyle, and is associated 
with a higher risk of mortality and dementia in elderly patients with T2D (132–134). Among elderly 
people with T2D, up to 30% have a significant number of depressive symptoms and 12% to 18% 
meet diagnostic criteria for major depression. A meta-analysis has shown that the odds ratio for 
depression in elderly people with T2D compared with those without was higher in males (OR 
1.9 95%CI 1.7-2.1) than in females (OR 1.3 95%CI 1.2-1.4) (135,136). Elderly people with T2D 
experience a higher risk of comorbid depression compared to those who do not have diabetes. 
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Having T2D can be associated with increases in the risk of subsequent development or 
recurrence of depression (137).  
      Comorbid depression in elderly people with T2D is strongly associated with increased 
burdens of disease symptoms, the decline in self-management and treatment adherence, as 
well as an increase in health care services utilization, medical expenditures, and risk of more 
complications (138–140). The impact of depression was examined by several studies focusing on 
whether it can be associated with increased risk of mortality in elderly people with T2D. It was 
found that depression is associated with a 1.5 to 2.6-fold increase in the risk of mortality among 
this population (141,142). In addition, the total annual health care costs were found to be 4.5 
times greater for older adults with both diabetes and depression compared to patients  with 
diabetes only (143). 
1.1.4.6 Frailty  
      Frailty can be defined depending on the presence of three or more of the following factors: 
weight loss, weakness, decreased physical activity, exhaustion, and slow gait speed. People 
with diabetes aged ≥ 65 years old are more likely to be frail than older adults without diabetes, 
where an estimated prevalence of approximately 11% of those elderly people with T2D are 
considered frail (144,145). Several studies have suggested that insulin resistance, adipose tissue 
inflammation, and skeletal muscle inflammation and dysfunction are related to the  likelihood 
of accelerated aging process and in the increase of frailty in elderly people with T2D (146,147). 
      Frailty is a state of increased vulnerability to minor stressors, leading to difficulties in the 
maintenance of homeostasis, which increases the risk of adverse outcomes, such as disability, 
falls, sarcopenia, and mortality in elderly people with T2D (148). It was estimated that the 
median life expectancy for elderly frail T2D people was only 1 year and 11 months (149). 
Sarcopenia (muscle loss due to aging) is one of the major contributors to frailty syndrome, 
which can be accelerated with diabetes. In a community study of 3,153 elderly T2D people aged 
≥ 65 years or more, appendicular lean mass loss in men with diabetes was twice that of men 
without diabetes (3% vs 1.5%), and in women with diabetes it was 1.8 times that of those 
without diabetes (3.4% vs 1.9%), over four years of follow up (150).  In addition, the occurrence 
of frailty depends on declining cardiopulmonary reserve and loss of executive function, as well 
as on low HbA1c. This was detected as a factor increasing the risk of frailty (151). Diabetes and 
frailty are interrelated, with sarcopenia and both hyperglycemia and hypoglycemia implicated 
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(152–154). Frailty is also strongly associated with the presence of CKD in elderly people with T2D, 
occurring in 21% of those with an eGFR < 45 ml/min/1.73m² (155). 
1.1.4.7 Polypharmacy  
      With the current change in socio-demographic characteristics in recent decades, and the 
increase of diabetes in elderly populations, multi-morbid conditions have become a critical, 
pressing public health issue across the world (156). Further, the foresight of medicines’ benefits 
and harms is asymmetric. Approval of medicines depends mostly on efficacy, while the 
evaluation of medicines’ full safety profile is left to post-marketing studies and spontaneous 
reporting. The medicines’ efficacy is mostly overvalued by the physicians, and sometimes their 
safety is underestimated as a result of the paucity of safety information, along with the scant 
understanding of the effectiveness of medicines in real-life (157).  
      The rising prevalence of multimorbidity leads to several treatment strategies frequently 
resulting in an increased risk of treatment complexity and uncertain treatment pathways. This 
consequently leads to high treatment burden and multiple medication usage, or as it is often 
called, polypharmacy, which can sometimes reduce the benefits and increase the risk or 
potential harms of the treatment (158). Elderly people with T2D are at high risk of polypharmacy 
as a result of multiple comorbid conditions associated with diabetes, which also poses ground 
for the consequence of long-term disease complications when compared with young adults 
with T2D (159,160). Polypharmacy can increase the risk of clinical complexity, treatment burden, 
drug-disease or drug-drug interactions, contributing to poor health outcomes, including frailty, 
falls or increasing the fall risks in the elderly, hospitalization or emergency room visits, 
functional disability, and/or cognitive decline as a result of treatment in adverse events (161–163). 
1.1.4.8 Overtreatment  
      In addition to polypharmacy, for elderly people with T2D with multiple serious comorbidities 
and functional decline, treatment intensification to reach optimal glycaemic can result in few or 
no benefits or even be harmful towards the same end. The glucose-lowering medicines with 
more risk of causing hypoglycaemia (such as insulin and sulfonylureas) were considered as the 
second most common medications associated with emergency department visits or 
hospitalizations reported to the U.S. Food and Drug Administration (FDA) (163). The problem of 
overtreatment received more attention regarding elderly people with T2D who were diagnosed 
with dementia, being at a much higher risk of hypoglycemia compared to those without 
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dementia, as well as the increased risk of detrimental drug interactions due to the presence of 
polypharmacy (164). 
      In patients with greater clinical complexity, intensive diabetes treatment could result in a 
significant increased risk-adjusted probability of severe hypoglycemia from 1.7% with standard 
treatment to 3% with intensive treatment (165). Given the heterogeneity of elderly people with 
T2D, an individualized approach is warranted to avoid overtreatment of frail older individuals. 
Diabetes healthcare management in elderly people with T2D therefore presents a difficult 
challenge. Clinical and functional complexity and diversity, along with multiple coexisting 
comorbid conditions in this population are factors demanding special attention. Treatment 
goals should be formulated with an awareness of the medical, functional, social, and financial 
environment of the elderly patients. Aspects of the geriatric syndromes that can adversely 
affect the successful management of diabetes include cognitive dysfunction, depression, 
physical disabilities, polypharmacy, and overtreatment.  
1.1.5 Addressing the current knowledge gap of polypharmacy and overtreatment 
      Older adults with T2D are heterogeneous in their health status. The scarcity of evidence 
regarding polypharmacy and overtreatment, as well as their impacts on health outcomes from 
randomized controlled trials (RCTs) and clinical practice guidelines represent crucial challenges 
to determining standard intervention strategies suitable to older adults (166). 
1.1.5.1 Data from randomized clinical trials  
      Regarding polypharmacy, only three RCTs (Table 1) were found. Two trials defined 
polypharmacy as the use of five or more medicines (167)(169). The RCT by Strain et al did not 
consider polypharmacy as part of the study outcomes that need to be measured (168). Whereas 
a trial by Vanassche et al (169), found that polypharmacy was associated with recurrent venous 
thromboembolism in patients using warfarin, as well as associated with increased risk of 
bleeding regardless of the treatment used. The analysis risk of bias revealed that the three trials 
were categorized with good quality. The analysis of the risk of bias can be found in 
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Table 1 Randomized controlled trials that assessed polypharmacy in older people with T2D 
Study 
Reference 
Study design  Participants 
number /  
mean age  ± 
standard 
deviation  





















Effectiveness of linagliptin 
in elderly adults with T2D  






The impact of 
polypharmacy was 
not examined  
Good quality  










Assessment of feasibility of 
setting individualized 
glycemic goals and factors 
influencing targets set in a 
clinical trial in elderly 
patients with T2D 






not considered by 
physicians when 
setting targets  
Good quality  
Vanassche 
et al. 2018 
(169) 
Double blind RCT  Total sample 
(8240) 









Determination of the 
effects of advanced age, 
comorbidities, and 
polypharmacy on the 
efficacy and safety of 
edoxaban and warfarin in 
patients with VTE 
Using of five or 















Good quality  
RCT: randomized controlled trial, T2D: type 2 diabetes, VTE: venous thromboembolism 
       Regarding the RCTs which addressed overtreatment in elderly people with T2D, the mean 
age was between 60 and 71.7 years old. The definition of overtreatment or treatment 
intensification based on HbA1c value was between < 6% to < 7%, except for one RCT which 
used the fasting blood glucose value of <121 mg/dL as a definition of glycemic intensification 
(175). The prevalence of participants receiving intensification was between 44.4% to 50%. Only 
the intensive blood glucose control and vascular outcomes in patients with T2D (ADVANCE) 
achieved a 10% relative reduction in the combined outcome of major macrovascular and 
microvascular events, primarily because of a 21% relative reduction in nephropathy (173). The 
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Veterans Affairs Diabetes (VADT) trial shows that a slow progression of albuminuria had little 
benefit from overtreatment (174).  
      The other RCTs failed to find any significant benefit either in a reduction of a major 
cardiovascular event (172)(173)(174)(175), restenosis (176), or risk of death from cardiovascular 
events (171) (173)(174) (177), death from hypoglycemia/hyperglycemia or from microvascular events 
(177), or reduction in microvascular complications (170). Furthermore, The Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial found that the use of intensive therapy increased 
mortality (172) (Table 2). The analysis risk of bias revealed that the three trials were categorized 
with good quality, two with fair quality, and two with poor quality. The analysis of the risk of 
bias can be found in (Supplementary Table 2). 
Table 2 Randomized controlled trials that assessed overtreatment in older people with T2D 
Study 
Reference   
Study design  Participants 
number / 
mean age  ± 
standard 
deviation 















Effects of intensive 
glycemic control on 
peripheral and 
autonomic neuropathy 






No reduction in overall 
prevalence of peripheral or 
autonomic neuropathy.  











Composite of all-cause 
mortality, non-fatal MI, 
stroke, acute coronary 
syndrome, 
endovascular or 
surgical intervention in 
the coronary or leg 
arteries, and 
amputation above the 
ankle 






No significant difference in 
reduction of the risk of death 
from any cause, non-fatal MI, 
stroke, acute coronary 
syndrome, leg amputation, 
coronary revascularization, or 
revascularization of the leg.  













Reduction of nonfatal 
MI, nonfatal stroke, or 
death from 
cardiovascular causes. 






the use of intensive therapy 
increased mortality and did not 
significantly reduce major 
cardiovascular events 






double 2 x 2 
Total sample 
(11,140) 




HbA1c ≤ 6.5%  
Number of 
participants 
a 10% relative reduction in the 
combined outcome of major 
macrovascular and 
Good quality  
 
 




(66 ± 6) retinopathy) and major 
adverse cardiovascular 





microvascular events, primarily 
because of a 21% relative 









(60.5 ± 9) 
Time from to first 
occurrence of a major 
cardiovascular event, a 
composite of MI, 
stroke, death from 
cardiovascular causes, 
congestive heart 












No significant effect on the 
rates of major cardiovascular 
events, death, or microvascular 
complications, except for 
progression of albuminuria 












(61.1 ± 9.7; 
60.9 ± 9.8) 
If diabetes treatment 
that targets 
abnormalities of the 
post-meal period 
reduces excess CV 
mortality and 
morbidity in patients 
with T2D and recent MI 







Similar levels of HbA1c 
achieved, and no difference in 
risk for future cardiovascular 
event rates 
 
Fair quality  
IDA trial 
2009 (176) 





control, achieved by 
adding or optimizing 
insulin treatment, will 
reduce the rate of 
restenosis after PCI in 
patients with T2D. 






Intensified treatment did not 
influence the rate of restenosis 











(71.7 ± 4.7) 
To evaluate long‐term, 
multiple risk factor 
intervention on 
physical, psychological, 
and mental prognosis, 
and development of 
complications and 
cardiovascular disease 
in elderly people with 
T2D 






No significant differences in 
fatal events ( MI, sudden death, 
stroke, death due to renal 
failure, death due to 
hyper/hypoglycemia,  
malignancy and pneumonia) or 
non-fatal events (MI, angina 
pectoris, coronary 
revascularization,   
hospitalization due to heart 
failure, stroke, diabetic ulcer or 
gangrene 
Poor quality  
VA CSDM: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes, PROactive: Prospective Pioglitazone 
Clinical Trial In Macrovascular Events, ACCORD: The Action to Control Cardiovascular Risk in Diabetes, ADVANCE: Action in Diabetes and 
Vascular Disease Preterax and Diamicron MR Controlled Evaluation, VADT: Veterans Affairs Diabetes Trial, HEART2D: Effects of prandial 
versus fasting glycemia on cardiovascular outcomes in type 2 diabetes, IDA: Insulin Diabetes Angioplasty study, JEDI: Japanese Elderly 
Diabetes Intervention Trial. RCT: randomized controlled trial, HbA1c: glycated hemoglobin, MI: myocardial infarction, CV: cardiovascular, 
T2D: type 2 diabetes, PCI: Percutaneous Coronary Intervention, FBG: fasting blood glucose 
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1.1.5.2 Data from clinical practice guidelines 
      In the European Diabetes Working Party for Older People with T2D guidelines (EDWPOP), 
the potential overtreatment was defined as an HbA1c level below 7.6%. This definition only 
included those who are frail, dependent, associated with chronic comorbid diseases, care home 
residents, and at high risk for hypoglycemia (178). The standards of medical care in diabetes 
published by the American Diabetes Association (ADA) discussed whether older adults with 
diabetes are at a higher risk than any other elderly population for several geriatric syndromes, 
including polypharmacy, which may have an effect on their self-management abilities (179). ADA 
mentioned that polypharmacy in older adults with diabetes in the long-term care settings such 
as in nursing homes and skilled nursing facilities are at high risk for hypoglycemia, along with 
their higher number of complications, comorbid conditions, and other risk factors (179). ADA also 
debated whether narrow glycemic control in the elderly with diabetes is considered as 
overtreatment, increasing the risk of hypoglycemia, which was regrettably shown to be a 
common clinical practice, suggesting the de-intensification of regimens in patients taking non-
insulin glucose-lowering medicines (179). 
      The European Association for the Study of Diabetes (EASD) and ADA in their joint statement 
addressed polypharmacy to the extent that it represents an additional important consideration 
alongside patient preferences, glycaemic targets, and comorbid conditions for the process of 
glucose-lowering medication selection. No specific recommendations were mentioned in the 
statement regarding polypharmacy or overtreatment for older adults (180). The International 
Diabetes Federation (IDF) guideline for the elderly with T2D included polypharmacy as one of 
the most important factors which can contribute to increasing the risk of adverse drug events 
and proposed to reduce it wherever possible (182). In addition, the IDF identified polypharmacy 
as one of the risk factors for hypoglycemia in the elderly with T2D, as well as one of the risk 
factors for falls in this population. Furthermore, IDF proposed  HbA1c level < 7% / 53 mmol/l as 
a threshold measure of potential overtreatment of older people who are at high risk for 
hypoglycemia (182). 
      The National Institute for Health and Care Excellence (NICE) recommends the 
implementation of an individualized approach for the management of adults with T2D, taking 
into consideration the risk of polypharmacy and their impact on risk and benefit of the drug 
treatment, with no specific recommendations for the elderly population (184). Finally, the recent 
Canadian Diabetes Association (CDA) guidelines recommended that in a selected elderly 
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population with T2D, such as those who are frail and residents of long-term care settings and at 
higher risk of hypoglycemia due to polypharmacy and other risk factors, deprescribing should 
be taken into consideration (185). The CDA also recommends that certain medicines such as 
statins and sulfonylureas be the first to deprescribe, due to the lack of benefit from these 
medicines for those with reduced life expectancy and at risk of hypoglycemia (Table 3).  










N.A.  N.A. Potential 
overtreatment 
HbA1c < 7.6% 
For frail (dependent; multisystem 
disease; care home residency 
including those with dementia) 
patients where the hypoglycaemia 
risk is high and symptom control 
and avoidance of metabolic 
decompensation is paramount, the 
target HbA1c range should be 7.6–
8.5% 
ADA² 2019 (179) N.A. Screening for geriatric syndromes may 
be appropriate in older adults 
experiencing limitations in their basic 
and instrumental activities of daily 
living as they may affect diabetes self-
management and be related to health-
related quality of life 
N.A. Overtreatment of diabetes is 
common in older adults and should 
be avoided 
Deintensification (or simplification) 
of complex regimens is 
recommended to reduce the risk of 
hypoglycemia, if it can be achieved 







N.A. N.A. N.A. Intensification of treatment 
beyond dual therapy to maintain 
glycemic targets requires 
consideration of the impact of 
medication side effects on 
comorbidities, as well as the 
burden of treatment and cost. 
 
Patients who are unable to 
maintain glycemic targets on basal 
insulin in combination with oral 
medications can have treatment 
intensified with GLP-1 receptor 
agonists, SGLT2 inhibitors, or 
prandial insulin 
IDF⁴ 2013 (182) N.A. Consideration of polypharmacy as one 
of factors that contribute to medicine 
related adverse events 
Consider the medicine burden and 
Proposed  
definition as An 
HbA1c < 7% / 53 
mmol/l 
An HbA1c < 7% / 53 mmol/l should 
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reduce polypharmacy, the complexity 
of the dose regimen, and consider 




N.A. N.A. N.A. N.A. 
NICE⁶  2015 
(184) 
N.A. Adopt an individualized approach to 
diabetes care that is tailored to the 
needs and circumstances of adults 
with type 2 diabetes, taking into 
account their personal preferences, 
comorbidities, risks from 
polypharmacy, and their ability to 
benefit from long-term interventions 
because of reduced life expectancy 
For adults with type 2 diabetes, 
discuss the benefits and risks of drug 
treatment, and the options available. 
Base the choice of drug treatment on 
the person's individual clinical 
circumstances, for example, 
comorbidities, risks from 
polypharmacy 
N.A. N.A. 
CDA⁷ 2018 (185) N.A. Older people with diabetes are 
frequently on multiple medications, 
many of which may be inappropriate 
in the setting of complex comorbidity 
and limited life expectancy 
In selected populations, deprescribing 
should be considered to reduce 
complexity of therapy, side effects and 
adverse drug interactions 
Drugs that can be considered first for 
deprescribing in these individuals 
include statins and sulfonylureas, 
because of lack of benefit in people 
with limited life expectancy and 
concerns about hypoglycemia, 
respectively. 
N.A. N.A. 
1 European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus, 2 American Diabetes Association, 
3 American Diabetes Association ₋ European Association for the Study of Diabetes, 4 International Diabetes Federation, 5 American College 
of Cardiology/American Heart Association, 6 The National Institute for Health and Care Excellence, 7 Canadian Diabetes Association, N.A.: 
not available  
      The evidence stemming from the clinical trials that reported the knowledge and/or the 
impact of polypharmacy in elderly people with T2D are scarce and limited. The definition of 
polypharmacy solely used in the RCTs is the use of five or more medicines. The primary 
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objective of these RCTs was not focused on the impact or the influence of polypharmacy, as 
there was no description of the population in those studies and only one trial which measured 
or reported the impact of polypharmacy on clinical, humanistic, or economic outcomes (169).  
RCTs that assessed or measured the impact of overtreatment in this population were very few. 
The risk of intensifying glycemic management in such RCTs outweighed the benefits, with the 
exception of two trials which found some benefit in reducing the microvascular complications 
(173)(174). 
      The clinical practice guidelines for the management of older adults with diabetes were not 
much different from the RCTs in the paucity of the evidence or in recommendations regarding 
polypharmacy and overtreatment. None of the major clinical practice guidelines defined the 
concept of polypharmacy, nor of overtreatment, except the EDWPOP and IDF’s guideline which 
potentially considered them as HbA1c < 7.6% (60 mmol/mol) and as HbA1c < 7% (53 
mmol/mol), respectively, signaling a possible overtreatment threshold (178)(182). 
       Some of these guidelines recommended checking for polypharmacy in elderly people with 
T2D as it could be a possible reason affecting their self-care management, reducing health-
related quality of life (179), and increasing the risk of adverse drug events (182). However, there 
was no clear methodology proposed by these guidelines for screening and detecting 
polypharmacy and overtreatment, or specific criteria for the elderly people with T2D to follow 
for screening. Additionally, there was no clear procedure or criteria for control and 
management of polypharmacy in most of the guidelines, except for NICE’s guideline 
recommendation for the individualized approach in managed care, which also discussed the 
benefits and risk of medicines (184). Moreover, IDF recommended the reduction of polypharmacy 
by reducing the dosage complexity and deprescribing medicines whenever safe and possible 
(182). The CDA guideline suggested that deprescribing should occur in selected elderly 
subgroups, especially those with complex comorbidities and limited life expectancy, starting 
firstly with statins and sulfonylureas (185).  
       No management methodology or clinical procedure was suggested by most clinical practice 
guidelines on how to avoid overtreatment, except for the considerations (Table 4) suggested by 
ADA’s guideline through the de-intensification or simplification of treatment (179), and the 
evidenced-based recommendations algorithm (Figure 1) by EDWPOP’s guideline for frail elderly 
people with T2D to avoid unnecessary overtreatment and polypharmacy (43). 
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Rationale/considerations When may regimen 
simplification be 
required? 




Healthy (few coexisting 
chronic illnesses, intact 
cognitive and functional 
status) 
A1C < 7.5% (58 
mmol/mol) 
• Patients can generally perform 
complex tasks to maintain good 
glycemic control when health is 
stable 
• During acute illness, patients 
may be more at risk for 
administration or dosing errors 
that can result in hypoglycemia, 
falls, fractures, etc. 
• If severe or recurrent 
hypoglycemia occurs in 
patients on insulin 
therapy (even if A1C is 
appropriate) 
• If wide glucose 
excursions are observed 
 
• If cognitive or functional 
decline occurs following 
acute illness 
• If severe or recurrent 
hypoglycemia occurs in 
patients on noninsulin 
therapies with high risk 
of hypoglycemia (even if 
A1C is appropriate) 
• If wide glucose 
excursions are observed 
• In the presence of 
polypharmacy 
Complex/intermediate 
(multiple coexisting chronic 
illnesses or 2+ instrumental 
ADL impairments or mild-to-
moderate cognitive 
impairment) 
A1C < 8% 
(64 
mmol/mol) 
• Comorbidities may affect self-
management abilities and 
capacity to avoid hypoglycemia 
• Long-acting medication 
formulations may decrease pill 
burden and complexity of 
medication regimen 
• If unable to manage 
complexity of an insulin 
regimen 
• If there is a significant 
change in social 
circumstances, such as 
loss of caregiver, change 
in living situation, or 
financial difficulties 
• If wide glucose 
excursions are observed 
 
• In the presence of 
polypharmacy 
Community-dwelling 
patients receiving care in a 










• Glycemic control is important 
for recovery, wound healing, 
hydration, and avoidance of 
infections 
• Patients recovering from 
illness may not have returned to 
baseline cognitive function at 
the time of discharge 
• Consider the type of support 
the patient will receive at home 
• If treatment regimen 
increased in complexity 
during hospitalization, it is 
reasonable, in many 
cases, to reinstate the 
prehospitalization 
medication regimen 
during the rehabilitation 
• If the hospitalization 
for acute illness 
resulted in weight loss, 
anorexia, short-term 
cognitive decline, 
and/or loss of physical 
functioning 
Very complex/poor health 
(long-term care or end-stage 
chronic illnesses or 
moderate-to-severe 
cognitive impairment or 2+ 
ADL dependencies) 
A1C < 8.5% (69 
mmol/) 
• No benefits of tight glycemic 
control in this population 
• Hypoglycemia should be 
avoided 
• Most important outcomes are 
maintenance of cognitive and 
functional status 
• If on an insulin regimen 
and the patient would like 
to decrease the number of 
injections and fingerstick 
blood glucose monitoring 
events each day 
• If the patient has an 
inconsistent eating 
• If on noninsulin agents 
with a high 
hypoglycemia risk in the 
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pattern • If taking any 
medications without 
clear benefits 





• Goal is to provide comfort and 
avoid tasks or interventions that 
cause pain or discomfort 
• Caregivers are important in 
providing medical care and 
maintaining quality of life 
• If there is pain or 
discomfort caused by 
treatment (e.g., injections 
or fingersticks) 
• If there is excessive 
caregiver stress due to 
treatment complexity 
• If taking any 
medications without 
clear benefits in 
improving symptoms 
and/or comfort 
Adapted from the Older Adults: Standards of Medical Care in Diabetes—2019, American Diabetes Association, Diabetes Care 2019 Jan; 42(Supplement 1): S139-
S147. https://doi.org/10.2337/dc19-S012 
Figure 1 Glucose lowering algorithm for frail, older people with T2D 
 
 
Adapted from European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary, Volume 37, 
Supplement 3, November 2011, Pages S27-S38, https://doi.org/10.1016/S1262-3636(11)70962-4  
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1.1.5.3 Bridging the knowledge gap using real-world data 
      Elderly people with T2D are often under-represented in RCTs, despite shouldering a 
disproportionate onus of T2D and consumption of prescribed medicines and therapies, limiting 
treatments' generalizability, effectiveness, and safety (186). This evidence gap hinders clinical 
decision-making for elderly patients, as the risks and benefits of treatment are unclear (26). 
Treatment of elderly patients with T2D is challenging because of the high prevalence of 
comorbidities, the use of polypharmacy, overtreatment, frailty, and age-related reduction in 
pancreatic islet function. Safety is therefore an important consideration for treatment, 
especially the avoidance of iatrogenic hypoglycemia which occurs frequently in elderly patients 
and can have severe consequences (187). Yet, there are no clinical practice guidelines that 
address the appropriateness of polypharmacy among the whole of the elderly adult population 
registering T2D therapeutic regimens; equally, there is a rarity of RCTs examining the health-
related outcomes associated with the use of polypharmacy in this population (188).  
      Despite the strong evidence of harms for certain types of medicines classes outweighing 
their benefits- as is the case for benzodiazepines or psychotropic medicines - there is an 
absence of strong evidence supporting the benefit-risk assessment of important classes, such as 
for anti-diabetic medicines (189). Moreover, the deprescribing considerations developed by the 
clinical practice guidelines for the management of elderly people with T2D are opaque and 
varied due to uncertainty originating in the lack of data from routine clinical practice (190). Real-
world data plays an important role in the evaluation of short- and long-term medicines’ safety 
through the evaluation of polypharmacy risks. These can range from drug-drug interactions, 
potentially inappropriate medicines influencing patients’ health-related quality of life in clinical 
practice for the elderly populations with T2D, to other outcomes including the risk of disease 
complications, hospitalization, and mortality (191). 
      Real-world data can also be used to assess the effectiveness of therapy in elderly people 
with T2D and to understand how diabetes therapy intensification can add the risk of severe 
hypoglycemia, and higher therapy cost through overtreatment (192). Clinical guidelines are 
mostly based on a single disease, with little attention paid to how such guidelines overlap or 
conflict with each other. For older people with multiple conditions, applying multiple sets of 
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      RCTs and regulatory approval processes focus on whether medicines work under ideal 
conditions. They may not provide enough information on how well the drug works under 
real‐world conditions, such as in the context of polypharmacy amongst the elderly patient 
populations, which limits the detection of drug-drug interactions and adverse drug reactions 
(193). Real-world studies are increasing the amount of  information which healthcare providers 
can use for clinical decision‐making by adding information that is not collected as part of RCTs, 
such as benefit-risk in underrepresented elderly people with T2D with several comorbidities 
and on polypharmacy (194). 
      In the era of real-world data, elderly people with T2D on polypharmacy are one of the 
patients’ groups in the greatest need of personalized medication therapy in routine clinical 
practice. Individual differences in drug response are wide-ranging and difficult to predict in this 
group. For these patients, it is clear that “one size does not fit all” (195). RCTs frequently assess a 
single distinguished intervention in a specific point in time and setting. They have limited 
possibility to investigate the complex treatments which are common in real life, such as 
polypharmacy and/or overtreatment, especially in the complex elderly population with T2D and 
comorbid conditions (196). Because of the ethical and feasibility reasons preventing the RCTs, 
one way forward might be to use a translational design with integration of clinical and 
epidemiological research to improve medication strategies for the T2D elderly population with 
polypharmacy and overtreatment (148). 
      Optimal management of T2D in elderly people who are not always included in RCTs 
currently represents a real challenge for the clinicians. The optimal glycemic target to achieve 
for elderly diabetic patients is still a point of contention in the presence of several factors such 
as frailty, limited life expectancy, falls, dementia, and risks from polypharmacy and 
overtreatment. More studies are required to provide strong evidence for the assessment of 
benefit and harm of polypharmacy, and equally, for overtreatment. More studies are required 
to provide strong evidence for the assessment of benefit and harm of polypharmacy and 
overtreatment derived from real-world observational studies may differ from the experienced 
by elderly people with T2D.  
      Polypharmacy is criticized for being a concept that is inherently too general and imprecise. 
In clinical routine practice, polypharmacy raises concerns, given that the net effects of multiple 
medicine use are unpredictable and can be harmful to an already impaired older adult with 
T2D, organ failure, and functional decline. The topic of polypharmacy and overtreatment 
research requires new directions to gain more robust evidence. This includes observational 
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studies and translational research, which requires interdisciplinary collaboration from both 
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Supplementary Tables  
Supplementary Table 1 Assessment of risk of bias for the randomized controlled trials concerning 
polypharmacy 



















Quality assessment  
Barnett et al. 2013 (167) Low risk  Low risk  Low risk  Unclear risk  Low risk  Low risk  Low risk  Good quality  
Strain et al. 2017 (168) Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Good quality  
Vanassche et al. 2018 
(169) 
Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Good quality  
 
Supplementary Table 2 Assessment of risk of bias for the randomized controlled trials concerning 
overtreatment 



















Quality assessment  
VA CSDM trial (170) Low risk  Unclear risk  Unclear risk  Unclear risk  Low risk  Low risk  Unclear 
risk  
Poor quality  
Proactive trial (171) Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Unclear 
risk  
Good quality  
ACCORD trial (172) Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Good quality  
ADVANCE  trial (173) Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Low risk  Good quality  
VADT trial (174) Low risk  Low risk  High risk  Unclear risk  Low risk  Low risk  Low risk  Fair quality  
HEART2D trial (175) Low risk Low risk  High risk  Low risk  Low risk  Low risk  Unclear 
risk  
Fair quality  
IDA trial (176) low risk Unclear risk  Unclear risk  Unclear risk  Low risk  Low risk  Unclear 
risk  
Poor quality  
JEDI trial (177) Low risk  Unclear risk  High risk High risk  Low risk  Low risk  Unclear 
risk  
Poor quality  
VA CSDM: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes, PROactive: Prospective Pioglitazone 
Clinical Trial In Macrovascular Events, ACCORD: The Action to Control Cardiovascular Risk in Diabetes, ADVANCE: Action in Diabetes and 
Vascular Disease Preterax and Diamicron MR Controlled Evaluation, VADT: Veterans Affairs Diabetes Trial, HEART2D: Effects of prandial 
versus fasting glycemia on cardiovascular outcomes in type 2 diabetes, IDA: Insulin Diabetes Angioplasty study, JEDI: Japanese Elderly 
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      As life expectancy continues to increase, so does the number of elderly people with 
diabetes, with more than 90% of people aged over 65 diagnosed with type 2 (T2D). Treatment 
of elderly people with T2D has its unique challenges, because of the high prevalence of 
comorbidities, polypharmacy, overtreatment, frailty, and other age-related syndromes. There is 
also the further burden of associated chronic conditions and disease-related complications, 
placing additional and often competing demands on T2D management.  
      The literature relating to polypharmacy and overtreatment has been expanded over recent 
decades. Despite this progress and its growing, the data relating to the spectrum of 
polypharmacy and overtreatment is conflicting in what regards elderly people aged 65 years or 
more with T2D. The concepts of polypharmacy and overtreatment are not clearly defined 
themselves, which inhibits the understanding of their impact on benefit-risk assessment of 
treatment in this population whose needs ultimately demand the restructuring of routine 
clinical practice. 
      This thesis is divided into three chapters. Chapter 1 introduces the major clinical challenges 
in elderly people with T2D and addresses the rationale behind the need to investigate the 
impact of polypharmacy and overtreatment in routine clinical practice Chapter 2 conducts a 
systematic review and meta-analysis of observational, cohort and cross-sectional design 
studies, and is followed by three observational, cross-sectional design studies. The latter 
implements data which include the criteria of being older adults (aged of 65 years old or more) 
with T2D. 
      Chapter 2.1 presents a brief description of research methods. Chapter 2.2 investigates the 
global view on the impact of polypharmacy on major clinical outcomes by systematically 
reviewing the available literature and critically appraising the available evidence through meta-
analysis. 
      Chapter 2.3 examines the prevalence of polypharmacy and describes the socio-demographic 
profile, identifying and addressing the potentially serious clinically relevant drug-drug 
interactions, and potentially inappropriate medicines. It then determines the impact of 
polypharmacy, potentially serious clinically relevant drug-drug interaction, and potentially 
inappropriate medicines on health-related quality of life using data from nationwide, 
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      Chapter 2.4 replicates this framework, determining the impact of polypharmacy, potentially 
serious clinically relevant drug-drug interaction and potentially inappropriate medicines on 
glycemic control and kidney function using data from the administrative database of the 
Portuguese Diabetes Association (APDP). 
     Chapter 2.5  investigates the prevalence, characteristics, and factors associated with 
potential overtreatment and undertreatment for older people with T2D, using the data from 
administrative database of the Portuguese Diabetes Association (APDP).  
      Chapter 3 encompass a general discussion where results of studies conducted are 
summarized and discussed as well as future recommendations on optimizing polypharmacy and 
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       This chapter provides the general outline of the research methodology that was used to 
answer the research questions, including study designs, the settings where each study took 
place, the participants selected to be included, the data collected, and the ethical obligation 
required. The specific data analysis and outcomes are described in detail in the methods section 
of each study conducted. 
2.1.1 Research designs  
      The research conducted using a systematic review of cross-sectional and cohort designs with 
meta-analysis of cohort designs, followed by three studies with cross-sectional design. The 
research designs, main outcomes, and settings (databases) are presented in Table 1. 
Table 1 Research designs, main outcomes, and settings (databases)  
Study Number  I II III IV 
Design Systematic review and meta-
analysis 
Cross-sectional Cross-sectional Cross-sectional 
Main outcomes Association between 
polypharmacy and all-cause 
mortality, myocardial 





clinically relevant DDIs 
and PIMs with health-






DDIs and PIMs with 
glycemic control, 





























Page | 84  
 
2.1.2 Research settings (Databases) 
       The description of the three research settings (databases) is described in detail in Table 2 
Table 2 Research settings 
Databases PubMed/Medline, 
ScienceDirect, and Web of 
Science 
MOMI (Modelo Observacional de 
Monitorizacao intensive) 
APDP (Associação Protectora dos 
Diabéticos de Portugal) 









• Pharmacy-based database of 
nationwide, intensive 
monitoring study that 
monitored a specific glucose 
lowering drugs (GLDs), 
conducted between 15th 
November 2014 and 30th 
November 2015 in Portugal 
(1)(2)(3) 
• MOMI Conducted at the 
Centre for Health, Evaluation 
& Research (CEFAR) of the 
National Association of 
Pharmacies (ANF) and was 
fully funded by ANF. 
• 670 community pharmacies 
(33.9% of total Portuguese 
community pharmacies), and 
1328 participants (760 of 
these participants aged ≥ 65 
years) included in MOMI. 
• Population consisted of T2D 
adult patients, first users 
(defined as who did not take 
the inception monitored drug 
• Administrative and 
consultation database of the 
Portuguese Diabetes 
Association (APDP). 
• APDP has been founded in 
1926, being the oldest 
member of the International 
Diabetes Federation (IDF). 
• APDP aids in the different 




and pathology) to 
approximately 6,000 
diabetics per year, from 
which 1,600 are new 
individuals. 
• These individuals usually  
sent by the Health Centers of 
the National Health Services 
and by practitioners of other 
institutions which collaborate 
with the Association.  
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within 6 months prior to 
recruitment, as self-reported 
by the patients) of the 
recently launched GLDs that 
were reimbursed in Portugal 
at the time of enrolment: 
dipeptidyl peptidase-4 
inhibitors (DPP-4) (sitagliptin, 
vildagliptin, saxagliptin and 
linagliptin) alone or in fixed-
dose combination with 
metformin, glucagon-like 
peptide-1 (GLP-1) (liraglutide 
and exenatide) or sodium-
glucose co-transporter 2 
inhibitors SGLT-2 
(dapagliflozin), cohort was 
divided into two subgroups: 
incident new users 
(participants who were using 
one of the monitored drugs 
for the first time and had no 
current or prior experience 
with DPP-4, GLP-1 or SGLT2) 
and prevalent new users 
(participants who had 
previously used/current use 
at least one drug of the 
monitored treatment classes: 
DPP-4, GLP-1 or SGLT2, but 
not the inception GLD) 
• MOMI data collected through  
1) baseline questionnaire by 
trained pharmacist during a 
• The APDP database regulated 
by APDPSoft, which is a 
software developed since 
1999, accompanies the 
evolution of the services 
provided by the APDP. 
Currently, this software 
supports and monitors 
several valences, especially in 
terms of clinical data file, 
markings management, 
laboratory parameters, 
invoicing the health 
subsystems, integration of 
numerous diagnosis 
equipment as well as an 
effective liaison with the 
electronic services of the 
Ministry of Health in Portugal 
(6–8). 
• The APDP database does not 
contain mortality, 
hypoglycemic episodes, 
frailty score, emergency 
visits, or hospitalization 
records. 
• APDP database did not 
reported the patients’’ signs 
or symptoms, medicines 
dosage form, concentration, 
frequency, method of 
administration, and 
medicines use history. 
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structured face-to-face 
interview; 2) telephone 
questionnaires and 3) 
pharmacy records. 
• MOMI database included 
socio-demographic, 
anthropometrics, age at time 
of T2D diagnosis, usual 
diabetes outpatient clinical 
care, co-morbidities and 
diabetes related 
conditions/complications  
and concomitant therapy and 
T2D treatment, baseline and 
6 months follow up data of 
health-related quality of life, 
data regarding GLDs adverse 
drug events and 
hypoglycemic episodes at 2 
weeks, 3 months and 6 
months, and data regarding 
persistence and adherence of 
GLDs. 
• All concurrent diseases were 
classified using the 
International Statistical 
Classification of Diseases and 
Related Health Problems 
10th Revision (ICD-10),  and 
all co-medication therapy 
and T2DM treatment were 
coded according to the 
Anatomic Therapeutic 
• The percentages of missing 
data related to some 
outcome variables are 
calculated. Multiple  
imputation procedure in SAS 
statistical software used to 
impute the missing data. 
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Classification (ATC) (4)(5) 
• Participants’ informed 
written consents and 
questionnaires data were 
stored in specific designed 
Microsoft Office Access® 
databases 
• All errors were appropriately 
corrected in the database, 
based on information written 
on the questionnaires. The 
percentage of missing data 
was calculated.  
• The data collected in MOMI 
did not include any patients’ 
signs, symptoms, or lab 
results, as well as the 
reported outcomes except 
for quality of life, only related 
to the specific GLDs. 
 
2.1.3 Research participants  
      Eligible participants included if they are: elderly people (aged 65 years or more), diagnosed 
with T2D, and have medical history/medicines records available. 
2.1.4 Data collection  
      In the (Chapter 2.2), the data collected from each study included author name, publication 
year, study design, study setting, study location, study outcomes, the definition of 
Polypharmacy, subjects’ demographic data, sample size, study duration and the statistical 
 
 
Page | 88  
 
model used. Individual data for the prevalence of polypharmacy were derived either directly or 
indirectly from each study. Polypharmacy defined as the use of a discrete definition and 
categorical thresholds (9). Studies were identified by searching electronic databases of 
PubMed/Medline, ScienceDirect, and Web of Science, through April 2019. No limit was set for 
the study setting or time frame. No limitation was considered for the date of acceptance or 
publication. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
guidelines were used to standardize the conduct and reporting of this systematic review and 
meta-analysis (10).  
      In the (Chapter 2.3), the data collected were sociodemographic data, body mass index 
(BMI), clinical care setting, T2D treatment and, T2D related complications, co-morbidities, and 
chronic conditions concomitant therapy. All elderly people with T2D from the MOMI study are 
included (N=670). Polypharmacy was defined as the use of five or more medicines (11). The 
medicines used checked for the potentially serious clinically relevant drug-drug interactions 
using IBM Micromedex drug interaction Platform (IBM® Corporation, 2019) (12). Potentially 
inappropriate medicines identified using Screening Tool of Older Persons' Prescriptions 
(STOPP) criteria version 2, the final list included 80 STOPP criteria, was agreed after two rounds 
of Delphi validation, which arranged according to the physiological systems of the body for ease 
of use and rapid application (13). 
      The quality of life was measured using the three-level EuroQol five-dimensional (EuroQol 5-
D-3L) questionnaire. The EQ-5D encompasses five dimensions influencing health (mobility, self-
care, usual activities, pain/discomfort, anxiety/depression) each with three levels of functioning 
(first level; no problem, second level; some problems, third level; severe problems) (14). The 
summary scores were computed to Portuguese preference weighted EQ-5D index scores using 
Portuguese values set. After that, the study participants finished the EQ-5D visual analog a scale 
(VAS). In the VAS, the patients evaluated their current health state on scale between zero 
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(worst possible health state) to one hundred (best possible health state), the high scores index 
together high VAS suggest best health state (15). 
      In the (Chapter 2.4), Socio-demographic data, BMI, diabetes duration, diabetes-related 
complications, last lab data including glycated hemoglobin (HbA1c), fasting blood glucose (FBG), 
creatinine, and last reading of systolic (SBP) and diastolic blood pressure (DBP), medicines used 
for treatment of both T2D and associated comorbidities were all collected. Participants were 
considered hypertensive if they have blood pressure ≥ 140/90 mmHg or they are on anti-
hypertensive medicines. For kidney function, we calculated the estimated glomerular filtration 
rate (eGFR) based on participant characteristics and serum creatinine using Modification of Diet 
in Renal Disease Study equation (MDRD-GFR)(16). Glycemic control refers to the typical levels of 
blood sugar (glucose) in a person with diabetes evaluated using HbA1c (17). The study included 
all the elderly people with T2D who registered during the year of 2018 at APDP (N=444). 
Polypharmacy was defined as the use of five or more medicines (11). The medicines used were 
analysed to identify the potentially serious clinically relevant drug-drug interactions using IBM 
Micromedex Platform (IBM® Corporation 2019) (12). Potentially inappropriate medicines were 
identified using STOPP criteria version 2 (13).  
      In the (Chapter 2.5), Socio-demographic data, BMI, diabetes duration, diabetes 
complications, last lab results including HbA1c, FBG, low-density lipoprotein (LDL), high-density 
lipoprotein (HDL), triglyceride (TG), total cholesterol (TC), creatinine, sodium, and potassium), 
as well as the last blood pressure record including both SBP and DBP, medicines used for the 
treatment of both T2D and associated comorbidities were retrieved from the administrative 
database of APDP. The study included all the elderly people with T2D who registered during the 
year of 2018 at APDP (N=444). Participants were considered hypertensive if they have blood 
pressure ≥ 140/90 mmHg or they were on anti-hypertensive medicines. For kidney function, we 
calculated the eGFR based on participant characteristics and serum creatinine using the 
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modification of diet in renal disease study equation (MDRD-GFR) (16). Polypharmacy was defined 
as the use of five or more medicines (11). 
      According to the action to control cardiovascular risk in diabetes (ACCORD) trial (18) a review 
by Lipska and colleagues (19), and the recommendations from European diabetes working party 
for older people with T2D clinical guideline (20), the majority of older people with T2D aged 65 
years old or more, the harm from HbA1c target lower than 7.5% or higher than 9% are likely to 
outweigh the benefit. Therefore, the potential overtreatment defined as HbA1c target of 
(<7.5%), appropriately on target HbA1c of (≥7.5%-≤9%), and potential undertreatment HbA1c 
target of (>9%) and were on treatment with glucose-lowering medicines in mono or 
combination therapy.  
2.1.5 Research statistical analysis  
      OpenMeta[Analyst] a cross-platform software for meta-analysis was used (21). All other 
statistical analysis performed using SAS software (22). 
2.1.6 Ethical obligations  
      The ethical approval for the original MOMI study (Modelo Observacional de Monitorizacao 
intensiva) was obtained from the Portuguese Data Protection Authority (5339/2014) and by the 
Ethics Committee of the Institute of Public Health of the University of Porto (CE14021) and was 
conducted in accordance with the ethical principles stated in the Declaration of Helsinki. A 
written, signed informed consent form was obtained from all participants prior to initiation of 
any study procedures. This study was registered in the European Network of Centers for 
Pharmacoepidemiology and Pharmacovigilance E-register of studies (ENCEPP/SDPP/8433). In 
addition, Ethical approval was also obtained from the Portuguese Diabetes Association (APDP) 
ethics committee for health, official number (70/2019) to use the data of elderly people with 
type 2 diabetes from in their administrative database.  
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2.2.1 Abstract  
Aim To summarize the existing literature concerning the association between polypharmacy 
and adverse health consequences in elderly patients with type 2 diabetes mellitus. 
Methods We searched four literature databases (PubMed/Medline, ScienceDirect and Web of 
Science) through April 2019. We included all studies that addressed the association between 
polypharmacy and all-cause of mortality, glycemic control, macrovacular complications, 
hospitalization, potentially inappropriate medicines, drug-drug interactions and fall. A statistical 
program OpenMeta [Analyst] was used. The pooled odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated with a random effects model. I² statistics was performed to 
assess heterogeneity. 
Results Out of sixteen studies, three studies were used for meta-analysis. A statistically 
significant association was found between polypharmacy and all-cause mortality (OR= 1.622, 
95% CI (1.606-1.637) P<0.001), and myocardial infarction (OR=1.962, 95% CI (1.942-1.982), 
P<0.001. Non-statistically significant association with evidence of moderate heterogeneity was 
found between polypharmacy and stroke (OR=1.335; 95% CI (0.532-3.346), P=0.538, I²=45%), 
and hospitalization (OR= 1.723; 95% CI (0.983-3.021), P=0.057, I²=57%). 
Conclusions Pooled risk estimates reveal that polypharmacy is associated with increased all-
cause mortality, macrovacular complications and hospitalization using categorical definitions. 
These findings assert the need for interventions that optimize the balance of benefits and 
harms in medicines prescribing. 
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2.2.2 Introduction  
      Type 2 diabetes mellitus is highly prevalent chronic condition among adults, being estimated 
that more than 500 million people diagnosed in 2018 worldwide with gradual elevation with 
aging and life expectancy (1). Elderly patients are usually associated with more chronic 
conditions such as hypertension, dyslipidemia, coronary heart disease, and chronic kidney 
disease (2)(3). Polypharmacy appears to be highly prevalent and important lineament. A cross-
sectional study in Canada found that (48%) of elderly frail patients with type 2 diabetes mellitus 
were taking ≥ 9 medications daily (4). Another study in Greece found that (43.4%) were using ≥ 7 
medications daily (5). Since multiple medications are needed to control the disease and 
associated comorbid conditions, those patients often require to take more than dozen of 
different classes of medications (6). 
      Polypharmacy can be associated with adverse outcomes, such as increase the risk of 
hypoglycemia, decline in medication adherence, risk of drug-drug interactions, and probability 
of worsen quality of life which can result in higher risk of hospitalization, mortality rate and 
healthcare costs (7). Management of those patients is a complex process due to patients 
characteristics, which require individualize medication regimen to balance the pressing to 
control the diabetes as well as other comorbid conditions and/or complications and minimizing 
and/or preventing medications related risks (8). 
      The international diabetes federation (IDF) guideline recommends to consider reducing 
polypharmacy, suggesting to perform comprehensive medication review, consider 
deprescribing when its safe and possible, dose titration, identify adherence difficulties, apply 
medications lists such as Beer’s or (STOPP) and screening tool to alert to right treatment 
(START), implementation of non-pharmacological options, providing individualized medication 
education, and involve family/caregivers in the care plan (8).  On the other hand, the American 
diabetes association guideline recommends the avoidance of polypharmacy and undergoing 
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deintensification of complex regimen whenever possible, taking into consideration special 
attention while prescribing and monitoring of pharmacological therapies, medications costs and 
presence of other comorbidities (9)(10).  
      When researching the literature on adverse health consequences of polypharmacy, it was 
noteworthy that there is no available synthesis of data examining multiple patient outcomes. It 
is therefore important to examine the available literature to determine the risk of adverse 
health consequences from polypharmacy among those patients (8). Greater knowledge about 
this problem is important, and early interventions should be designed and implemented (9). 
Aim 
      To summarize the existing literature concerning the association between Polypharmacy and 
adverse health consequences in elderly type 2 diabetes mellitus patients. 
2.2.3 Methods 
      The preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
guidelines were used to standardize the conduct and reporting of this systematic review and 
meta-analysis (11).  
Study Characteristics 
      Observational studies (cross-sectional studies, cohort studies, case series, and case-control 
studies), interventional studies (randomized controlled trials, and quasi-experimental studies) 
designs were considered. Only studies published in English were included.  
Types of Participants 
      Participants who were aged ≥ 65 years old and diagnosed with type 2 diabetes mellitus. We 
included studies that defined polypharmacy as a discrete definition and studies using 
categorical thresholds (12)(13). 
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Primary outcomes  
      All-cause of mortality (risk of death) 
      Glycemic control, for the purpose of the this review we considered the following categories 
of elderly patients’ glycemic target according to IDF global guideline for managing older people 
with type 2 diabetes mellitus. (A) Functionally independent (HbA1c target is 7.0-7.5%), sub-
category (A) frail (HbA1c target up to 8.5%). (B) Functionally dependent (HbA1c target is 7.0-
8.0%), sub-category (B) dementia (HbA1c target up to 8.5%) (8). 
      Macrovascular complications which including coronary artery diseases (CAD), heart failure 
(HF), cerebrovascular disease (CVD) and stroke (10).  
      Hospitalization or hospital Re-admission (including all‐cause hospital admissions and 
unplanned re-hospitalization) (14). 
Secondary outcomes 
      Studies were reported the association between polypharmacy and potentially inappropriate 
medicines (15), drug–drug interaction (16), and fall or fall risk (17). 
Information Sources  
     Studies were identified by searching electronic databases of PubMed/Medline, 
ScienceDirect, and Web of Science, through April 2019. No limit was set for the study setting or 
time frame. No limitation was considered for date of acceptance or publication.  
Search Strategy   
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Study Selection  
     All titles and abstracts identified in the databases above were screened for eligibility by one 
author (L.M). Two review authors independently evaluated full texts of all potentially eligible 
studies for appropriateness for inclusion without prior consideration of the results (AP.M, L.M). 
Any disagreements were resolved by discussion or feedback from a third and fourth authors (JF. 
R, C.T). 
Data Item 
      The following information was extracted: author name, publication year, study design, study 
setting, study location, study outcomes, definition of Polypharmacy, participants demographic 
data: age groups (if applicable), gender, sample size, study duration and statistical model used. 
Quality (Risk of Bias) assessment for the individual studies 
       Two review authors independently assessed the quality for each study. Any disagreements 
were resolved by discussion or a third author (JF. R). We used the Newcastle-Ottawa Scale 
(NOS) for observational cohort and modified version for cross-sectional studies which was used 
in previous studies (18). Using a point” Star” system to judge on the three broad perspectives, a 
maximum of one ‘star’ for each h item within the ‘Selection’ and ‘Exposure/Outcome’ 
categories; maximum of two ‘stars’ for ‘Comparability’ for cohort studies.  
       For the modified tool for cross-sectional studies, a maximum five stars for the selection 
category, two stars for the comparability category and three stars for outcome category. The 
scale scores varied depending on the study design: for cross-sectional studies it ranged from 0 
(lowest grade) to 9 (highest grade) and for cohort studies from 0 (lowest grade) to 10 (highest 
grade), Studies with scores above the median were classified as good quality studies, for cross-
sectional studies > 5 and for cohort studies > 6. 
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Data Synthesis   
      Individual data for prevalence of polypharmacy were derived either directly or indirectly 
from  each study. To address the association of polypharmacy with adverse health 
consequences, we calculated the odd ratio (OR) and their respective 95% confidence intervals, 
and P value was set to be < 0.05. Meta-analysis was implemented when there were two or 
more studies with same design identified the same outcome using random-effect model, and I² 
test was used to identify the heterogeneity. OpenMeta[Analyst] a cross-platform software for 
meta-analysis was used (19). 
2.2.4 Results  
Study selection  
      The search of the electronic databases provided a total of 1859 citations. After screening the 
titles and abstracts for duplicates, 1823 were remained. Of these, 1663 were removed due to 
either the full text copy was not available, or the papers did not publish in English. The full texts 
of the remaining 160 citations were examined in more detail. Of these, 143 studies did not 
meet the inclusion criteria. Finally, sixteen studies were included in the systematic review and 
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The PRISMA Flow Diagram 
 
Records identified through 
database searching 



















Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 1,823) 
Records screened 
(n = 1,823) 
Records excluded 
(n = 1,663) 
Full-text articles assessed 
for eligibility 
(n = 160) 
Full-text articles excluded, with 
reasons 
(n = 144) 
 
• Seminar (1) 
• Clinical Consultation (1) 
• Commentary (1) 
• Editorial (1) 
• Report (2) 
• Pilot Study (1) 
• Review (25) 
• No Patient Involved (1) 
• Diabetes type unspecified 
(62) 
• No Polypharmacy 
description (35) 
• No elderly patients 
included (2) 




Studies included in 
qualitative synthesis 
(n = 0) 
Studies included in 
quantitative synthesis  
(n = 16) 
  
Figure 2 The PRISMA flow diagram for the included studies 
      The studies publication date was 2018 (n=1), 2017 (n=1), 2016 (n=3), 2015 (n=5), 2013 (n=3), 
2012 (n=2), and 2010 (n=1). The studies duration was between 4 months to 10 years. The 
studies conducted mainly in USA (n=7), Australia (n=2), Malaysia (n=2), UK (n=1), Chile (n=1), 
Brazil (n=1), Italy (n=1), and Japan (n=1). 
      The total number of patients included in this review was 1,205,821, in which 50.22% of 
these were females. 1,179,325 (97.80% of the total number of patients) were elderly. The most 
common definition of polypharmacy was using five or more medications found in 50% of the 
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Table 1  Characteristics of the Included Studies 
Source  Study 
location 
Study Setting  Sample 
size 
  Age 
group  
      (%)   
Female N (%) Study 
Frame 
  
Study outcomes  Statistical 
analysis   
 Definition of 
PolyPharmacy  
Cohort Studies   
Yashkin, 
2018  
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reference antibiotic 





Using of five or 
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(100) 




















10 medicines)  
Huri, 
2013 
Malaysia  tertiary hospital 
database  
208 ≥ 65 
(43.3) 
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Beer’s criteria  
Chi-squared 
test 
Using six or 
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delivery system  hypoglycemia  
Cross-Sectional Studies  
Araújo, 
2013  














capillary glucose  
non-
parametric x² 
Using five or 
more medicines  
Caughey, 
2010  














medicines  using 




Using five or 
more medicines  
Huri. 
2015 
Malaysia  Premier 
teaching 
hospital 
242 ≥ 65 
(56.2) 














Using five or 
more medicines  
Weiss, 
2012  


















Using five or 
more medicines  
Noale, 
2016 
Italy  diabetes centers 1342 ≥ 65 
(100) 










Using five or 









168 ≥ 65 
(100) 




Risk factors of falls  Multiple 
logistic 
regression 
Using more than 
five medicines 
 
      The review found that between 26% to 48.7% of elderly diabetes type 2 patients had HbA1c 
between (8.0% to ≥ 8.5%) despite receiving treatment intensification. Median time to 
treatment intensification was shorter in those on polypharmacy (18.5 months) than those 
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      The prevalence of potentially inappropriate (PIMs) medicines was varied among the studies, 
ranging from 22.7% to 79%  using Beer’s and 48% using STOPP criteria. The most common 
identified PIMs were using of metformin in elderly patients with type 2 diabetes mellitus aged ≥ 
85 years old, benzodiazepines, tricyclic anti-depressants, aspirin, non-steroidal anti-
inflammatory drugs (NSAIDs) and beta-blockers. Polypharmacy was associated with presence of 
PIMs (23)(24)(25). 
      Severe hypoglycemia was reported from the interaction between sulfonylureas (glyburide 
and glipizide) with co-trimoxazole antibiotic more in patients on polypharmacy. Interactions 
between oral hypoglycemic agents (metformin, glyburide, metformin plus glyburide and 
acarbose) with hydrochlorothiazide, furosemide, angiotensin-converting enzyme inhibitors 
(ACEIs), simvastatin and prednisolone were also reported (26)(27). No association was reported 
between fall or fall risk and polypharmacy (28) 
Risk of bias assessment  
      Assessment of risk of bias is found in Table 2  





















of interest was 
not present at 
start of study 
Comparability 
of cohorts on 
the basis of 
















Yashkin 2017  + + + + + + + + 8 
Tan (2015)  + + + + ++ +   7 
Caughey 
(2017)  
+ + + + ++ +   7 
Hamada (2016)  + + + + + + +  7 
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Patel (2012)  + + + + + + + + 8 
Huri (2013) + + +  + + +   6 
Ajmera (2015)  + + + + ++ + + + 9 
Raval (2015)  + + + + + + + + 8 
Arellano (2016)  + + + + + +   6 
Lipska (2013)  + + + + + +   6 




















+ + + + + ++ + 8 
Caughey, 
2010  
+   + + ++  5 
Huri, 2015  + + + + + ++ + 8 
Weiss, 
2012 
+ + + + + ++ + 8 
Noale, 
2016  
+ + + + + ++ + 8 
Chiba, 
2015 
+  + + + ++ + 7 
 
Table 3 summarizes the estimated ORs (95% CIs) obtained from each study for the association 
between polypharmacy with all-cause mortality, myocardial infarction, stroke, and 
hospitalization. 
Table 3  ORs and 95% CIs for the association between polypharmacy with all-cause mortality, myocardial 
infarction, stroke, and hospitalization 
Outcome  Study reference  Study design  Odd ratio (95% CI) 
All-cause 
mortality 
Yashkin et al. 2018 Cohort  1.622 (1.606 to 1.637) 
Patel et al. 2012 Cohort 1.169 (0.468 to 2.918) 
Noale et al. 2016 Cross-sectional  4.569 (3.056 to 6.829) 
Myocardial 
infarction  
Yashkin et al. 2018 Cohort   1.962 (1.942 to 1.982) 
Patel et al. 2012 Cohort  1.544 (0.526 to 4.596) 
Noale et al. 2016 Cross-sectional 4.67 (3.01 to 7.25) 
Stroke  Yashkin et al. 2018 Cohort  1.718 (1.701 to 1.735) 
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Patel et al. 2012 Cohort  0.559 (0.109 to 2.860) 
Noale et al. 2016 Cross-sectional  1.56 (0.96 to 2.52) 
Hospitalization  Raval et al. 2015 Cohort  1.438 (1.371 to 1.509) 
Patel et al. 2012 Cohort  2.714 (1.197 to 6.149) 
 
      The association between polypharmacy and all-cause of mortality was reported in two 
cohort studies (29)(30) and one cross-sectional study (31). When combining the estimated effects 
based on cohort studies, polypharmacy was significantly associated with all-cause mortality 
(pooled OR, 1.622; 95% CI 1.606 to 1.637, P<0.001, I²=0%) figure 2. Including the cross-sectional 
study, a non-statistically significant association with evidence of high heterogeneity was 
observed (pooled OR, 2.151; 95% CI 0.971 to 4.765, P=0.059, I²=92%).  
Figure 3. Meta-analysis of cohort studies of polypharmacy and all-cause mortality, ordered by date of 
publication 














cause   
mortality 
risk  in 
control 
group  









Yashkin, 2018 358,456 445,222 358,456 499,165 1.622 1.606 1.637 99.989 
Patel, 2012 16 105 8 60 1.169 0.468 2.918 0.011 




Tau²    Q (DF=1)     I²     Het. P value  
0.000   0.493       0%      0.483      
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      The association between polypharmacy and myocardial infarction was reported in two 
cohort (29)(30) and one cross-sectional study (31). When combining the estimated effects based 
on cohort studies, polypharmacy was significantly associated with myocardial infarction (pooled 
OR, 1.962; 95% CI 1.942 to 1.982, P<0.001, I²=0%) figure 3. Including the cross-sectional study, 
a significant association was also observed, with evidence of level of heterogeneity (pooled OR, 
2.790; 95% CI 1.140 to 6.828, P=0.025, I²=94%).  
Figure 4 Meta-analysis of cohort studies of polypharmacy and MI, ordered by date of publication 











had MI in 
control 
group  













339,212 412,534 339,212 483,081 1.962 1.942 1.982 99.99 
Patel, 
2012 
13 105 5 60 1.544 0.526 4.596 0.009 
                                                                 
 
      Data on the association between polypharmacy and stroke was reported in two cohort 
(29)(30) and one cross-sectional study (31). When combining the estimated effects based on 
cohort studies, a non-significant association between polypharmacy and stroke was observed 
(pooled OR, 1.335; 95% CI 0.532 to 3.346, P=0.538, I²=45%) figure 4. Including the cross-
sectional study, a significant association was observed, with evidence of high level of 
heterogeneity (pooled OR, 1.929; 95% CI 1.164 to 3.199, P=0.011, I²=76%). 
Heterogeneity  
 Tau²      Q (DF=1)     I²    Het. P value 
 0.000    0.177         0%    P=0.674 
Overall effect (OR=1.962, 95% CI (1.942 to 1.982), 
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Figure 5 Meta-analysis of cohort studies of polypharmacy and stroke, ordered by date of publication 
Study No of subjects 
had stroke in  
polypharmacy 
group 




No of subjects 
had stroke in 
control group  






Lower       
95% CI 





341,610 420,981 341,610 477,977 1.718 1.701 1.735 77.508 
Patel, 2012 3 105 3 60 0.559 0.109 2.860 22.492 
                                                                                
 
      Data regarding the association between polypharmacy and hospitalization was reported in 
two cohort studies (30)(32). When combining the estimated effects of these studies, a non-
sgnificnat association between polypharmacy and hospitalization with moderate evidence of 
heterogenity was observed (pooled OR, 1.723; 95% CI 0.983 to 3.021, P=0.057, I²=57%)  figure 5     
Figure 5 Meta-analysis of cohort studies of polypharmacy and hospitalization, ordered by date of publication 




























2222 12,653 24,488 189,843 1.438  1.371 1.509 71.547 
Patel, 
2012 
34 105 9 60 2.714 1.197 6.149 28.453 
Heterogeneity  
Tau^2    Q (DF=1)     I²     Het. P value 
0.284     1.818       45%    0.178 
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2.2.5 Discussion  
      The increase in categorical threshold from 5 or more medicines was associated with high 
risk of by 62% in all-cause mortality, 96% with myocardial infarction, 33% with stroke and 72% 
with hospitalization. The risk did not increased in dose-dependent manner, which can be 
explained by low number of elderly patients with type 2 diabetes mellitus using 10 or more 
medicines per day (33)(34). These findings were not agreed with previous systematic reviews, 
which found that the association between polypharmacy and mortality (33), as well as dementia 
(35) increased in a dose-dependent patterns when the threshold values for the number of 
medicines defining polypharmacy increased.  
      A meta-analysis of five prospective randomized controlled trials of intensive glucose 
lowering therapy (but not polypharmacy) effect on cardiovascular outcomes and death in 
elderly patients with type 2 diabetes mellitus found that, 17% reduction in events of non-fatal 
MI (OR=0.83, 95% CI (0.75-0.93), 15% reduction in events of coronary heart disease (OR=0.85, 
95% CI (0.77-0.93) and no significant effect on events of stroke (OR=0.93, 95% CI (0.81-1.06) or 
all-cause mortality (OR=1.02, 95% CI (0.87-1.19) (36).  
      The review found between 26% to 48.7% of elderly diabetes mellitus type 2 patients 
received treatment intensification. Despite that, these patients mostly had higher HbA1c value 
between (8.0% to ≥ 8.5%). large real-world observational study of 17493 type 2 diabetes 
Heterogeneity  
Tau^2   Q (DF=1)     I²          Het. P value 
0.114    2.305        57%        0.129 
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mellitus patients, found that treatment intensification was less likely the older the patient, and 
more likely the higher the first HbA1c value, up to an HbA1c threshold of 9% (37) 
      Clinical inertia, which is defined as the failure to initiate or intensify therapy in a timely 
manner according to evidence‐based clinical guidelines, greater comorbidity, long duration of 
diabetes, aging, and higher use of oral hypoglycemic agents can be a key reason for 
uncontrolled hyperglycemia (38). it can be also applied for the failure of clinician to stop or 
reduce therapy no longer needed (reverse clinical inertia) (39). 
      A review found that clinical inertia can be occur at all stages of diabetes treatment. 
Medication non-adherence to glucose lowering medicines may range from 53% to 65% at 1 
year, can be responsible for higher HbA1c values in about 23% of cases (40). 
      Our findings agreed with clinical guidelines for the treatment of older adults with Type 2 
diabetes mellitus in which the HbA1c in those population should be up to 8.5% whenever 
appropriate, treatment intensification should be used at appropriate time with caution 
especially with elderly to avoid the risk of hypoglycemia and other adverse events (38).  
      Polypharmacy was also found associated with risk of potentially inappropriate medicines, 
with prevalence between 22.7% – 79% Beer’s criteria and 48% using STOPP criteria. These 
results in agreement with previous reviews conducted in Europe and United States (41)(42)(43). 
Principle PIMs identified were similar to those found in previous reviews (43)(44). 
      The review did not found any association between polypharmacy and fall or fall risk only in 
one study. Previous review and large cohort study found that older adults with type 2 diabetes 
mellitus are associated with greater risk of falls, especially in insulin-treated patients, without 
measuring the impact of polypharmacy (45)(46).  
      Another large cohort study of type 2 diabetes mellitus found that using four or more (not a 
definition of polypharmacy in the study) can be associated increasing risk of fall, with no 
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specific glucose lowering drug involvement in fall risk. The study revaled that examining the 
relationship between medications and falls would benefit from using formal definition of 
polypharmacy and what mechanisms link polypharmacy to adverse events (47).  
      Even most of studies included in this review were of good quality, these studies are 
observational, and number of medications cannot be assigned to patients, since those who are 
on polypharmacy are associated with adverse health consequence more than those who are 
taking fewer medicines.  
      Therefore, risk of confounding, follow up, and sampling bias cannot be ignored and 
particularly important. However, other types of bias may be present. Presence of these biases 
result in apparent evidence of heterogeneity in the studies used in meta-analysis.  
      Because of concerns regarding confounding and complexity between polypharmacy and 
adverse health outcomes, it is more suggested to conduct randomized controlled trials that 
may provide more definitive solutions regarding to these issues. 
      The meta-analysis has several limitations; the quality of meta-analysis was affected by the 
quality of included studies. Firstly, studies used several definitions of polypharmacy and non-
polypharmacy (for example: in non-polypharmacy definition, patients may be classified as using 
4 or less, 5 or less, less than 13 medicines), based on the definition of polypharmacy. 
      The definition of polypharmacy that most studies used did not provide any information on 
duration, definition of number of medications and if non-prescription medicines were used. 
Moreover, information regarding all comorbid conditions and/or diabetes complications was 
not fully reported, also some studies were excluded patients had specific complications, and 
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      The  number of studies that involved in meta-analysis for assessment of overall effect of the 
association between polypharmacy and adverse health consequences in elderly with type 2 
diabetes melllitus was low; this can be associated with several explanation, little information is 
available in the literature about such associations in those population, most of studies 
evaluated these adverse health consequences did not consider polypharmacy as risk factor. 
      Poor representation of elderly population in clinical trials, even they are more prone to 
adverse effects due to comorbidities and polypharmacy. Moreover, a few large prospective 
cohort studies seek to overcome these limitations from clinical trials which can be considered 
as representative of patients on polypharmacy, but they were limited by either small sample 
size or follow up periods.  
      In addition, studies weighted with high percentage were accounted for the overall effect of 
meta-analysis, as well as using of unadjusted estimates of risk of association with polypharmacy 
can exceeded the adjusted estimates. Many studies were excluded for this review because 
either reported exposure or outcome, were not of interest. 
2.2.6 Conclusion  
      Distinguishing the potential risks of polypharmacy in elderly type 2 diabetes mellitus 
patients is clinically important. Our goal was to summarize the existing knowledge regarding 
this topic, which may reveal support for a statistical association between polypharmacy and 
several adverse health outcomes.  
      Polypharmacy has been and always will be common among those patients due to the need 
to control diabetes and other comorbid conditions. Unfortunately, with this increase in the use 
of multiple medicines may come with an increased risk for negative health outcomes. The 
results of this systematic review were mixed, with some studies demonstrated the association 
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between polypharmacy and adverse health consquences, and other studies failed to find this 
association.  
      This can raise the question of whether polypharmacy is solely a marker of inappropriate 
medicines use, and whether it is also a marker of underprescribing, which may lead to underuse 
of appropriate medicines, and increase the risk of adverse health consquences in those 
population, in addition to Multimorbidity, aging, scarcity of scientific evidence, risk of adverse 
events and economic issues (48). 
      Appropriate monitoring should be implemented, including necessary laboratory testing and 
patient education regarding how to monitor themselves for potential adverse events and what 
to do when they occur. Interventions designed for improvement of medication 
appropriateness, which includes a deprescribing, are generally effective at improving surrogate 
clinical markers, but the effect on long-term outcomes, such as mortality, is not well 
established.  
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Supplementary data  
Search Strategy  
PubMed/Medline  
Search Query 
#11 ("medication errors"[MeSH Terms] OR ("medication"[All Fields] AND 
"errors"[All Fields]) OR "medication errors"[All Fields] OR ("medication"[All 
Fields] AND "error"[All Fields]) OR "medication error"[All Fields]) AND 
("polypharmacy"[MeSH Terms] OR "polypharmacy"[All Fields]) AND "AND 
"[All Fields] AND ("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] 
AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields] OR 
"diabetes"[All Fields] OR "AND "[All Fields] AND ("aged"[MeSH Terms] OR 
"aged"[All Fields] OR "elderly"[All Fields]) 
#10 "Falls"[All Fields] AND "Polypharmacy"[All Fields] AND "diabetes"[All Fields] 
AND "Elderly"[All Fields] 
#9 "Potentially inappropriate medication"[All Fields] AND "Polypharmacy"[All 
Fields] AND "diabetes"[All Fields] AND "Elderly"[All Fields] 
#8 Search Polypharmacy[Title] AND Diabetes[Title] AND type[Title] AND 2[Title] 
AND Medication[Title] AND Adherence[Title] 
#7 Search (("Polypharmacy") AND "Diabetes type 2") AND "Hospitalization" 
#6 Search (("Polypharmacy") AND "Diabetes type 2") AND "Adverse events" 
Schema: all 
#5 Search (("Polypharmacy") AND "Diabetes type 2") AND "Adverse events" 
#4 Search (("Polypharmacy") AND "Diabetes Type 2") AND "Drug-Drug 
Interactions Schema: all 
#3 Search (("Polypharmacy") AND "Diabetes Type 2") AND "Drug-Drug 
Interactions 
#2 Search Polypharmacy[Title] AND Diabetes[Title] AND Type[Title] AND 2[Title] 
AND Glycemic[Title] AND control[Title] 
#1 Search (("Polypharmacy") AND "Diabetes Type 2") AND "Glycemic control" 
 
Science Direct  
"Polypharmacy" AND "Diabetes Type 2" AND "Glycemic Control" OR "Polypharmacy" AND "Diabetes" 
AND "Glycemic control" OR "Polypharmacy" AND "Diabetes Type 2" AND "Drug-Drug Interactions" OR 
"Polypharmacy" AND "Diabetes" AND "Drug-Drug Interactions" OR "Polypharmacy" AND "Diabetes 
Type 2" AND "Adverse event" OR "Polypharmacy" AND "Diabetes" AND "Adverse events" OR 
"Polypharmacy" AND "Diabetes" AND "Hospitalization" OR "Polypharmacy" AND "Diabetes Type 2" 
AND "Hospitalization" OR "Potentially inappropriate medication" AND "Polypharmacy" AND 
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"diabetes" AND "Elderly" OR "Falls" AND "Polypharmacy" AND "diabetes" AND "Elderly" OR 
"Medication Error AND "Polypharmacy" AND "diabetes" AND "Elderly". 
Web of Science  
TOPIC: ("Polypharmacy" AND "Diabetes" AND "Elderly" AND "Glycemic Control") Refined by: Open 
Access: (OPEN ACCESS), Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, 
ESCI, CCR-EXPANDED, IC. TOPIC: (Polypharmacy AND Diabetes type 2 AND Glycemic Control), 
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC. 
TOPIC: ("Polypharmacy" AND "Diabetes" AND "Elderly" AND "Drug-Drug Interactions") Refined by: 
Open Access: (OPEN ACCESS), Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI, CCR-EXPANDED, IC. TOPIC: (Polypharmacy AND Diabetes type 2 AND Drug-Drug 
Interactions), Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-
EXPANDED, IC. 
TOPIC: ("Polypharmacy" AND "Diabetes" AND "Elderly" AND "Adverse Events"), Timespan: All years. 
Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC. TOPIC: 
(Polypharmacy AND Diabetes type 2 AND adverse events), Timespan: All years. Indexes: SCI-
EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC. 
TOPIC: ("Polypharmacy" AND "Diabetes" AND "Elderly" AND "Hospitalization"), Timespan: All years. 
Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC. TOPIC: 
(Polypharmacy AND Diabetes type 2 AND Hospitalization), Timespan: All years. Indexes: SCI-
EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC. 
TOPIC: ("Potentially inappropriate medication" AND "Polypharmacy" AND "diabetes" AND 
"Elderly")Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-
EXPANDED, IC. 
TOPIC: ("Falls" AND "Polypharmacy" AND "diabetes" AND "Elderly")Timespan: All years. Indexes: SCI-
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2.3.1 Abstract  
      The aim of the study is to investigate the patterns of polypharmacy, clinical-relevant drug-
drug interactions (DDIs) and potentially inappropriate medicines (PIMs), and whether 
polypharmacy, potential serious clinically-relevant DDIs or PIMs can be associated with low 
quality of life (QoL) index scores of older adults with type 2 diabetes (T2D). A cross-sectional 
study was conducted using data of 670 elderly T2D sub-cohort from a nationwide pharmacy-
based intensive monitoring study of inception cohort of T2D in Portugal. 72.09% were found on 
polypharmacy (≥ 5 medicines). Participants on polypharmacy were mostly females (p=0.0115); 
more obese (p=0.0131); have more comorbid conditions (p<0.0001); more diabetes 
complications (p<0.0001); and use more of glucose lowering drugs (p=0.0326); insulin 
(p<0.0001);chronic medicines (p<0.0001); and have higher diabetes duration (p=0.0088) than 
those without polypharmacy. 10.59% of the participants found to have potential serious 
clinically relevant DDIs. The most frequent drug-combinations were angiotensin-converting 
enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARBs), aspirin with Selective 
serotonin reuptake inhibitors (SSRIs) and clopidogrel with calcium channel blockers. PIMs found 
in 36.11% of the participants. The most common PIMs were benzodiazepines, long-acting 
sulfonylureas, and iron overdose. The adjusted multivariate models show that Polypharmacy 
and PIMs and potential serious clinically relevant DDIs were associated with lower QoL index 
scores (OR 1.80 95% CI 1.15-2.82) and (OR 1.57 95% CI 1.07-2.28), (OR 1.34 95% CI 0.73-2.48), 
respectively. The study shows that polypharmacy, potential serious clinical-relevant DDIs and 
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2.3.2 Introduction  
      The prevalence of elderly people with type 2 diabetes (T2D) has been increasing globally. In 
2018, it was estimated that there were more than 500 million people diagnosed with T2D (1), 
and more than half were elderly (2). Elderly people with T2D are at higher risk of polypharmacy 
as result of multimoridity and aging (3). 
      Polypharmacy can be associated with several unintended therapeutic outcomes such as 
increasing the incidence of potential serious drug-drug interactions (DDIs) that can be harmful 
and life-threatening and use of potentially inappropriate medicines (PIMs) (4,5,6,7).  Despite that, 
there is a paucity in addressing the risk of potential clinicaly relevant serious DDIs and PIMs. 
Only one study found that at least one potential serious clinically relevant DDIs was found 
(7.10%)8, and two studies found that the prevalence of PIMs was found between (22.70%-
68.10%) (9,10). Moreover, there is a lack of evidence on whether the presence of polypharmacy 
and its consequences can impact quality of life (QoL).    
      Therefore, the aims of this study was to investigate the patterns of polypharmacy, clinical-
relevant drug-drug interactions (DDIs) and potentially inappropriate medicines (PIMs), and 
whether polypharmacy, potential serious clinically-relevant DDIs or PIMs can be associated with 
low QoL index scores of older adults with T2D. 
2.3.3 Methods    
      A cross-sectional study was conducted using the baseline data of elderly (aged 65 years or 
more) cohort from a nationwide pharmacy-based intensive monitoring study of inception 
cohort of T2D patients using the recently launched glucose lowering drugs (GLDs). Pharmacists 
and participants recruitment procedures have been described in detailed elsewhere (11).  
Invitation letters were sent to all pharmacies from the National Association of Pharmacies that 
satisfied the inclusion criteria. The pharmacists who agreed to participate were invited to 
attend a training session in which the study was explained. 
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      The eligible study population consisted of first users of the new GLD (defined as users who 
did not take the inception-monitored drug within the 6 months prior to recruitment, as self-
reported by the patients) that were that were reimbursed in Portugal at the time of enrollment: 
dipeptidyl peptidase-4 inhibitor (DPP-4) alone or in fixed-dose combination with metformin, 
glucagon like peptide 1 receptor agonists (GLP-1 ra) or sodium-glucose transport protein 2 
(SLGT-2). In this context, the inception drug corresponded to the GLD within the monitored 
therapeutic classes (DPP-4, GLP-1 ra or SLGT-2) which the patient was identified with at cohort 
entry. 
      The cohort was divided into two subgroups according to participants’ T2D treatment 
experience: incident new users; participants who were using one of the monitored drugs for 
the first time and had no current or prior experience with DPP-4, GLP-1 ra or SGLT2 and 
prevalent new users; participants who had previously used or were still using least one drug of 
the monitored treatment classes: DPP-4, GLP-1 ra or SGLT2, but not the inception GLD. 
      At recruitment, participants had a structured face-to-face interview with a trained 
pharmacist to collect the sociodemographic data (birth date, gender, highest educational level 
completed, co-residence status, and number of people living in the subject’s household), 
anthropometric (weight and height were measured by pharmacy staff to calculate the body 
mass index (BMI)) which categorized as (underweight < 18.50 Kg/m²), (normal: 18.50-24.99 
Kg/m²), (overweight: 25.00-29.99 Kg/m²) and (obese: ≥30 Kg/m²). Self-reported data was 
collected on clinical characteristics (age at time of T2D diagnosis, clinical care setting), T2D 
treatment, T2D related complications, co-morbidities, and concomitant therapy.  
Data Analysis  
      Study participants were divided into two subgroups according to the presence or absence of 
polypharmacy. Polypharmacy was defined as the use of five or more medicines, which is the 
most widely accepted definition in the literature (12).  
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      The medicines used were checked for the DDIs using IBM Micromedex Platform (IBM® 
Corporation, 2019) (13). This platform classify them according to their severity as: 
contraindicated-the drugs are contraindicated for concurrent use; major interaction potential 
life-threatening and/or requiring medical intervention to minimize or prevent serious adverse 
effects; moderate interaction - may result in exacerbation of the patient's condition and/or 
require an alteration in therapy; and minor interaction-would have limited clinical effects, and 
generally would not require a major alteration in therapy. Micromedex platform also addresses 
the potential adverse effect of the interaction, mechanism of the interaction, onset of the 
interaction, rate of scientific evidence (Excellent/Good/Fair/Unknown), and the proposed 
clinical management of the interaction. 
       We defined potentially serious clinically relevant DDIs as those having a severity of major 
drug-drug interaction or when the drug combination is contraindicated with scientific evidence 
rating of excellent (defined as controlled studies that have clearly established the existence of 
the interaction) according to Micromedex.  PIMs were identified using STOPP criteria version 2, 
the final list included 80 STOPP criteria, was agreed after two rounds of Delphi validation, which 
arranged according to the physiological systems of the body for ease of use and rapid 
application (14). In terms of predictive validity, it modestly discriminates for outcomes such as 
adverse drug events, emergency department visits, and hospital admissions. The STOPP criteria 
version 2 has a high sensitivity in detecting PIMs and good inter-rater reliability (15,16,17).  
      The QoL was measured using the three-level EuroQol five-dimensional (EuroQol 5-D-3L) 
questionnaire. The EQ-5D encompass five dimensions influencing health (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) each with three levels of functioning (first 
level; no problem, second level; some problems, third level; severe problems). The summary 
scores was computed to Portuguese preference weighted EQ-5D index scores using Portuguese 
values set (18). After that, the study participants finished the EQ-5D visual analogue scale (VAS). 
In the VAS, the patients evaluated their current health state on scale between zero (worst 
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possible health state) to one hundred (best possible health state), the high scores index 
together high VAS suggest best health state (19). 
Statistical Analysis  
      A database was created including information on socio-demographic characteristics, 
comorbidities, and prescribed medicines including both T2D and other chronic medicines, 
potential (contraindication, serious, moderate, and minor) DDIs, and PIMs. Data were described 
as absolute and relative counts and means (± standard deviation). 
      A multivariate binary logistic regression model to assess the adjusted associations between 
polypharmacy, potential serious clinically relevant DDIs, potentially inappropriate medicines 
and lower quality of life scores. Based on Portuguese elderly population preferences, mean 
index score of QoL was considered 0.60 as cutoff value (20). Results of this analysis were 
presented as adjusted odds ratios (ORs) and their respective 95% confidence intervals (CIs). 
Data analysis was performed using SAS® software. 
2.3.4 Results  
Characteristics of Study Population 
      Of the 1328 adults with T2D recruited in the original cohort, 670 were elderly people with 
T2D included in the current study. Of these, 483 (72.09%) were on polypharmacy. Among those 
on polypharmacy, 75.57% (n=365) and 24.43% (n=118) were using 5-9 and ≥10 different 
medicines, respectively. Participants on polypharmacy were significantly more females 
(p=0.0115), more obese (p=0.0131), had a higher duration of diabetes (p=0.0088), more 
comorbid conditions (p<0.0001), more diabetes complications (p<0.0001), using more GLDs 
treatment (p=0.0326), insulin use (p<0.0001), and more chronic medicines (p<0.0001) 
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Table 1 Descriptive characteristics of study population according to polypharmacy 
Characteristics  Total sample (N=670) T2D on Polypharmacy  (N=483)                        T2D Not on Polypharmacy (N=187) P value  
Gender M/F (%)  338/332 (50.45/49.55) 229/254 (47.41/52.59) 109/78 (58.29/41.71) P=0.0115 
Age (Mean ± SD) 
65-74 (%) 
75-84 (%) 
≥ 85 (%)  
 73.01 ± 6.22 
 432 (64.48) 
 203 (30.30) 
 35  (5.22) 










Underweight (< 18.5 kg/m²) 
Normal (18.5 – 24.99 Kg/m²) 
Pre-obese (25 – 29.99 Kg/m²) 
Obese (≥ 30 K/m²) 
 
 
 2 (0.29) 
 108 (16.12) 
 277 (41.34) 
 265 (39.55) 












NR = (6) 
P=0.0131 
Educational Level (%) 
No Education 
Primary (1-9 Years) 
Secondary (10-12 Years)  
Superior (> 12 Years) 
 
 128 (19.10) 
 425 (63.43) 
 54 (8.06) 
 41 (6.12) 





















 21 (3.13) 
 4 (0.60) 
 605 (90.29) 
 37 (5.52) 


















 135 (20.14) 
 531 (79.25) 







150 (80.21)  
NR= (2) 
P=0.5906 
Duration of Diabetes (%) 






 57 (8.50) 
 52 (7.76) 
 85 (12.68) 
 77 (11.49) 
 348 (51.94) 














NR = (24) 
P=0.0088 
Healthcare Setting (%) 
Primary Care 
Non-Primary care  
 
 469 (70.00) 












 629 (93.88) 








Comorbid conditions (%) 
Hypertension  
Renal Failure  
Heart Failure  
Dyslipidaemia  










 531 (79.25) 
 72 (10.74) 
 125 (18.65) 
 398 (59.40) 
 24 (3.58) 
 25 (3.73) 
 31 (4.62) 
 19 (2.83) 
 21 (3.13), NR = (332) 
 23 (3.43) 
 11 (1.64) 
 16 (2.38) 















































 179 (26.71) 
 482 (71.94) 








(NR = 3) 
P<0.0001 
Retinopathy (%) 
Nephropathy (%)  
Diabetic Foot (%) 
 120 (17.91) 
 74 (11.04) 










Diabetes Medicines (%) 
Oral GLD treatment  
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Insulin  117 (17.46) 106 (21.95) 11 (5.88) P<0.0001 




 458 (68.35) 
 193 (28.80), NR = (19) 
 




75 (40.11); NR= (19) 
P<0.0001 
Renin-angiotensin system medicines  
Beta-blocking agents 
Diuretics 
Calcium channel blockers 
Lipid lowering medicines  
Anti-thrombotic   
Acid related disorders medicines  
Psycholeptics  
Psychoanaleptics 
 458 (68.35) 
 173 (25.28) 
 172 (25.67) 
 144 (21.49) 
 398 (59.40) 
 259 (38.65) 
 212 (31.64) 
 167 (24.92) 











12 (6.42); NR= (19) 
12 (6.42); NR= (19) 
14 (7.49); NR= (19) 
55 (29.41) 
20 (10.70); NR= (19) 
16 (8.56); NR= (19) 
14 (7.49); NR= (19) 










Potentially serious clinically relevant 
drug-drug interactions  
 71 (10.59) 70 (14.49) 1 (0.53) P<0.00001 
Potentially inappropriate medicines   242 (36.11) 219 (45.34) 23 (12.30) P<0.00001 
BMI body mass index; N.R. non-respondents to the questionnaire in the original study; GLD: glucose lowering drugs, these includes: Gliptins (either alone or in 
combination), GLP-1 agonists, SGLT2-inhbitors, or any combination of any two diabetes study medicines. 
 
Identification of potentially serious clinically relevant DDIs  
      Of 670 elderly adults with T2D, 71 (10.59% of total cohort) had potential serious clinically 
relevant DDIs. Among the most frequent drug-combinations that contributed to potential 
serious clinically relevant DDIs were angiotensin-converting enzyme (ACE) inhibitors with 
angiotensin-receptor blockers (ARBs) (24.71%), aspirin with selective serotonin reuptake 
inhibitors (SSRIs) (19.10%) and clopidogrel with calcium channel blockers (13.84%) (Figure 1). 
The full description of these DDIs presented in (Table 2).  
Figure 1 The prevalence of drug combinations that contributed to the potentially serious clinically relevant drug-
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Table 2 Description and frequency of potential serious clinically relevant drug-drug interactions 
Drug\medicines 
class 
Drug\medicines class Potential adverse effect Mechanism Onset N (%) 
ACE inhibitors¹ 
(C09AA)  
ARBs (C09CA)² Risk of Hypotension, syncope, 
hyperkalemia, changes in renal 
function, acute renal failure 







Selective serotonin reuptake (SSRIs) 
inhibitors (N06A) 
Risk of bleeding depletion of platelet serotonin by 






Dihydropyridine derivatives (C08CA), 
SELECTIVE CALCIUM CHANNEL 
BLOCKERS WITH DIRECT CARDIAC 
EFFECTS (C08D) 
Risk of decreased antiplatelet 
effect and increased risk of 
thrombotic events 







Proton pump inhibitors (A02BC) Risk of reduced antiplatelet 
activity 
decreased inhibition of platelet 
aggregation of clopidogrel by PPIs 
Rapid  10 (11.23) 
Simvastatin 
(C10AA01) 
Diltiazem (C08DB01), Verapamil 
(C08DA01) Amiodarone (C01BD01) 
increased risk of myopathy, 
including rhabdomyolysis 
inhibition of CYP3A4-mediated 
simvastatin metabolism 





Risk of digitalis toxicity (nausea, 
vomiting, arrhythmias) 
diuretic-induced hypokalemia and 
hypomagnesemia enhance Na-K-
ATPase inhibition by cardiac 
glycosides 
Delayed  5 (5.61) 





Warfarin (B01AA03) increased risk of bleeding and 
an increased risk of 
rhabdomyolysis 
competition for cytochrome P450 
3A4-mediated metabolism 
Delayed  4 (4.49) 
Aspirin 
(B01AC06) 
Metamizole (N02BB02) Risk of reduced efficacy of 
aspirin 







Warfarin (B01AA03) increased INR and an increased 
risk of bleeding 
increased exposure to warfarin Delayed  1 (1.12) 
Digoxin 
(C01AA05) 
Verapamil (C08DA01) increased serum digoxin 
concentrations, risk of digitalis 
toxicity and increased risk of 
complete heart block 
inhibition of renal and/or extrarenal 
digoxin clearance; additive effects 
on AV node conduction 
Rapid  1 (1.12) 
Digoxin 
(C01AA05) 
Amiodarone (C01BD01) result in digoxin toxicity and 
potentiated effects of 
amiodarone 
inhibition of p-glycoprotein by 
amiodarone, and reduction of 
digoxin clearance; interference with 






Potassium chloride (A12BA01) Risk of hyperkalemia lowered aldosterone levels Delayed  1 (1.12) 
Pravastatin 
(C10AA03) 
Darunavir (J05AE10) increased exposure to 
pravastatin 
inhibition of CYP3A-mediated 
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Identification of potentially inappropriate medicines 
      Of the study cohort, 242 (36.11%) had at least one PIMs. Of these, 176 (72.72%) had one 
PIM, 49 (20.24%) had two PIMs, and 17 had more than two PIMs (7.02%). The mean of PIMs 
was (1.36 ± 0.78) per patient.  The most prevalent PIMs were benzodiazepines (43.50%), long-
acting sulfonylureas, glibenclamide or glimepiride (9.37%), and higher dose of iron supplements 
(4.83%) (Figure 2). The full description of potentially inappropriate medicines presented in 
(Table 3).  
Figure 2 The prevalence of potentially inappropriate medicines according to organ system or medicines class  
 








Endocrine System Sulphonylureas with a long duration of action with type 2 diabetes mellitus  31 (9.37) 
Cardiovascular System Using of Centrally acting antihypertensives  15 (4.53) 
Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias  10 (3.02) 
Loop diuretic as first-line treatment for hypertension 5 (1.51) 
Beta-blocker in combination with verapamil or diltiazem  1 (0.30) 
Verapamil or diltiazem with NYHA¹ Class III or IV heart failure 1 (0.30) 
Antiplatelet/Anticoagulant 
Drugs 
Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 
in patients with stable coronary, cerebrovascular or peripheral arterial disease 
2 (0.60) 
 
Long-term aspirin at doses greater than 160mg per day  8 (2.42) 
NSAID² and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in 
combination  
5 (1.51) 
NSAID² with concurrent antiplatelet agent(s) without PPI³ prophylaxis  5 (1.51) 
The use of Ticlopidine 6 (1.81) 
Central Nervous System Initiation of Tricyclic Antidepressants (TCAs) as first-line antidepressant treatment  12 (3.63) 
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and Psychotropic Drugs Use of first-generation antihistamines  9 (2.72) 
Gastrointestinal System Oral elemental iron doses greater than 200 mg daily 16 (4.83) 
Musculoskeletal System COX-2 selective NSAIDs with concurrent cardiovascular disease  2 (0.60) 
Analgesic Drugs  Use of oral or transdermal strong opioids  12 (3.63)  
Drugs that predictably 
increase the risk of falls in 
older people 
Benzodiazepines  144 (43.50) 
Hypnotic Z-drugs e.g., zopiclone, zolpidem, zaleplon 13 (3.93)  
Neuroleptic drugs 16 (4.83) 
Indication of Medication Duplication drug class prescription   18 (5.44) 
 Total  331 
1 New York Heart Association Functional Classification; 2 Non-steroidal anti-inflammatory drugs; 3 proton pump inhibitors  
Quality of life  
      Elderly patients with T2D in the study who were on polypharmacy have some to more 
severe problems in mobility (p=0.0004), usual activity (p=0.0001), personal care (p=0.0001), 
pain (0.0007), and anxiety and depression (p=0.0365), low mean VAS score (63.19±21.24 vs. 
69.30±19.97, p<0.0001) and low mean index score (0.58±0.32 vs. 0.72±0.24, p<0.0001), 
compared with those not on polypharmacy. The elderly people with T2D with potential serious 
clinically relevant DDI have less problems in all EuroQol 5-D-3L dimensions, but with low mean 
VAS score (62.00±20.56 vs. 65.16±21.11, p=0.3466) and low index score (0.54±0.37 vs. 
0.63±0.29, p=0.0637) compared with those without potential serious clinically relevant DDIs. 
Elderly people with T2D with at least one PIM have some to severe problems in mobility 
(p=0.0346), and pain (p=0.0031), with low mean VAS score (62.32±21.89 vs. 66.33±20.45, 
p=0.0387) and low mean index score (0.57±0.30 vs. 0.65±0.30, p=0.0003) compared with those 









Page | 140  
 
    Table 4 Descriptive analysis of patients with\without polypharmacy, with\without potential clinically relevant 
drug interactions and with\without potentially inappropriate medicines according to their EuroQol 5-D-3L 
Patient 
Classification 
Mobility ¹ Personal care² Usual activity³ Pain⁴ Anxiety and depression⁵ VAS⁶ 
score 
(mean 

























































































































































































































































































































































P value  0.0346 0.0929 0.0524 0.0031 0.2852 0.0387 0.0003 
1-number of non-respondents = 21, 2-number of non-respondents =21, 3-number of non-respondents for =21, 4-number of non-respondents =22, 5-number of 
non-respondents=25, 6-number of non-respondents for=88. 
 
       On the adjusted multivariate analysis, polypharmacy, potential serious clinically relevant 
DDIs and potentially inappropriate medicines were associated with lower index scores (OR 1.80 




Page | 141  
 
Table 5 Results of adjusted multivariate models analyzing polypharmacy with QoL, potential serious clinically 
relevant drug-drug interactions and potentially inappropriate medicines with QoL 
Model 1 Model 2  Model 3 
Parameter OR 95% CI Parameter OR 95% CI Parameter  OR 95% CI  
Polypharmacy 1.80 1.15-2.82 Potential serious 
clinically relevant DDIs 
1.34 0.73-2.48 PIM¹ 1.57 1.07-2.28 
Male   0.47 0.32-0.68 Male  0.45 0.31-0.66 Male  0.47 0.33-0.69 
Age (74-85) 1.63 1.08-2.47 Age (74-85) 1.66 1.10-2.50 Age (74-85) 1.66 1.10-2.52 
Obesity  1.89 1.09-3.27 Obesity  1.92 1.11-3.32 Obesity  1.97 1.14-3.41 
Chronic 
conditions  
3.44 1.24-9.58 Chronic conditions 4.25 1.56-11.59 Chronic conditions 4.04 1.47-11.09 
Complications  2.06 1.34-3.16 Complications  2.14 1.40-3.28 Complications  2.18 1.42-3.35 
1 potentially inappropriate medicine  
2.3.5 Discussion  
      This study show high prevalence of polypharmacy in a cohort of elderly people with T2D 
when comparing to other countries such as Sweden (56.70%) (21), Italy (57.10%) (22), and Greece 
(22.50%) (23). This can be explained by a higher overall prevalence of polypharmacy in older 
population with chronic diseases in Portugal (24). Polypharmacy was more prevalent in the 
elderly women with T2D. this finding was reported in previously studies (25,26,27). It can be 
explained that women tend to be more concerned about their health and seek health services 
more often (27).  Obesity was associated with polypharmacy, a finding also in agreement with 
pre-existing literature (22,28), which could be due to the presence of multimorbid conditions 
(28,29). 
      Duration of diabetes, presence of comorbid conditions and diabetes complications were 
associated with polypharmacy. T2D itself with wide array of comorbidities such as 
hypertension, dyslipidaemia and heart failure, in addition to renal complications can increases 
the chance of multiple medicines use (30).     
 
 
Page | 142  
 
      10.59% of the study cohort were found to have potentially serious clinically relevant DDIs, 
which considered higher than previously reported (7.10%) (8). However, a direct comparison is 
unattainable due to the differences in comorbid conditions and medicines prescribed and 
different platforms used for assessing DDIs. These harmful potential interactions may result in 
increased risk of thrombotic events from decreased antiplatelet effect or bleeding, followed by 
hypotension or renal failure from cardiovascular medicines, myopathy with statin therapy and 
increased digoxin concentrations causing risk of toxicity.        
      Our results were different from previously reported study by Dumbreck and colleagues 
whom selected three clinical guidelines produced by the National Institute for Health and Care 
Excellence (NICE) including T2D, and systematically looked for potentially serious drug-drug 
interactions in relation to another 11 NICE guidelines found that the most common category 
was cardiovascular related harm such as significant hypotension or bradycardia, followed by 
increased lithium or digoxin concentrations causing risk of toxicity, myopathy with statin 
treatment, and renal or serum potassium associated harms (31). 
      The most common medicines class combinations involved in potential serious clinically 
relevant DDIs were ACE inhibitors and ARBs. Prescribers seem to be less aware of the risk from 
this combination, as it counts for more than (24%) of the total potential serious clinically 
relevant DDIs.  Both (VALIANT) and (ONTARGET) trials revealed that concurrent use of both ACE 
inhibitors and ARBs was not associated with reduce the risk of death from cardiovascular 
causes, myocardial infarction, stroke or hospitalization from heart failure but had significantly 
increased risk of hypotension, syncope, renal dysfunction, and hyperkalemia, with a trend 
toward an increased risk of renal dysfunction requiring dialysis (32,33). 
      Clopidogrel was the most prevalent interacting medicine involved in potential serious 
clinically relevant DDIs (24.71%). This can be explained by higher prevalence of heart diseases 
and use of antiplatelet agents. Concurrent use of clopidogrel and proton pump inhibitors may 
be associated with high-risk of thrombotic events. A recent meta-analysis found that this 
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combination associated with increased in composite major adverse cardiac events which is a 
composite outcome typically comprised of non-fatal myocardial infarction, non-fatal stroke, 
and cardiovascular death (HR 1.28; 95% CI 1.24–1.32), myocardial infarction (HR 1.51; 95% CI 
1.40–1.62) and stroke (HR 1.46; 95% CI 1.15–1.86) (34).  
      Interaction between calcium channel blockers and clopidogrel can be also associated with 
reduced clopidogrel effect. Nevertheless, there are controversies in the literature, since some 
studies found a reduction in the effect of clopidogrel with this combination (35,36), and other 
studies could not establish any evidence of reduction in the anti-platelet activity of clopidogrel 
(37,38).    
      The prevalence of PIMs was found 36.11%. This finding is in agreement with previous 
studies (22.70-68.10%) (9,10). Comparing to the literature, our findings show high prevalence of 
benzodiazepines use (43.50% vs 5.9%-14.80%) (9,10). 
      Benzodiazepines are associated with a higher risk of falls in older adults (39), A study 
conducted in Ireland found that, the use of benzodiazepines was associated with serious falls 
when coupled with polypharmacy (adjusted relative risk (aRR) 1.40, 95% CI 1.04–1.87), and 
associated with a greater number of falls (adjusted incident rate ratio (aIRR) 1.32, 95% CI 1.05–
1.65), independent of polypharmacy (40). 
      The use of long-acting sulfonylureas was the 2nd major PIMs (9.37%) reported. Previous 
study found that the use of these long-acting sulfonylureas was associated with increased risk 
of hip fracture (aOR 1.46, 95 % CI 1.17–1.82) and the risk become higher in those with 
documented hypoglycemia (aOR 2.42, 95 % CI 1.35–4.34) (41). The use of higher doses of oral 
elemental iron was also reported in the study (4.83%), which can be associated with abdominal 
discomfort, nausea, vomiting, changes in bowel movements, and black stools (42). 
      The study revealed that polypharmacy (using 5 or more medicines) was associated with 
increased risk of low quality of life.  A study in Spain of elderly population (52.50% of them with 
T2D) found that the of poor quality of life was only associated when polypharmacy defined as 
the use of 10 or more medicines (43). In addition, the study found that the presence of at least 
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one potentially inappropriate medicine, and potential clinically relevant DDIs can be associated 
with increasing the risk of poor health related quality of life in elderly with T2D. To the best of 
our knowledge, these results have not previously been reported.  
      Previous study by Antonio De Vincentis and colleagues found that only polypharmacy which 
considered as simple measure surpass PIM and DDI indicators of quality of therapy as it 
correlate of primary clinical outcomes, that are mortality and rehospitalization (44) 
Some limitations were present in the study. Presence of information bias which characterized 
by inaccuracy of exact comorbid condition diagnosis and data regarding lab results (e.g. 
estimated glomerular filtration rate) were not reported. The data analysed in the present study 
were baseline data, and we do not know if the patients were really consumed all dispensed 
medicines.  
      The drug-drug interactions found in this study were only potential; in other words, no actual 
outcomes or consequences were evaluated. Finally, due to the nature of the cross-sectional 
design, we could not have the opportunity to explore the impact of polypharmacy on symptoms 
burden or quality of life over time. 
      This study reveals that polypharmacy is common and highly prevalent in cohort of elderly 
people with T2D, which can be due to disease burden and presence of multimorbid conditions.  
The prevalence of potential serious clinically relevant DDIs are relatively low and the medicines 
concerned are few. The monitoring of patients treated with clopidogrel and other 
cardiovascular medicines should be improved. Great attention should be considered while 
prescribing two different class of cardiovascular medicines with synergism effect that could 
have potential impact renal function and electrolyte balance, especially in elderly. Precise and 
updated information on interacting drugs could prevent the occurrence of known interactions, 
particularly when therapeutic alternatives exist. 
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      Defining the clinical relevance of a DDI is extremely important due to the presence of 
thousands of theoretically potential DDIs. High-quality evidence to support the existence of 
many DDIs is required, which can be established through real-world observational studies.  
STOPP criteria represent the more common avoidable instances of inappropriate prescribing in 
older people in day-to-day clinical practice. Based on our results, risk of fall, fracture or fracture 
risk, hypoglycemia and even gastrointestinal side effects can be avoided if prescribers assessed 
appropriately those elderly patients’ medicines use. 
      The selection and use of PIM criteria for research or practice should take into consideration 
considered the circumstances and requirements for each case as the relationships with 
outcomes can be different substantially between tools (45) 
      One of the challenges facing healthcare professionals is that the actual harms of both drug-
drug interactions and potentially inappropriate medicines which are poorly quantified in real-
world populations in which people are typically older, frail, have more comorbid conditions and 
receiving more medicines. Future studies should have the ability to explore the influence of 
possible adverse drug events as results of drug-drug interactions and potentially inappropriate 
medicines due to polypharmacy on elderly with T2D and the impact on quality of life over time 
in real-world. 
2.3.6 Conclusions 
      The use of polypharmacy is highly prevalent among cohort of elderly people with T2D. This 
population is at higher risk of potential serious clinically relevant DDIs and PIMs as result of 
polypharmacy.  The prevalence of potential serious clinically relevant DDIs found relatively low 
and can be associated with increased risk of poorer quality of life, like polypharmacy and 
potentially inappropriate medicines. Prospective studies are required to observe the clinical 
outcomes of the potential serious clinically relevant DDIs and presence of PIMs in real-world 
clinical practice. Health Interventions including pharmacist’s medication use review and 
deprescribing strategies may help to improve  patient-centered outcomes. 
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2.4.1 Abstract  
Purpose to describe and assess the impact of polypharmacy, and its potential adverse reactions; 
serious clinically-relevant drug-drug interactions (DDIs) and inappropriate medicines (PIMs) on 
glycemic target, and kidney function in a sample of older adults with type 2 diabetes (T2D)  
Methods cross-sectional study was performed in a real-world database included 444 elderly 
people with T2D from the Portuguese Diabetes Association, aged ≥ 65 years, and registered in 
2018. DDIs were analyzed using Micromedex drug-interaction platform and PIMs identified 
using STOPP criteria version-2 
Results polypharmacy was identified in 43.6% of patients. This group of patients shown to be 
more females (50% vs.39.6%, P=0.0208), higher HbA1c targets (P=0.0275), longer diabetes 
duration (66.4% vs.54.4%, P=0.0019), more hypertensive (87% vs.62.9%, P<0.0001), using more 
insulin (38.1% vs.26%, P=0.0062), sulfonylureas (37.1% vs.15.6%, P<0.0001), GLP-1 receptor-
agonists (9.7% vs.3.6%, P=0.0077), metformin-DPP-4 inhibitors (41.2% vs.29.2%, P=0.0081), and 
SGLT2 inhibitors (19% vs.9.6%, P=0.0040) 
8.7% of patients had potentially serious clinically-relevant DDIs, mainly due to interacting 
medicine pairs dexamethasone and fluoroquinolones. Furthermore, 23.4% had PIMs, and 
cardiovascular medicines accounted for largest therapeutic group associated. Polypharmacy 
found to be associated with two-fold greater odds of having HbA1c ≤8%. Whereas PIMs 
associated with 2.5-fold greater odds of having HbA1c ≤9%, and 5.5-folds greater odds of having 
severe kidney function.  
Conclusions these findings suggested that there is a potential association between 
polypharmacy and PIMs and altered glycemic control, and PIMs with the deterioration of kidney 
function.  
Keywords drug-drug interactions, potentially inappropriate medicines, glycemic control, kidney 
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2.4.2 Introduction 
      The pharmacological management of elderly people with type 2 diabetes (T2D) represents a 
major challenge for health care professionals. At least 50% of older adults with T2D have three 
or more comorbid chronic conditions (1), as well as the presence of diabetes complications and 
geriatric syndromes (2), which can add more intricacy to the pharmacological therapy, leading to 
polypharmacy. The presence of polypharmacy in elderly people with T2D may be linked to 
negative effects, that can result in more harm than benefit (3). This may include severe, life-
threatening drug-drug interactions (DDIs), prescription of potentially inappropriate medicines 
(PIMs), that can be associated with the consequence of the decreased quality of life (4). There 
are a few studies that addressed the impact of polypharmacy on kidney function in older adults 
(5). To the best of our knowledge, no previous studies reported the impact of polypharmacy, 
potentially serious clinically relevant DDIs and PIMs on glycemic target, and kidney function in 
older people with T2D. Therefore, the study aimed to investigate the association of 
polypharmacy, potentially serious clinically relevant DDIs and PIMs with glycemic target, and 
kidney function in older people with T2D.          
2.4.3 Methods  
      A cross-sectional study was conducted using the administrative database of the Portuguese 
Diabetes Association (APDP). APDP is the eldest member of the International Diabetes 
Federation (IDF) and is considered a specialty care diabetes institution in Portugal that provides 
support in the different fields of diabetes (diabetology, cardiology, urology, psychology, 
psychiatry, ophthalmology, and pathology) (6). Participants were included in the study if they 
were diagnosed with T2D, aged 65 years or more, and registered in 2018.   
      Socio-demographic data, body mass index (BMI), diabetes duration, diabetes-related 
complications, laboratory data including the last measured each of glycated hemoglobin 
(HbA1c), fasting blood glucose (FBG), serum creatinine, systolic and diastolic blood pressure, 
medicines used for the treatment of both T2D and associated comorbidities were all collected.  
Participants were considered hypertensive if they have blood pressure ≥ 140/90 mmHg or they 
are on anti-hypertensive medicines. For chronic kidney disease (CKD), we calculated the 
estimated glomerular filtration rate (eGFR) based on participant characteristics and serum 
creatinine using the Modification of Diet in Renal Disease Study equation (MDRD-GFR)(7). 
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      In the current study, potential serious clinical-relevant DDIs defined as those drug-drug 
interactions that considered contraindicated or may potentially harmful and life-threatening 
and require medical intervention to minimize or prevent serious adverse effects based on the 
excellent quality of scientific evidence (defined as those with established controlled studies)(4), 
using the IBM Micromedex Platform (IBM® Corporation 2019) (9).  
      PIMs were identified using STOPP criteria version 2. The criteria was developed following an 
extensive literature review and two rounds of Delphi consensus validation. The STOPP criteria 
are classified according to organ systems (e.g., cardiovascular system) to facilitate easy and 
rapid medicines review. For each criterion, the tool contains a brief explanation of why a 
medicine or a combination of medicines is considered potentially inappropriate (10). 
Statistical analysis  
      Descriptive data were presented as frequencies and percentages or mean ± SD. Comparison 
of the difference in the mean of each glycemic targets, and kidney function according to the 
exposure to polypharmacy, potentially serious clinically relevant DDIs, and PIMs was tested for 
statistical significance using the paired Wilcoxon two-Sample test, the P-value was set to be 
<0.05.  Besides, the association between polypharmacy, potentially serious clinically relevant 
DDIs and PIMs with HbA1c targets of ≤ 7.00%, ≤ 8.00%, ≤ 9.00%, and > 9.00%, and severe stage 
kidney function (eGFR <30mL/min/1.73 m²) was tested using multivariable linear regressions 
models. SAS statistical program (Cary, NC, USA) was used for all analyses. 
2.4.4 Results  
      A total of 444 elderly people with T2D were included in the study. Polypharmacy was found 
in 43.6% of the patients. Patients on polypharmacy have shown to be more females (50% 
vs.39.6%, P=0.0208), with higher HbA1c targets of ≤ 8.00%, ≤ 9.00% (P=0.0275), and longer 
duration of diabetes (66.4% vs.54.4%, P=0.0019), more hypertensive (87% vs.62.9%, P<0.0001), 
using more insulin (38.1% vs.26%, P=0.0062), sulfonylureas (37.1% vs.15.6%, P<0.0001), GLP-1 
receptor-agonists (9.7% vs.3.6%, P=0.0077), metformin in combination with DPP-4 inhibitors 
(41.2% vs.29.2%, P=0.0081), SGLT2 inhibitors (19% vs.9.6%, P=0.0040), compared to those not 
on polypharmacy. Table 1 describes the differences between study participants characteristics 
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Table 1 Descriptive characteristics of study participants according to exposure to polypharmacy 
Characteristics  
n (%) or Mean ± SD 
T2D on Polypharmacy  
(N=194) 
T2D Not on Polypharmacy 
(N=250) 
P value 




≥ 85   










Underweight (< 18.5 kg/m²) 
Normal (18.5 – 24.99 Kg/m²) 
Pre-obese (25 – 29.99 Kg/m²) 













(NR = 16) 
P=0.0607 
















FBG 184.9 ± 71.4 
(NR=2) 
179.1 ± 68.2 
(NR=6) 
 



























168 (86.5), (NR=1) 
144 (74.2), (NR=7) 
97 (50), (NR=27) 
28 (14.4), (NR=1) 
 
153 (61.2), (NR=7) 
167 (66.8), (NR=9) 







CKD category  
1-(estimated GFR ≥ 90mL/min/1.73 m²) 
2-(estimated GFR 60-89mL/min/1.73 m²) 
3A-(estimated GFR 59-45mL/min/1.73 m²) 
3B-(estimated GFR 44-30mL/min/1.73 m²) 
4-(estimated GFR 15-29mL/min/1.73 m²) 


























Cardiovascular diseases  























Diabetes Medicines  




DPP-4 inhibitors  
Metformin + DPP-4 inhibitors  
SGLT2 inhibitors  




























Potentially serious clinically relevant DDIs 35 (89.7) 4 (10.3) P<0.0001 
Potentially inappropriate medicines  77 (74) 27 (26) P<0.0001 
BMI: body mass index, FBG: fasting blood glucose, HbA1c: glycated hemoglobin, CKD: chronic kidney disease, GLP-1 ra: Glucagon-like peptide-1 receptor agonist, 
DPP-4 inhibitors: dipeptidyl peptidase-4 inhibitor, SGLT2 inhibitors: Sodium-glucose Cotransporter-2 Inhibitors, NR: not reported  
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      Among the 444 older people with T2D, 39 (8.7% of total patients) were found to have 
potential serious clinically relevant DDIs. The most identified interacting medicine pairs were 
dexamethasone and fluroquinolones (27.2%), followed by clopidogrel and calcium channel 
blockers (13.6%), and clopidogrel with proton pump inhibitors (13.6%) Figure 1. The full 
description of the potentially serious clinically relevant DDIs presented in Table 2.    
Figure 1 The prevalence of medicines pairs that contributed to potentially serious clinically relevant drug-drug 
interactions 
 
Table 2 Description of the potentially serious clinically relevant drug-drug interactions 





increased risk of tendon rupture additive effect of risk for 
tendon rupture  
Delayed  12 (27.2) 
Clopidogrel 
(B01AC04) 
Calcium channel blocker 
(C08) 
decreased antiplatelet effect and increased 
risk of thrombotic events. 
inhibition of CYP3A-mediated 






Proton pump inhibitors 
(A02BC) 
may result in reduced antiplatelet activity decreased inhibition of platelet 
aggregation of clopidogrel 
Rapid  6 (13.6) 
Aspirin (B01AC06) Selective serotonin 
reuptake inhibitors 
(N06AB) 
increased risk of bleeding depletion of platelet serotonin 














increased risk of hypotension, syncope, 
hyperkalemia, changes in renal function, acute 
renal failure 







Diltiazem (C08DB01) increased serum concentrations of simvastatin 
and increased risk of myopathy, including 
rhabdomyolysis. 
inhibition of CYP3A4-mediated 
simvastatin metabolism by 
diltiazem 
Rapid  2 (4.5) 
Warfarin (B01AA03) Simvastatin (C10AA01) increased risk of bleeding and an increased risk 
of rhabdomyolysis. 
competition for cytochrome 
P450 3A4-mediated metabolism 
Delayed  1 (2.2) 
Warfarin (B01AA03) Levofloxacin (S01AE05) increased risk of bleeding disruption of vitamin K 
synthesis 
Delayed 1 (2.2) 
Warfarin (B01AA03) Amiodarone (C01BD01) increased INR and an increased risk of 
bleeding. 
increased exposure to warfarin Delayed  1 (2.2) 
Zolpidem (N05CF02) Ciprofloxacin (S01AE03) increased zolpidem plasma concentrations. Unknown  not 
specified 
1 (2.2) 
Lisinopril (C09AA03) Amlodipine (C08CA01) increased risk of hypotension, syncope, 
hyperkalemia, changes in renal function, acute 
renal failure. 
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      According to the STOPP criteria version 2, 133 PIMs were found amongst 104 (23.4%) of the 
total patients. Of these, 80 patients (76.9%) have one PIM, 20 patients (19.2%) have two PIMs, 
and four patients (3.8%) have more than two PIMs. The highest frequency of PIMs use related 
to the cardiovascular system (29.3%), followed by drugs that predictably increase the risk of 
falls in older people (24.2%), and the endocrine system (14.2%) Figure 2. The full description of 
the PIMs presented in Table 3. 
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      Table 3 The description of potentially inappropriate medicines according to STOPP criteria 
         NSAIDs: Non-steroidal anti-inflammatory drugs  
 
      The comparison among participants’ HBA1c, and eGFR according to the exposure to 
polypharmacy, potentially serious clinically relevant DDIs and PIMs presented in (Figure 3, 
Figure 4, Figure 5), and the mean difference described in Table 4.  
Figure 3 comparison between participants' HbA1c and eGFR according to the exposure to polypharmacy 
 







Endocrine System Sulphonylureas with a long duration of action with type 2 diabetes mellitus  19 (14.2) 
Cardiovascular System Using of Centrally acting antihypertensives  5 (3.7) 
Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias  2 (1.5) 
Loop diuretic as first-line treatment for hypertension 3 (2.2) 
ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia 28 (21) 
Aldosterone antagonists with concurrent potassium-conserving drugs without monitoring of serum 




Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in 
patients with stable coronary, cerebrovascular or peripheral arterial disease 
1 (0.7) 
 
Aspirin plus clopidogrel as secondary stroke prevention, (no evidence of added benefit over clopidogrel 
monotherapy). 
2 (1.5) 
NSAID¹ and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination 1 (0.7) 
Central Nervous System 
and Psychotropic Drugs 
 
Initiation of Tricyclic Antidepressants (TCAs) as first-line antidepressant treatment  3 (2.2) 
Use of first-generation antihistamines  1 (0.7) 
Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia.  1 (0.7) 
Musculoskeletal System NSAID with concurrent corticosteroids without PPI prophylaxis 10 (7.5) 
NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure 2 (1.5) 
Analgesic Drugs  Use of oral or transdermal strong opioids  6 (4.5) 
Drugs that predictably 
increase the risk of falls in 
older people 
Benzodiazepines  23 (17.2) 
Hypnotic Z-drugs e.g., zopiclone, zolpidem, zaleplon 6 (4.5) 
Neuroleptic drugs 4 (3) 
Renal system  Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis) 10 (7.5) 
NSAID’s if eGFR < 50 ml/min/1.73m2 4 (3) 
Factor Xa inhibitors if eGFR < 15 ml/min/1.73m2  1 (0.7) 
 Total  133 
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Figure 4 Comparison between participants HbA1c and eGFR according to the exposure to potentially serious 
clinically relevant drug-drug interactions 
 
                                                  





       
      The adjusted multivariate logistic regression revealed that the multiple medicines use 
(polypharmacy) were associated with a higher odd of HbA1c target of ≤ 8% (OR 2, 95% 1-3.9, 
P=0.0315). On the other hand, the presence of PIMs has associated with a higher odd of HbA1c 
target of ≤ 9% (OR 2.5, 95%CI 1-6.5, P=0.0490), and severe kidney function (OR 5.5, 95%CI 2.1-
14.1, P=0.0003) (Table 5). 
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Table 4 Mean difference in HbA1c, and eGFR according to exposure to polypharmacy, potentially serious 
clinically relevant drug-drug interaction, and inappropriate medicines 
 HbA1c target Kidney function  
Polypharmacy (Yes vs No) 
P value  
7.5 ± 1.5 vs 7.3 ± 1.5 
P=0.0215 
76.1 ± 42.6 vs 83 ± 42.5 
P=0.1309 
Potentially serious clinically relevant DDIs (Yes vs No) 
P value  
7.8 ± 1.5 vs 7.3 ± 1.5  
P=0.0651 
74.4 ± 42.8 vs 80.5 ± 42.5 
P=0.3402 
PIMs (Yes vs No) 
P value  
7.5 ± 1.5 vs 7.3 ± 1.5 
P=0.0527 
66.9 ± 42.8 vs 84 ± 42.5 
P=0.0002 
PIMs: potentially inappropriate medicines, DDIs: drug-drug interactions 
Table 5 The association between polypharmacy, potentially serious clinically relevant drug-drug interactions, 
and inappropriate medicines with HbA1c target, and eGFR 
 Polypharmacy Potentially serious 
clinically relevant DDIs 
PIMs 
OR (95% CI)  OR (95% CI) OR (95% CI) 
HbA1c target  
HbA1c ≤ 7.00% vs. ≤ 6.00% 
HbA1c ≤ 8.00% vs. ≤ 6.00% 
HbA1c ≤ 9.00% vs. ≤ 6.00% 
















Severe kidney Function  







PIMs: potentially inappropriate medicines; DDIs: drug-drug interactions  
2.4.5 Discussion  
      In a sample of older people with T2D from a diabetes specialty care institution, the findings 
suggest that polypharmacy and PIMs can alter the glycemic targets of these patients. While 
only PIMs have found to have an impact on kidney function. Patients on polypharmacy found to 
have average age above 70 years, frequently females, had higher glycemic targets, a longer 
mean of FBG, longer duration of disease, more hypertensive with fewer diabetes complications, 
and using more insulin, sulfonylureas, GLP-1 receptor agonists, metformin in combination with 
DPP-4 inhibitors, and SGLT2 inhibitors than those not on polypharmacy. Similar results were 
found by Noale et al. Although, the study reported a higher prevalence of polypharmacy 
(57.1%) and a higher prevalence of diabetes complications (11).  
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      These differences might be due to the different healthcare settings where the patients 
received their diabetes care. Naole et al reported that the data of older adults with T2D were 
collected from 57 primary care centers (11). While in our study, the data were collected from the 
administrative database of a diabetes specialty care institution, that is, the APDP.  
      McAlister et al, found that patients receiving care in diabetes specialty care institution were 
seen more often by primary care physician and by all doctors, were more likely to be treated 
with insulin and a combination of oral hypoglycaemic agents, and more likely to receive 
efficacious treatment to prevent atherosclerotic complications (12), and ensuring a better 
quality of care in terms of process measures (13). 
      The study has shown that potentially serious clinically relevant DDIs are less frequent when 
compared to that previously found in-home health care by Ibrahim et al, where the prevalence 
reached 38.8% (14). Nevertheless, it should be noted that the drug-interaction platform used 
was different, and therefore, the classification of interactions may not be equivalent, as well as 
the medicines regimens of older diabetic patients are monitored systematically and frequently 
in specialty care diabetes institutions than in home health care services.  
      The most common potentially serious clinically relevant DDIs interacting medicine pair was 
found between dexamethasone and fluoroquinolones which can increase the risk of tendon 
rupture. Persson et al found that in older adults with diabetes, the excess risk of any tendon 
rupture was much higher for concomitant fluoroquinolones and corticosteroids use versus 
corticosteroids alone (OR 21.2, 95%CI 11.3–31.2), and the risk of any tendon rupture was higher 
among concomitant corticosteroids use (OR 6.6, 95%CI 3.9–11.1) (15). 
      Fluoroquinolones might be avoided in individuals who have had previous serious side 
effects. They should be used with special caution in the elderly people greater than 60 years, 
corticosteroid therapy, kidney failure, obesity, hyperlipidemia, diabetes, and history of 
musculoskeletal disorders, because these patients are at a higher risk of tendon disorders, 
especially Achilles tendonitis. Since the use of a corticosteroid with fluoroquinolones increases 
this risk, the combined use of these medicines is recommended to be avoided (16,17). 
      The interaction between the calcium channel blockers and clopidogrel can be associated 
with a reduction of the clopidogrel efficacy through limiting the ability to inhibit platelet 
aggregation, which accounted for 13.6% of the most interacting medicine pairs identified in the 
study. There are controversies in the literature regarding this interaction, since some studies 
found a reduction in the effect of clopidogrel with this combination (18)(19), and other studies 
could not confirm any evidence of a reduction in the anti-platelet activity of clopidogrel (20)(21).    
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      Another important potential DDI was found from a combination of clopidogrel and proton 
pump inhibitors, which can result in reduced clopidogrel effect and possible adverse 
cardiovascular events. A meta-analysis by Serbin et al found that concomitant use of this 
combination was significantly associated with an increase in the composite major adverse 
cardiac event (MACE) (HR 1.28; 95% CI 1.24–1.32), myocardial infarction (HR 1.51; 95% CI 1.40–
1.62) and stroke (HR 1.46; 95% CI 1.15–1.86) (22). Whereas Pang et al found that patients using 
clopidogrel without PPIs were observed to be associated with less risk of MACE (RR 0.82, 95%CI 
0.77–0.88), myocardial infarction recurrence (RR 0.72, 95%CI 0.57–0.90), stent thrombosis(RR 
0.71,95%CI 0.56–0.92), Target vessel revascularization (RR 0.77, 95%CI 0.63–0.93) and stroke 
(RR 0.72, 95%CI 0.67–0.76). this effect mainly appears from the use of omeprazole or 
esomeprazole with clopidogrel (23). 
      The most common PIM reported in the study was the use of ACE inhibitors or ARBs in 
patients with hyperkalemia. Hyperkalemia is common in older adults with diabetes who have  
cardiorenal comorbidities and often limits the use of guideline-recommended ACE inhibitors 
and ARB’s in the subgroups of patients who are expected to derive the greatest benefit, 
especially in those with chronic kidney disease (24).  Bandak et al found that hyperkalemia within 
the first year of ACE inhibitors or ARBs treatment was relatively uncommon among people with 
eGFR>60 mL/min per 1.73 m² (25). Older age, lower eGFR, diabetes, heart failure, and use of ACE 
inhibitors or ARBs were all associated with higher hyperkalemia risk (26).  
      The increased odds of polypharmacy and PIMs are associated with alteration of HbA1c 
targets of ≤ 8.00% and ≤ 9.00% in the current study. Achieving strict glycemic targets in elderly 
people with T2D through polypharmacy can be associated with diminishing benefits and greater 
risks of harm and clinically meaningless. Timbie et al found that a significant proportion of 
people with diabetes will fail to achieve glycemic targets despite using high doses of multiple, 
conventional treatments (27). In the light of European and American clinical practice guidelines 
for the management of older adults with T2D (28,29), several randomized controlled trials (RCTs) 
(30–32), and observational data (33,34), the harms associated with HbA1c targets lower than 7.5% 
or higher than 9% are likely to outweigh the benefits for the majority of older adults age 65 
years or more with T2D. Taken together, the current finding suggests that there might be an 
impact of both polypharmacy and PIMs on HbA1c targets but did not exceed the recommended 
limits.   
      The increased odds of PIMs are also associated with severe kidney function in the current 
study. Previous studies either found that polypharmacy was associated with severe kidney 
function (OR 2.8, 95%CI 1.4-5.7) as reported by Dorks et al (35), or did not find any association 
between PIMs and severe kidney disease as reported by Secora et al (5). Ueda et al found that 
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insulin therapy, serum albumin, mean blood pressure, and hemoglobin, were independent and 
significant factors of progression to renal failure (36).  Whereas Kaewput et al found that the risk 
factors associated with progression to end-stage kidney disease were diabetes duration, 
systolic blood pressure, serum uric acid, albuminuria, and baseline eGFR.  
      In the current study, 16 patients were exposed to the use of non-steroidal anti-inflammatory 
drugs (NSAIDs), which identified in the study as one of the PIMs that might be associated with 
an increased risk of severe kidney disease. Physiologically, NSAIDs have been shown to inhibit 
cyclooxygenase function, reduce prostaglandin production, and change hemodynamics in the 
kidney, leading to acute kidney failure and glomerular filtration rate alteration (37). A greater 
risk of chronic kidney disease attributable to NSAIDs use was noted among people with T2D 
aged ≥ 65 years than for those aged < 65 years (38).  
      However, renal outcomes related to the use of NSAIDs, especially the progression to 
end‐stage kidney disease, in population‐based studies remain inconclusive (39). Previous results 
from observational studies have indicated that NSAIDs could further deteriorate already 
impaired renal function. it was shown that patients with chronic kidney disease who took 
non‐selective NSAIDs, compared with those who did not, were 56% more likely to develop 
end‐stage kidney disease (40). Besides, it has been documented that high‐dose NSAID use in the 
elderly with chronic kidney disease was a significant risk factor that accelerated chronic kidney 
disease progression (41). By contrast, the harmful effects of NSAIDs on kidney function could not 
be confirmed in some epidemiological studies. Therefore, NSAIDs should be prescribed with 
caution, especially in older adults with T2D at high risk for kidney disease progression. 
      Some potential limitations exist in the current study. For example, in the interaction 
between fluoroquinolones and dexamethasone, we cannot confirm if the patients were on 
long-term dexamethasone for two main reasons: firstly, the administrative database of the 
APDP only show the last updated medications used for each patient. Secondly, based on our 
study design, we did not follow the patients prospectively, and then we can be sure about the 
duration of the use of dexamethasone. Ultimately, we can confirm that patients started 
dexamethasone after the diagnosis of T2D and while they are being treated at APDP. Although, 
we cannot confirm how long the patients were using dexamethasone.  
      The sample of the study is relatively small, and the data collected from one specialty care 
diabetes institution (the APDP), this can reduce the generalized directly on the national level. 
Several possible confounders that might impact the associations found in the study such as age, 
female gender, number of comorbidities, complications, BMI, and duration of diabetes for 
which we did adjust all. We defined polypharmacy as the use of five or more medicines. Using 
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other definitions (e.g., 10 or more medicines) might form a barrier against concluding the 
impact of polypharmacy on glycemic targets. Similarly, the DDIs can be classified as major, 
moderate, and minor according to the MICROMEDEX platform. The current definition has been 
chosen to identify the clinically important DDIs based on strong scientific evidence, that might 
influence on the other hand the impact on glycemic target or kidney function.  
      The study showed that polypharmacy is prevalent among elderly people with T2D in 
specialty care diabetes institution and underlines the importance of assessing the conditions 
leading to multiple prescriptions. The study found that the presence of polypharmacy can be 
associated with older adults’ HbA1c targets. Most patients’ HbA1c levels increase over time, 
older adults and their clinicians must decide whether to intensify or de-intensify therapy.  
      The risks of treatment to achieve HbA1c targets in older adults should be carefully weighed 
with the benefits at the individual level. Although, the net benefit of intensifying treatment 
with polypharmacy remains unclear. Currently, there are no RCTs assessed the benefit-harm of 
polypharmacy in older adults with T2D. The study has shown that potentially serious clinically 
relevant DDIs could be a cause of adverse events and outcomes. Although they are relatively 
low, it seems that DDIs identified can be associated with severe, life-threatening adverse 
consequences. 
      The study findings revealed that not only polypharmacy can be associated with glycemic 
targets, but also the presence of PIMs can pose the same risk. Clinicians should be frequently, 
and carefully review and update the list of medicines with special awareness to the medicines 
that can interfere with diabetes management, individualize their glycemic targets, and provide 
them with patient-centered care.  
      The study also adds another important finding, that is, the presence of PIMs can be 
associated with the risk of severe kidney function. While the use of HbA1c could be helpful to 
evaluate glycemic targets, attention to kidney function might also be monitored more 
frequently. Providers might also look for nephrotoxic medicines when reviewing their 
medicines lists.  
2.4.6 Conclusion 
      In a sample of older people with T2D from specialty care institution, the results have shown 
that polypharmacy, potentially serious clinically relevant DDIs, and PIMs are prevalent in this 
population as expected. The findings also suggest that the presence of polypharmacy and PIMs 
might put these patients at high-risk of glycemic targets alteration, and the impact on the 
deterioration of kidney function more likely to be from the use of PIMs. Considering these 
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findings, it appears crucial to ensure that iatrogenic risks remain minimal for this population 
who is already vulnerable to these outcomes and mainly rely on hastening to help and do no 
harm. 
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CHAPTER 2.5  
OVERTREATMENT AND UNDERTREATMENT IN A SAMPLE OF 
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2.5.1 Abstract  
Background and objectives 
In older adults with type 2 diabetes (T2D), overtreatment remains prevalent and 
undertreatment ignored. The main objective is to estimate the prevalence and examine factors 
associated with potential overtreatment and undertreatment. 
Method  
Observational study conducted within an administrative database of older adults with T2D who 
registered in 2018 at the Portuguese Diabetes Association. Participants were categorized either 
as potentially overtreated (HbA1c≤7.5%), appropriately on target (HbA1c≥7.5–≤9%), or 
potentially undertreated (HbA1c>9%).  
Results  
Of 444 participants, potential overtreatment, and undertreatment were found in 60.5% and 
12.6% of the study population. Taking the patients on target as a comparator, the group of 
potentially overtreated showed to be more males (61.3% vs.52.2%), less-obese (34.1% vs.39.2), 
higher cardiovascular diseases (13.7% vs.11%), peripheral vascular diseases (16.7% vs.12.8%), 
diabetic foot (10% vs.4.5%), and severe kidney disease (5.2% vs.4.5%). Conversely, the 
potentially undertreated participants were more females (64.2% vs.47.7%), obese (49% 
vs.39.2%), had more dyslipidemia (69% vs.63.1%), peripheral vascular disease (14.2% vs.12.8%), 
diabetic foot (8.9% vs.4.5%), and infections (14.2% vs.11.9%). 
The odds of potential overtreatment were mostly decreased by 59% of females, 73.5% in those 
with retinopathy, and 86.3% in insulin, 65.4% sulfonylureas, and 66.8% in SGLT2 inhibitors 
users. Contrariwise, an increase in the odds of potential undertreatment was more than 
4.8times higher in insulin, and more than 3.1times higher in sulfonylureas users.  
Conclusion  
Potential overtreatment and undertreatment in older adults with T2D in routine clinical 
practice should guide the clinicians to balance the use of newer antidiabetic agents considering 
its safety profile regarding hypoglycemia.   
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2.5.2 Introduction  
      Globally, with the overall aging of the population, the prevalence of diabetes raises. 
According to the international diabetes federation (IDF) in 2019, it was estimated that the 
number of older adults aged between 65-99 years old with diabetes reached more than 135 
million cases worldwide. This number expected to increase to more than 276 million cases 
achieving a prevalence of 19.6% by 2045, who majorly elderly diagnosed with type 2 diabetes 
(T2D) according to IDF (1). Older adults with T2D are a heterogenous, vulnerable, and frail 
population, at high-risk for microvascular and cardiovascular complications, geriatric syndromes 
(such as falls, dementia, and polypharmacy), hypoglycemia, or hyperglycemia than young adults 
(2) and historically excluded from traditional randomized clinical trials (RCTs) (3).  
      As a result, the literature is scarce regarding the benefits and risks associated with 
treatment intensification in the older T2D population (4). Despite the potential for harm, 
overtreatment remains common because of many health system factors including financial 
incentives, malpractice concerns, performance measures, practice behavior, and time limits (5). 
On the other hand, there is less attention to the undertreatment of older adults with T2D 
whom otherwise healthy, to achieve modest glycemic control. Consequently, clinical inertia can 
result in uncontrolled hyperglycemia in older T2D individuals that could potentially result in 
serious microvascular and macrovascular harm (6). 
      Besides, the definition of overtreatment and undertreatment is still debatable and unclear 
due to the differences in recent clinical diabetes practice guidelines, especially in the details of 
its recommendations for elderly people with diabetes categories and their glycaemic targets 
(2,7–9). Using a data of older adults with T2D from the Portuguese Diabetes Association (APDP), 
we aimed to investigate whether there is a shift toward the use of newer medicines, with low-
risk of hypoglycemia according to the updated guideline recommendations (9–11), and to 
examine the characteristics and factors associated with individualized diabetes management 
focusing on potential overtreatment/undertreatment. 
2.5.3 Methods  
      A cross-sectional study conducted using the administrative database of older adults with 
T2D of the Portuguese Diabetes Association (APDP). The APDP is the world’s oldest diabetes 
association and a senior member of the IDF. Individuals were included if they are diagnosed 
with T2D, aged 65 years or more, and registered at APDP in 2018. 543 were identified according 
to the above-mentioned criteria. Of these, 99 individuals were excluded from the analysis as 
they just visited APDP for special consultation with no medical history and/or medicines 
records. Socio-demographic data, body mass index (BMI), diabetes duration, diabetes 
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complications, laboratory results including glycated hemoglobin (HbA1c), fasting blood glucose 
(FBG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), total 
cholesterol (TC), serum each of creatinine, sodium, and potassium, as well as the last blood 
pressure record (including both systolic (SBP) and diastolic blood pressure (DBP), medicines 
used for treatment of T2D and associated comorbidities were retrieved from the database of 
APDP.  
      Participants were considered hypertensive if they have blood pressure ≥ 140/90 mmHg or 
they were on anti-hypertensive medicines. For chronic kidney disease (CKD), we calculated the 
estimated glomerular filtration rate (eGFR) based on participant characteristics and serum 
creatinine using modification of diet in renal disease study equation (MDRD-GFR) (12). 
Polypharmacy was defined as the use of five or more medicines (13). According to the action to 
control cardiovascular risk in diabetes (ACCORD) trial (14) the review by Lipska and colleagues 
(15), and the recommendations from the European diabetes working party for older people with 
T2D clinical guideline (11), the majority of older people with T2D aged 65 years old or more, the 
harm from HbA1c target lower than 7.5% or higher than 9% are likely to outweigh the benefit. 
Therefore, the potential overtreatment defined as HbA1c target of (<7.5%), appropriately on 
target HbA1c between (≥7.5-≤9%), and potential undertreatment HbA1c target of  (>9%), and 
were on treatment with glucose-lowering medicines in mono or combination therapy.  
Statistical analysis  
      Participants were divided into categories of glycemic control: potentially overtreated 
(HbA1c <7.5%), appropriately on target (HbA1c ≥7.5-≤9%), and potentially undertreated 
(HbA1c>9%). We compared the demographic and clinical factors of these groups using t-test for 
categorical variables and Kruskal-Wallis test for continuous variables. P-value was set to be < 
0.05. Multivariable binary logistic regression was used to explore factors associated with 
potential overtreatment and undertreatment compared to appropriately on target. Covariates 
in the model included age, sex, polypharmacy, gender, obesity (BMI≥ 30 K/m²), diabetes 
duration, comorbidities, macrovascular and microvascular complications, infections, estimated 
GFR, serum sodium, serum potassium, SBP, serum LDL, insulin use, and other glucose-lowering 
medicines. analyses were carried out using the SAS program (SAS Institute, Inc., Cary, NC). 
2.5.4 Results  
      Of 444 older adults with T2D aged 65 years or older, 434 (97.7%) had documented the 
HbA1c test. Most of the study participants were males with a mean age of (72.9 ± 6.8). More 
than 35% were obese and almost 60% had more than 10 years of duration of diabetes with 
mean HbA1c (7.4 ± 1.5%). The study participants were diagnosed with other comorbid 
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conditions such as hypertension and chronic kidney disease (in more than 70% of the 
participants), and almost 50% have diagnosed with dyslipidemia. More than 20% of study 
participants have documented diabetes complications, mainly macrovascular complications, 
and retinopathy. 
      Polypharmacy was found in more than 40% of the study individuals. Approximately, 65% 
were using 1 or 2 of diabetes medicines and more than 25% were using 3 or more. 30.3% of the 
study participants treated with insulin, 25% with sulfonylureas, compared to 17.1% using of 
dipeptidyl peptidase-4 (DPP4) inhibitor, 13.7% using gliflozins, and 6.3% using glucagon-like 
peptide-1 (GLP-1) receptor agonist (Table 1). 269 (60.5%) participants were considered as 
potentially overtreated, 109 (24.5%) participants were appropriately on target, and 56 (12.6%) 
participants were potentially undertreated. Older adults with T2D who considered potentially 
overtreated were frequently males, with mean of age (72.9 ± 6.4) and 46.1% were pre-obese. 
The mean HbA1c was (6.5 ± 1.5%) and more than half had a longer duration of diabetes, 
associated with hypertension, dyslipidemia, and CKD especially severe stage (estimated GFR 
<30mL/min/1.73 m2). 
Table 1 General Characteristics of the Study participants  
Characteristics n (%) or 


















Underweight (BMI < 18.5 kg/m²) 
Normal (BMI 18.5 – 24.99 Kg/m²) 
Pre-obese (BMI 25 – 29.99 Kg/m²) 








Duration of Diabetes 













Potential overtreatment (HbA1c <7.5%) 
Appropriately on target (HbA1c≥7.5-≤9%) 
Potential undertreatment (HbA1c>9%) 






FBG  181.6 ± 70.7 
(NR=8) 
Medical History  
 
 










321 (72.2)  
(NR=8) 










144 ± 20 
78.5 ± 11.4 






≥ 100mg/dL  
HDL 
> 40mg/dL for men, > 50mg/dL for women 
< 40mg/dL for men, < 50mg/dL for women 
TG 
















1-(estimated GFR ≥ 90mL/min/1.73 m2) 
2-(estimated GFR 60-89mL/min/1.73 m2) 
3A-(estimated GFR 59-45mL/min/1.73 m2) 
3B-(estimated GFR 44-30mL/min/1.73 m2) 
4-(estimated GFR 15-29mL/min/1.73 m2) 










< 135 mEq/L 
135-145 mEq/L 
> 145 mEq/L 
Potassium  
< 3.5 mEq/L 
3.5-5 mEq/L 














Cardiovascular diseases  











































Metformin + DPP-4 inhibitors 
SGLT2 inhibitors 












BMI: body mass index, HbA1c: Glycated hemoglobin, FBG: fasting blood glucose, CKD: chronic kidney disease, SBP: systolic blood pressure, DBP: diastolic blood 
pressure, TC: total cholesterol, LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglyceride,  GLP-1 ra: Glucagon-like peptide-1 receptor agonists, 
DPP-4 inhibitors: Dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors: Sodium-glucose Cotransporter-2 inhibitors, NR: not reported. 
      Besides, more than 30% have macrovascular and more than 35% have microvascular 
complications. Polypharmacy was reported in more than 40% of them and they were treated 
with a mean of 1.5 ± 1.1 glucose-lowering medicines, mostly treated with metformin, 
metformin in combination with DPP-4 inhibitors and sulfonylureas. Older adults with T2D who 
were considered potentially undertreated were frequently females, with mean of age (71.9 ± 
6.4) and 49% were obese. The mean HbA1c was 10.3 ± 1.5% and more than two-thirds had a 
longer duration of diabetes, have diagnosed with hypertension, dyslipidemia, and CKD. Besides, 
23.2% have macrovascular and 30.3% have microvascular complications. Polypharmacy was 
reported in 42.8% of them and they were treated with a mean of (2.3 ± 1.1) diabetes medicines, 
mostly treated with insulin, metformin in combination with DPP-4 inhibitors, and sulfonylureas 
(Table 2).  
Table 2 Participants Characteristics Stratified According to Individuals with a glycated haemoglobin target 
categorized as appropriately on target, potentially overtreated or undertreated 
                                         HbA1c achieved  
 
 
Participant characteristics  
Potentially overtreated              
(HbA1c <7.5%)                            
(N=269) 
n (%) or Mean ± SD 
Appropriately on 
target             
(HbA1c ≥7.5-≤9%)                         
(N=109) 
n (%) or Mean ± SD 
Potentially 
undertreated                    
(HbA1c > 9%)                                        
(N=56) 
n (%) or Mean ± SD 

















(≥ 85 years) 
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BMI  
Underweight (BMI < 18.5 kg/m²) 
Normal (BMI 18.5 – 24.99 Kg/m²) 
Pre-obese (BMI 25 – 29.99 Kg/m²) 




















HbA1c 6.5 ± 1.5 8.1 ± 1.5 10.3 ± 1.5  
FBG 155.6 ± 70.7  (N.R =3) 200.1 ± 71 269.1 ± 71  


































































Severe stage kidney disease                      
(estimated GFR <30mL/min/1.73 m2) 
14 (5.2) 
(NR=2) 


































































142.8 ± 20.3 
(NR=4) 
109.5 ± 31.3 
(NR=56) 
140.1 ± 2.5 
(NR=6) 
4.4 ± 0.4 
(NR=6) 
145 ± 19.3 
 
116.4 ± 33.1 
(NR=14) 
139.8 ± 2.3 
 
4.5 ± 0.4 
146.4 ± 18.4 
(NR=1) 
123.2 ± 38.7 
(NR=1) 
138.2 ± 2.7 
 





















Number of diabetes medicines  1.5 ± 1.1 2.3 ± 1.1 2.3 ± 1.1  
Insulin use 41 (15.2) 53 (48.6) 41 (73.2) P<0.0001 
Other diabetes medicines  
Metformin 
Sulfonylureas 





































BMI: body mass index, HbA1c: Glycated hemoglobin, FBG: fasting blood glucose, CKD: chronic kidney disease, SBP: systolic blood pressure, LDL: low-density 
lipoprotein,  GLP-1 ra: Glucagon-like peptide-1 receptor agonists, DPP-4 inhibitors: Dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors: Sodium-glucose 
Cotransporter-2 inhibitors, NR: not reported. 
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      In the adjusted multivariable logistic regression, female gender, FBG, retinopathy, use of 
insulin, sulfonylureas, and sodium-glucose co-transporter-2 (SGLT2) inhibitors were statistically 
significant associated with decline in the potential overtreatment. Conversely, the use of 
insulin, and sulfonylureas were significantly associated with greater odds of potential 
undertreatment, and diabetes duration was significantly associated with lower odds of 
potential undertreatment (Table 3). 
Table 3 Variables Associated with Potential Overtreatment/Undertreatment                
 
Variables 
Potential overtreatment  Potential undertreatment  
Odd Ratio (OR) 95% confidence interval (CI) Odd Ratio (OR) 95% confidence interval (CI) 
Polypharmacy  1.273  0.645 to 2.512 0.718 0.257 to 2.005 
Age group (75-84 years) vs age group (65-74 years) 
Age group (≥ 85 years) vs age group (65-74 years) 
1.008 
2.946 
0.487 to 2.084 
0.491 to 17.663 
0.380 
1.045 
0.128 to 1.133 
0.094 to 11.673 
Gender Female vs Male  0.410 0.213 to 0.789 2.690 0.989 to 7.315 
Diabetes Duration 0.988 0.956 to 1.021 0.935 0.887 to 0.986 
Obesity  0.852 0.426 to 1.705 2.017 0.762 to 5.341 
Estimated  GFR 0.997 0.990 to 1.004 1.007 0.997 to 1.018 
Macrovascular complications  
Cardiovascular disease 





0.357 to 3.574 





0.032 to 3.005 
0.124 to 17.497 











0.075 to 0.937 
0.443 to 8.622 
0.090 to 2.590 







0.014 to 1.459 
0.208 to 25.760 
0.005 to 1.086 
Glucose lowering medicines  
Insulin use  
Metformin  
Sulfonylureas  
DPP-4 inhibitors  
Metformin + DPP-4 inhibitors 









0.063 to 0.298 
0.381 to 1.444 
0.165 to 0.724 
0.500 to 3.178 
0.553 to 2.310 









1.602 to 14.855 
0.158 to 1.261 
1.056 to 9.548 
0.202 to 3.430 
0.200 to 1.760 
0.122 to 1.422 
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Metformin + SGLT2 inhibitors  
GLP-1 agonists  
1.277 
0.897 
0.297 to 5.486 
0.251 to 3.200 
0.104 
0.340 
0.005 to 2.388 
0.063 to 1.849 
Systolic blood pressure (SBP) 1.009 0.993 to 1.025 1.008 0.984 to 1.032 
Low-density lipoprotein (LDL) 0.991 0.981 to 1.001 1.005 0.993 to 1.018 
Serum sodium  3.879 0.391 to 38.461 5.745 0.350 to 94.230 
Serum potassium  0.685 0.268 to 1.751 3.415 0.983 to 11.860 
Infections (unspecified)  0.484 0.164 to 1.425 2.084 0.528 to 8.220 
 
2.5.5 Discussion  
      In the present study, a low prevalence of use of newer medicines with low-risk of 
hypoglycemia was found among the treatment of elderly people with T2D. These results appear 
opposite to the guideline recommendations and place those individuals as high-risk of 
hypoglycemia and other adverse outcomes (7,8,11). Hypoglycemia is a common adverse effect, 
especially with sulfonylureas that have the highest rates of serious hypoglycemia. Although, 
differences in hypoglycemic rates are varied among different types of sulfonylureas (16). 
      Similarly, using claims data from more than one and a half million people with T2D from 
2006 to 2013 in the united states of America, there was a slight increase in the use of GLP-1 
receptor agonist (2-3.4% age 65-74 years; 0.4-1% age ≥75 years), a greater increase in DPP-4 
inhibitors (0.4-14.1% age 65-74 years; 0.1-10.8% age ≥75 years), and insulin (16.4-23.6% age 65-
74 years; 17.2-20.4% age ≥75 years), and a slight decline in sulfonylureas (39.4-33.9% age 65-74 
years; 37.9-32.9% age ≥75 years) as well as in other medicines including SGLT2- inhibitors (2.6-
1.8% age 64-74 years; 2-1.7% age ≥75 years). Rates of severe hypoglycemia were highest 
among the elderly people with T2D (17).  
      The study has shown that more than 60% were potentially received tight glycemic control 
and more than 12% were potentially undertreated.  Contrary to the expectations, the use of 
insulin and sulfonylureas were associated with less likelihood of potentially tight glycemic 
control and more likely to be associated with potential undertreatment (18,19). Shah et al 
addressed that less than one-half of diabetes individuals with high HbA1c levels had treatment 
intensification. Diabetes specialists were found to be more aggressive with insulin therapy than 
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      The results showed that SGLT2 inhibitors were used more in the potentially overtreated 
group, which can be associated with less hypoglycemia to those elderly people with T2D. A 
Recent meta-analysis confirms that, efficacy profile of gliflozins is unchanged by age, and the 
hazard ratio (HR) for major cardiovascular events (MACE) was (HR 0.87, 95%CI 0.81–0.94) in 
elderly T2D people taking a statin and (HR 0.88, 95%CI 0.77–1.01) for elderly T2D people not 
taking a statin (21). The study also shown that a potential non-statistically significant association 
between polypharmacy and potential overtreatment. McCracken and colleagues also found an 
association between polypharmacy and overtreatment (Relative risk (RR) 4.0, 95%CI 0.97 to 
16.41) that approached the statistical significance (p=0.054) (22). This potential association could 
serve as a clinical indicator for tighter glycemic and overall management.  
      In addition, the study found that neuropathy was less associated with those who received 
potentially tight glycemic control. The VA Cooperative Study on T2D (VA CSDM) found that, no 
effect of glycemic intensification on the prevalence of neuropathy (23). Diabetes duration was 
found less associated with potential undertreatment. A non-significant association was 
previously reported with either overtreatment or undertreatment with diabetes duration (24). 
Clinicians frequently converge their management of risk factors on gaining specific targets of 
HbA1c, and other important outcomes such as blood pressure and lipid profile. This may be 
suitable for young adults with T2D, but older adults could not achieve the same benefits, 
especially when it takes a long time to provide its influence on outcomes and could result in the 
prompt potential for harm. 
      On the other hand, the opposing concept that clashes when clinicians consider management 
for T2D, which is the undertreatment of healthy older adults can result in clinical inertia. Many 
older adults with T2D can experience years of blood glucose levels above recommended targets 
and, consequently, higher microvascular and macrovascular risk.  
      Some potential limitations exist in the current study. Firstly, the study have cross-sectional 
design, which limits us to distinguish the harms from potential overtreatment/undertreatment 
and may limit the generalizability of the results. Secondly, there are several factors were not 
reported in the APDP administrative database (such as hypoglycemia episodes, hospitalization, 
death records) as these data are not intended primarily for research more than it is for 
administrative purposes. Which can be considered as one of the disadvantages of real-world 
data. Thirdly, the study may associate with a relatively small sample size, that could reduce the 
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      Our data show that there is a critical need to revise the management of older adults with 
T2D. Firstly, the clinical practice guideline developers should clearly define the concept of 
overtreatment and undertreatment of older adults. The definition should not be based solely 
on the HbA1c level but also involve the presence of comorbidities, complications, life 
expectancy, electrolyte balance, the risk for hypoglycemia or hyperglycemia, polypharmacy, 
and treatment costs. Secondly, our results suggest the need for more real-world observational 
studies due to the exclusion of older, and especially frail older adults from most traditional RCTs 
of diabetes interventions which left us with large scarcity in our knowledge of how best to 
address T2D management in the elderly group with the highest prevalence rates. 
      Lipska and colleagues suggested evidence-informed steps that could help clinicians to make 
individualized treatment. These steps included assessments of potential benefits and harms of 
intensive glycemic control. The need for treatment, duration of diabetes, cognitive impairment, 
and estimated life expectancy can be used to determine the likelihood of harms associated with 
treatment. In addition to patient preferences that should play a major role in determining the 
appropriate glycemic target as well as reducing polypharmacy (15). 
      Thirdly, even with the lack of certainty that found in some factors, acknowledging the 
presence potential overtreatment and undertreatment from routine clinical practice could help 
the clinicians to re-evaluate therapy that may cause more harm than benefit among those 
elderly people with T2D with advanced and/or multiple comorbidities, which may lower their 
risk of hypoglycemia or hyperglycemia. Fourthly, although the concept of overtreatment and 
undertreatment still not well defined, our assumed criteria are based on important key 
references, including results from a clinical trial, clinical practice guidelines recommendations, 
and critical review on the management of older adults with T2D. Finally, the use of an 
administrative database has several key advantages for measuring benefit-risk in real-world 
clinical practice; it can be implemented speedily and less costly compared than experimental 
studies providing health outcomes on a large special population such as the elderly vulnerable 
individuals that usually are not included so frequently in clinical trials (25). 
2.5.6 Conclusion 
      Our key findings show that potential overtreatment and undertreatment have a higher 
prevalence among elderly T2D people that mostly in severe condition and currently under the 
care of a very specialized unit for diabetes care. Therefore, most of these patients at higher risk 
for hypoglycemia and hyperglycemia that can result in poor health outcomes.  Insofar, the need 
for ensuring better access to diabetes care, linking glycemic targets to patients’ goals and 
preferences, minimizing short-term and long-term complications, reducing polypharmacy, and 
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improving quality of life still are aims of the utmost importance in the management of diabetes 
patients. In addition, more real-world studies in the safety and effectiveness of current 
therapies are required to move from reliance on surrogate markers toward mortality outcomes 
identifying medicines that achieve the aims of diabetes care. 
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       The knowledge gap between the randomized controlled trials (RCTs) and the clinical 
practice guidelines regarding the definition and the impact of polypharmacy and overtreatment 
on patients' health-related outcomes can impose safety challenges in medication practices. In 
recent decades, the risks are increasing due to higher polypharmacy, drug-drug interactions, 
inadequate prescribing, leading causes for safety severe and moderate outcomes.  
      In Chapter 2.2, a systematic review and meta-analysis was conducted to investigate the 
impact of polypharmacy on different health outcomes using observational studies from routine 
clinical practice in older adults with T2D. Previous reviews by Fraval et al (1), Mathur et al (2), 
Lipska et al (3), and Dardano et al (4) were not systematic reviews and did not focus specifically 
on the concept of polypharmacy and concluded only that the presence of polypharmacy could 
be associated with a greater risk of hypoglycemia.  
      Systematic reviews and meta-analysis aim to identify, evaluate, and summarize the findings 
of all relevant individual studies over a health-related issue, thus being considered the best 
source of evidence-making, and more accessible to decision-makers (5). A systematic review and 
meta-analysis of observational studies is used when RCTs evidence is considered inexistent; 
RCTs may be considered infeasible or unethical, not reporting long-term or less common 
serious outcomes (particularly harms), or not reflecting use in real-world settings in terms of 
populations included, especially the elderly population (6).  
      The findings of the current study have shown that there is a recent investigation regarding 
polypharmacy in older adults with T2D, as they reflect data published between 2012 and 2018. 
Within the same time frame, clinical practice guidelines started mentioning polypharmacy as 
one of the major geriatric syndromes, as stated in the Standards of Medical Care in Diabetes 
2012 (7). Accordingly, it can be considered a contributing factor to medicine-related adverse 
events and hypoglycemia, as mentioned in the International Diabetes Federation (IDF) guideline 
for older adults with T2D (8). 
      The findings have shown that the prevalence of polypharmacy reached more than 90% in 
older adults with T2D, defining the concept in numerical value mostly as using five or more 
medicines. Similarly, a global systematic review by Jokanovic et al of 44 studies assessing 
medication use in older adults aged ≥ 65 years in long-term care facilities found a 38.1–91.2% 
prevalence of polypharmacy where it was defined as ≥ 5 medications (9). In Europe, a cross-
sectional analysis by Midãoa et al found that the prevalence of polypharmacy using the same 
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      The word polypharmacy is derived from the ancient Greek “polús” meaning “many”, and 
“pharmakeía” meaning “the use of drugs”(11). Despite the increasing prevalence of 
polypharmacy, the term continues to lack of clear universal consensus clinical definition, being 
mostly described in practice as the number of medicines exceeding a simple numeric threshold. 
The King’s Fund report and the Scottish government’s polypharmacy model of care group 
advocated that the definition of polypharmacy can be based on the appropriateness of 
medicines used, being classified as either appropriate or problematic (12,13). The World Health 
Organization (WHO), on the other hand, advanced that the term ‘polypharmacy’ naturally 
implies whether it is appropriate to prescribe several medications or not, although it is often 
assumed to be the same as being inappropriate (14). 
      The use of a numerical definition for polypharmacy might be more convenient than the 
qualitative term, as it is more straightforward to implement in clinical database systems and 
readily applicable to epidemiological studies. In addition, some researchers suggest that the use 
of five or more medicines as a definition of polypharmacy can be used to estimate the 
medication-related adverse effects for frailty, disability, mortality, and falls in the older 
population intending to reduce medicines-related harm (15). 
      To the best of our knowledge this, systematic review and meta-analysis is the first to 
address the association between polypharmacy and mortality, myocardial infarction (MI), 
stroke, and hospitalization in elderly people with T2D. The result of the random effect model in 
meta-analysis has shown that Polypharmacy was associated with 62% risk of all-cause 
mortality. The meta-analysis includes two cohort observational studies which have shown no 
sign of heterogeneity, with low risk of bias.  
      The systematic review and meta-analysis by Leelakanok et al addressing the association 
between polypharmacy and risk of death in general older adults supports the findings present 
in this thesis. The former study uses both discrete (having odds of 8% increase in risk of death) 
and categorical definitions of polypharmacy, where using 1-4 medicines, 5 medicines, and 6-9 
medicines were significantly associated with greater odds of death (24%, 31%, and 59%, 
respectively). Excessive polypharmacy (10 or more medicines) was also associated with greater 
odds of death (96%). Although a higher level of heterogeneity (I²= 91.5%) was found in the 
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      While mortality hazards naturally increase with advancing age, the factors associated with 
this risk in older people with T2D become more complex, and include diabetes-related tissue 
damage and complications, polypharmacy, comorbidity, mental and physical frailty. Forbes et al 
found that the mortality gap between older people with and without T2D remains persistent, 
with excess mortality being 10% greater than in the general population, especially in older 
people with longer duration of T2D (17). Polypharmacy is a significant problem in the elderly 
with T2D where people need to take multiple hypoglycemic therapies, antihypertensives, and 
lipid-lowering therapies, conveying additional mortality hazards in older age (18). The number of 
prescribed medicines is high in people with T2D, and higher for older individuals with T2D than 
for those with Type 1 diabetes (T1D) (19).  
      Simultaneously, there are several lessons learned from previous large RCTs, namely the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (20), especially from the post-
hoc analyses of the ACCORD study by Riddle et al (21). The well-known epidemiological 
relationship between glucose levels and greater risk of mortality has been confirmed in 
ACCORD with (+66% per 1% HbA1c) in the intensified strategy arm, to weak (+14% per 1% 
HbA1c) in the standard strategy arm. The inappropriate intensification led to polypharmacy: 
42% of participants in the intensive therapy group were receiving 3 or more classes of oral 
agents, either alone (17%) or in combination with insulin (25%); in the standard group, such 
combinations were used in 19% of the participants (21). This use of multiple combinations of 
glucose-lowering medications in ways that are not used in standard care could have played a 
role in increasing mortality.  
      The systematic review and meta-analysis have shown that older adults with T2D on 
polypharmacy stand at the odds of 96% of having risk of MI. A retrospective cohort study by 
Zullo et al of 4,787 nursing home residents aged ≥ 65 years between 2007-2010 examined the 
effect of using more guideline-recommended medicines after MI in the frailest and oldest 
segment of the U.S. population. It found that prescribing 3 or 4 secondary prevention medicines 
to predominantly frail, older adults was associated with a 26% relative decrease in mortality 
compared with individuals who received 1 medication after acute MI. Although, the use of 
polypharmacy for secondary prevention was associated with a 30% relative increase in 
functional decline after excluding antiplatelet medicines from the exposure (22). It should be 
noted, however, that guidelines’ recommendations for secondary prevention of cardiovascular 
diseases are conflicting. Therefore, these medications should be interrupted with caution, 




Page | 202  
 
      The systematic review and meta-analysis found that older adults with T2D on polypharmacy 
might be at a 33% higher risk of having a stroke. The question of whether a similar trend may 
be representative of the relationship between observed increases in older adults with T2D and 
risk of stroke deserves further investigation. It is worth advancing that a systematic review by 
Gallagher et al could not find an association between polypharmacy and risk of stroke in elderly 
people with atrial fibrillation (AF)(23). According to the American Diabetes Association (ADA) 
guideline, however, older individuals with T2D have higher rates of stroke than those without 
diabetes (24), although the guideline did not declare any risk factors that could be contributing 
to stroke in elderly people with T2D, or any specific recommendations to avoid (24). Moreover, 
an analysis of a 1,424,378, nationally representative sample of people in Scotland, showed that 
multimorbidity (18% have diabetes) and polypharmacy were more common in elderly people 
with a diagnosis of stroke, but no association was examined between polypharmacy and risk of 
stroke (25).  
      Alternatively, a very recent retrospective analysis by Mentias et al was conducted between 
2015 and 2017 to evaluate patients with newly diagnosis of AF who initiated an oral 
anticoagulant (i.e. apixaban 5 mg twice daily, rivaroxaban 20 mg once daily, or warfarin) within 
90 days of diagnosis, in which polypharmacy was categorized from low (≤3), to moderate (4-8), 
or high (≥9); it subsequently found that among individuals with high polypharmacy there may 
be a 2.3 times higher stroke risk with apixaban compared with warfarin, and 1.38 times stroke 
risk with rivaroxaban. However, differences were of borderline significance (26).  
      The systematic review and meta-analysis found that there is 72% greater odds of 
hospitalization in older adults with T2D on polypharmacy. Older adults are more likely to 
require hospitalization than younger adults, and those with diabetes are at very high risk of 
requiring hospitalization. The clinical practice guidelines provide a framework to clinicians for 
the management of older adults with T2D (24), yet these guidelines provide evidence-based 
orientation for inpatient treatment of adults who are not critically ill, not being based  on either 
age or comorbidities (24,27).  
      Due to the lack of evidence on the subject, a recent cohort study by Anderson et al was 
conducted with 16,178 older adults with diabetes hospitalized in the veterans’ health 
administration national health system and, found that 1 in 10 patients were discharged with 
intensified diabetes medications resulting in polypharmacy. Nearly 50% of patients receiving 
treatment intensification had already reached outpatient blood glucose goals or had limited life 
expectancy. The median number of medications for this cohort was 9, and one-fourth of 
patients was on 12 or more medicines (28). Hospitalization is common in people with T2D: 
nearly 1 in 4 diabetes-related hospital admissions were due to hypoglycemia. While the overall 
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rate of hypoglycemia-associated admission was low, the age-specific rate was nearly 2.5 times 
higher in older adults (29), especially in those using both insulin and sulfonylurea as the most 
likely to experience a hypoglycemia-related hospitalization (30).  
     No association between polypharmacy and glycemic control in older adults with T2D was 
found in the systemic review and meta-analysis. The review by Lipska et al (3), mentioned that 
diabetes polypharmacy (not overall therapy) can be associated with diminished benefits and 
greater risks of harm. The first glucose-lowering medication which often starts at higher HbA1c 
levels, compared with the levels when the second agent starts, decreases HbA1c more than 
subsequent medications. Starting a second or third medication for glycemic control leads to 
smaller reductions in HbA1c, as opposed to starting that same medication as monotherapy (3).  
      The systematic review also could not find an association between fall or fall risk and 
polypharmacy in older adults with T2D. However, many studies in the general older population 
have found this association. A systematic review by Ming et al found that polypharmacy (using 
four or more medicines) caused 1.5–2 times higher possibility of recurrent falls in older adults 
(31). Dahlawani et al found that using ≥ 4 medicines meant the rate of falls was 18% higher in 
people with polypharmacy compared with people without, whereas when using ≥10 medicines, 
polypharmacy was associated with a 50% higher rate of falls (32). Additionally, Woollcott et al, 
showed that the use of antidepressants and benzodiazepines is prevalent in older adults with 
T2D and demonstrated a significant association with falls (33).  
      Despite not being presented as a primary outcome, the systematic review also reported that 
the presence of severe hypoglycemia led to an increase in the risk of emergency visits due to 
the interaction between sulfonylureas (glyburide and glipizide) and co-trimoxazole antibiotic 
found mainly in older adults with T2D on polypharmacy. Sulfonylureas are used in the 
management of T2D and a known adverse effect of sulfonylureas is hypoglycaemia, with a 
reported rate of 1.23 hospitalizations per 100 patients per year (34). Further, the use of long-
acting sulfonylurea glyburide is known to be associated with 90% a greater hypoglycaemic risk 
than glipizide (35). Ultimately, hypoglycaemia can result in significant morbidity, including 
deterioration in cognitive function, higher risk of dementia, strokes, and death (36), especially in 
older adults with T2D. Nevertheless, this sulfonylurea is still being widely prescribed by 
clinicians to this population. 
      Although the systematic review and meta-analysis examined the association between 
polypharmacy and critical outcomes, there are other important outcomes which either could 
not be addressed due to the lack of studies, namely kidney function or quality of life that 
usually address the association with disease not the treatment (37), or did not show an 
 
 
Page | 204  
 
association with polypharmacy, such as glycemic control. Additionally, there is not only a lack of 
studies reporting serious or severe drug-drug interactions which can be considered clinically 
significant, but also a lack of knowledge about what are the main potentially inappropriate 
medicines that can impact the management of older adults with T2D.  
      Chapter 2.3 presents a cross-sectional study conducted using data taken from older adults 
with T2D from a nationwide, pharmacy-based intensive monitoring study of glucose-lowering 
medicines in Portugal that took place between 2014-2015. The study’s main aim was to 
investigate whether the presence of polypharmacy, potentially serious clinically relevant DDIs, 
and potentially inappropriate medicines (PIMs) can be associated with the low quality of life of 
older adults with T2D.  
      The study found that older adults with T2D on polypharmacy are associated with 80% 
greater odds of having a lower quality of life than those not on polypharmacy. Laiteerapong et 
al found that geriatric syndromes were associated with lower physical health-related quality of 
life (HRQL), and only hypoglycemia was associated with lower mental HRQL. No association 
between quality of life and polypharmacy was tested (38). In the general older population, a 
study by Schenker et al evaluated associations between polypharmacy, symptom burden, and 
quality of life. It found that higher polypharmacy (use of ≥ 14 medicines) was associated with 
lower quality of life. Adjusting for symptom burden weakened the association between 
polypharmacy and quality of life without a significant interaction, suggesting that worse quality 
of life associated with polypharmacy may be related to medication-associated symptoms (39).  
      The study has shown that those on potentially inappropriate medicines (PIMs) were 
associated with 57% greater odds of having a lower quality of life than those not on PIMs. Older 
adults with T2D frequently seek more health advice and worry more about their health, as its 
management is more complex than that of the general older population; this can lead to 
multiple prescribers’ visits, from the GPs to the endocrinologists, which in turn can result in 
more prescriptions. Part of these medicines are inappropriate to use for their age and 
treatment of their current health problems which will ultimately increase the risk of harm from 
these medicines towards hospitalization and lower quality of life.   
      In the general older population, literature on the impact of PIMs on the quality of life agrees 
with our findings. In a prospective cohort study, which linked pharmacy dispensing data by 
Wallace et al, of 904 older adults aged 70 years or more between 2010-2012, found that the 
presence of PIMs was associated with adverse drug events, poorer health-related quality of life, 
and ≥ 1 accident, and emergency visit (40). Additionally, Harrison et al, also found that the 
increasing numbers of PIMs were also associated with lower EuroQol Five Dimensions 
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Questionnaire scores and Dementia Quality of Life Questionnaire-Self-Report-Utility scores (41). 
The PIMs most often used in the study (benzodiazepines and long-acting sulfonylureas) have all 
been associated with negative consequences, such as impaired cognition, increased risk fall and 
fractures, which can lead to more hospitalization or re-hospitalization and a decline in quality of 
life.  
      There might be an association between potentially serious clinically relevant drug-drug 
interactions (DDIs) and the low quality of life index score, but it does not reach the statistical 
significance level, which is obviously due to low prevalence of these interactions in the older 
adults with T2D in the study. The association may be indirect; these interactions are more 
possibly results of polypharmacy and are potentially associated with a high risk of adverse drug 
reactions and life-threatening complications leading to hospitalizations, morbidity, and reduced 
quality of life. 
      These potentially serious clinically relevant DDIs are mostly related to cardiovascular 
medicines. Such interactions can be associated with an increased risk of thrombotic events, 
hypotension or renal failure, myopathy, and risk of digoxin toxicity. No potential hypoglycemic 
risk was identified from these interactions in the study, which can be due to the original study 
focusing on specific type hypoglycemic agents, that is, the newer medicines (glucagon-like 
peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-
glucose transport protein 2 (SGLT2) inhibitors). These agents are less associated with risk of 
hypoglycemia and have a less known interaction profile than old very well-known hypoglycemic 
medicines such insulin and sulfonylureas.  
      Although the study provides that polypharmacy, DDIs and PIMs might have an impact on the 
quality of life of older adults with T2D, these data are baseline and results may differ if the 
impact of these risk factors would be measured prospectively. The sample size of this 
population is relatively small. However, even if data were collected from a nationwide study, it 
could not be considered representative of all of the older adults with T2D on national and 
international levels, as the data used only included patients using certain types of glucose-
lowering medicines. The relevant identified DDIs and PIMs are both potential, and their real-life 
impact needs further studies. In addition, the data did not include any laboratory findings, 
which limits our analysis. Furthermore, due to the nature of the study design, we are not sure 
whether the prescribed medicines for both T2D and other chronic and comorbid conditions 
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      Chapter 2.4 presents a cross-sectional study conducted with data of older adults with T2D 
who registered in 2018 through the administrative database of the Portuguese Diabetes 
Association (APDP). Administrative data sets provide a readily available source of real-world 
health care data on a large population of underrepresented patients in RCT such the elderly 
population (42). The study’s main aim is to examine whether the presence of polypharmacy and 
potentially serious clinically relevant DDIs or PIMs can have an impact on glycemic control and 
kidney function.  
      The study findings suggest that older adults with T2D on polypharmacy are associated with 
twice the odds of having HbA1c ≤ 8%. The ADA clinical practice guideline recommended that 
“older adults who are otherwise healthy with few coexisting chronic illnesses and intact 
cognitive function and functional status should have lower glycemic goals (such as HbA1c 
<7.5%), while those with multiple coexisting chronic illnesses, cognitive impairment or 
functional dependence should have less stringent glycemic goals (such as HbA1c <8–8.5%)” (24).  
      On the other hand, the European Diabetes Working Party for Older People stated that a 
range of HbA1c between 7–7.5% is suggested for older patients with T2D without major 
comorbidities, and 7.6–8.5% for frail patients (dependent, multisystem disease, home care 
residency including those with dementia), where the hypoglycemia risk may be high and the 
likelihood of benefit relatively low (43). Furthermore, the majority of adults older than 65 years, 
the harms associated with a haemoglobin HbA1c target lower than 7.5% or higher than 9% are 
likely to outweigh the benefits, based on several RCTs and observational studies (3)(44). Taken 
together, there might be an impact of polypharmacy on glycemic control, but it did not cross 
the recommended targets.  
      Conversely, the presence of polypharmacy can be associated with a harmful impact on 
glycemic control in older adults with T2D. Although it is not significant, the study found that 
polypharmacy might be associated with the likelihood of having a higher glycemic target 
(HbA1c > 9%), meaning that using multiple medicines may not be necessarily helpful in 
achieving therapeutic targets. Rational medication prescription dictates that the fewest 
medications be used to achieve the therapeutic goals as determined by clinician and patient.  
      In the UK Prospective Diabetes Study (UKPDS) Group, Turner et al concluded that the 
progressive deterioration of diabetes control was such that after 3 years, approximately 50% of 
patients could attain this goal with monotherapy, and after 9 years this declined to 
approximately 25% (45). Moreover, the meta-analysis by Bloomgarden et al showed that for 
patients with baseline HbA1c levels between 9% to 9.9%, oral agents decreased HbA1c levels by 
1%. For patients with baseline HbA1c levels between 8% to 8.9%, oral agents decreased HbA1c 
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levels by only 0.6%; and for patients with baseline HbA1c levels between 6% to 6.9%, the 
average reduction was only 0.2% (46). Timbie et al adds that a significant proportion of people 
with diabetes will fail to achieve targets despite using high doses of multiple, conventional 
treatments, which raises concerns about the polypharmacy burden needed for tight risk factor 
control (47). 
      The study also found that the presence of PIMs was associated with 2.5 times greater odds 
of having HbA1c ≤ 9%. Several potentially inappropriate medicines used by older adults with 
T2D may interfere with glycemic control. Recent reports suggest that newer antipsychotic 
medications may also contribute to clinically significant hyperglycemia through inducing 
glucose regulatory dysfunction. Hyperglycemia and diabetic ketoacidosis can result in the 
increase of HbA1c levels, with multiple reports for clozapine and olanzapine, and more limited 
reports of significant hyperglycemia for quetiapine and risperidone (48–51). Fluoroquinolones are 
the only class of antibiotics consistently associated with the development of hyperglycemia (52). 
Other medicines that can cause hyperglycemia include thiazide diuretics, statins, and 
corticosteroids (53).  
      Older adults with T2D in the study who associated with at least one PIM are at 5.5-fold 
greater odds of having severe kidney function. Diabetic kidney disease is the leading cause of 
chronic kidney disease resulting in end-stage renal disease and premature death in older adults 
with diabetes (54). Elderly people with severe kidney function, especially those on hemodialysis, 
were prescribed PIMs more often than previously reported for the general elderly population 
(55).  
      The most identified kidney-based PIMs in the study which might be associated with risk 
severe kidney disease is the use of non-steroidal anti-inflammatory drugs (NSAIDs) for those 
with a creatinine clearance below 30mL/min/1.73m². NSAIDs are the most widely used drugs 
among the elderly people, the benefit-risk balance of individual NSAIDs is chiefly driven by their 
gastrointestinal, cardiovascular, and kidney safety profile. The clinical practice guidelines (56) for 
the management of older adults with T2D has for many years recommended the use of aspirin 
for primary and secondary prevention of cardiovascular diseases, as the death of diabetic 
patients over the age of 65 years is 68% attributable to coronary heart disease (CHD) and 16% 
to strokes (57). However, the side effects and potential toxicities of long-term NSAID use have 
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      NSAIDs have been identified as nephrotoxic agents with both acute and chronic effects on 
kidney function. While the short-term biological effects of sodium retention, edema, and acute 
renal failure with NSAIDs are well documented, limited scientific data are reporting the safety 
of these drugs on kidney function when NSAIDs are taken chronically or when they are taken by 
patients with pre-existing kidney disease. Existing data regarding long-term NSAID exposure is 
inconsistent. It was shown that patients with chronic kidney disease who took non‐selective 
NSAIDs compared with those who did not were 56% more likely to develop end‐stage kidney 
disease and require dialysis. Further, it has been documented that high dose NSAID use in the 
elderly with chronic kidney disease was a significant risk factor that accelerated chronic kidney 
disease progression (58,59).  
      Additionally, there might be other factors playing a role along with NSAIDs in the 
acceleration of kidney failure. Older people with T2D who have hypertension and/or are taking 
anti‐hypertensive drugs, such as angiotensin-converting enzyme (ACE) inhibitors/ angiotensin II 
receptor blockers (ARBs), were in a high‐risk chronic kidney disease group, and had more 
chronic kidney disease‐related risk factors. Besides, it has been noted that poor glycaemic 
control in older people with T2D is one of the key risk factors leading to the development and 
progression of chronic kidney disease (60,61).  
      Older adults with T2D and chronic kidney disease might suffer from drug-disease 
interactions more than drug-drug interactions. Dumbreck et al found that drug-disease 
interactions were common in chronic kidney disease, which occurred with T2D. These authors 
concluded that guideline developers should always explicitly decide whether chronic kidney 
disease is common enough in the real-world population, with the disease under consideration, 
to require comment or modification of recommendations. Prevalence of comorbidity with 
chronic kidney disease was about 4% in patients with depression, 14% in patients with T2D, and 
23% in patients with heart failure. Ultimately, it might be better that guideline developers 
consider chronic kidney disease with heart failure and possibly T2D (62). 
     Despite the associations found between polypharmacy and its potential adverse reaction 
with glycemic control and kidney function, the data of older adults with T2D used in the study 
were the last updated data, and there is variability in the date of the last update among the 
included patients. For example, the HbA1c of a patient might be lastly updated 6 months before 
data collection, and new HbA1c might show different results. The same applies for the 
medicines, as many of these patients have their medicines list updated three or four months 
before data collection, which might also show different findings if a change occurs or the 
patient stops taking the prescribed medicines. The data used in the study was only according to 
those registered in 2018, and the results might be different if other patients from previous 
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years were included. Data regarding the chronic conditions and diabetes-related complications 
as well as laboratory data are incomplete for all patients, which also limits our analysis. Besides, 
the medicines recorded are only those related to T2D and to chronic and acute associated 
conditions; no OTC or herbal and/or supplements were recorded, nor was any dosage form, 
concentration, or frequency of administration, underestimating the prevalence of the potential 
serious clinically relevant DDI in the study. Although the data are collected from the most 
specialized diabetes institution in Portugal, it is not possible to generalize the results to the 
older adults with T2D on the national level, as these data are only collected from a single 
diabetes institution. Additionally, the results from the analysis of DDIs and PIMs are merely 
potential, and we do not know if it can have the same impact in real-life.  
      While the descriptive characteristics between the older adults with T2D in the previous two 
studies in the thesis did not show a major difference, the prevalence of polypharmacy (43.6% 
vs.72%), potentially serious clinically relevant DDIs (8.7% vs.10.5%), and PIMs (24.2% vs.36.1%) 
is lower in the study conducted within the APDP database, despite using the same study design, 
polypharmacy definition and the same explicit criteria for identifying PIMs and Micromedex 
drug-interaction platforms for DDIs.   
      The data of older adults with T2D in the previous study (Chapter 2.3) derived from a 
nationwide, pharmacy-based intensive monitoring (MOMI) study in Portugal of a T2D 
population whose only incident or prevalence of specific glucose-lowering medicines was with 
the GLP-1 receptor agonists, DPP-4 inhibitors and SGLT2 inhibitors. The data of the sample of 
this study (Chapter 2.4) derived from the most specialized diabetes institution in Portugal 
(APDP), which makes this study more representative for the purposes of this study, as it is 
capturing a population of T2D with different use of glucose-lowering medicines. In addition to 
medicines for T2D and other chronic conditions, the original MOMI database also captured 
over-the-counter medicines (OTC), supplements, and herbal medicines. Oppositely, the APDP 
database includes only T2D and other chronic and acute conditions medications. This is taken as 
having impacted the increase in the prevalence of polypharmacy, DDIs, and PIMs.  
      Chapter 2.5 analyses the concepts of overtreatment and undertreatment by conducting a 
cross-sectional study using the data of the older adults with T2D from the administrative 
database of APDP. Participants were categorized according to their HbA1c level from potentially 
overtreated (HbA1c≤7.5%), to appropriately on target (HbA1c≥7.5–≤9%) or potentially 
undertreated (HbA1c>9%).  The reason behind choosing these glycemic targets is that several 
RCTs (65–67), observational studies (68,69), and the recommendation from clinical practice 
guidelines suggest that the harms associated with an HbA1c target lower than 7.5% or higher 
than 9% are likely to outweigh the benefits. With the current availability of hypoglycemic 
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agents with low risk of hypoglycemia, one could argue that the proposed glycemic target might 
be lower than that which has been suggested. If medicines with low treatment burden and 
hypoglycemia risk are the only required, a lower HbA1c target may be appropriate for older 
adults with T2D, considering life expectancy, other chronic conditions and/or diabetes related 
complications (70,71).  
     The results of the study have shown that the prevalence of potential overtreatment was 
identified in more than 60% of study participants. Comparing to older adults with T2D who are 
considered potentially on target, the group of potentially overtreated participants has shown to 
be more males, less obese, who have higher prevalence of macrovascular complications, 
neuropathy, and diabetic foot, and those associated with a higher prevalence of severe chronic 
kidney disease. These results suggest that attempts to achieve an intensive glycemic target 
below 7.5% will lead to net harm in most older adults with T2D, whereas the cardiovascular and 
microvascular benefits are uncertain for the majority of older adults with T2D, and the marginal 
benefits of decreasing HbA1c lower than 7.5% seems to be small (72).  
      On the other hand, our (the APDP) study identified more than 12% of the study participants 
as potentially undertreated, shown to be more females, obese, with a higher prevalence of 
dyslipidemia, peripheral vascular disease, infections, and diabetic foot, and using more insulin 
compared to potentially on-target participants. There is uncertainty behind the proper glycemic 
targets for this group of older adults with T2D. Nevertheless, there is a general consensus that 
HbA1c values higher than 9% should be avoided because they can lead to immediate 
symptoms, which might include polyuria, possibly occurring at blood glucose levels above the 
renal threshold (>180–200 mg/dL), which might lead to dehydration. In addition, hyperglycemia 
may cause fatigue, increased risk for infection, and/or cognitive impairment (73). 
     An important reason behind the undertreatment of older adults with T2D may be clinical 
inertia, which can be defined as the failure to start or intensify glycemic therapy when it is 
clinically indicated and inhibits the achievement of a proper glycemic target. Delayed treatment 
of older adults with T2D does not appear to be specific of primary care comparatively to 
specialty care despite some differences found (74). Given the complexity of T2D management in 
older adults, it is impossible to determine the extent to which apparent clinical inertia may 
reflect routine clinical practice in a reasonable or at least understandable manner. One possible 
explanation for this is that the clinical inertia is more related to clinician behavior, especially 
when dealing with those elderly patients who are asymptomatic despite elevated HbA1c level, 
and because of the fear of adverse consequences of treatment intensification such as 
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      Additionally, current practice guidelines would likely favor initiating or intensifying 
pharmacotherapy. A variety of factors could nevertheless delay this decision, including the 
clinician’s knowledge of attitudes towards evidence-based guidelines, clinical judgment and 
experience, ability to implement an appropriate decision in a given clinical and organizational 
context, and awareness of the patients’ behaviors, and preferences. Another important issue is 
the absence of a universally accepted measure to quantify clinical inertia. Moreover, the clinical 
practice guidelines recommend a step-wise intensification following the loss of glycemic 
control. It remains unclear how this should be implemented in older adults, who are 
heterogeneous and may suffer from multiple comorbidities, complications, and/or chronic 
conditions, nor is it clear whether the intensification can carry more benefits than harm in 
those patients.  
      The study has found that the odds of potential overtreatment decreased by 59% in the case 
of females, by 73.5% in those with retinopathy, by 86.3% in those on insulin, by 65.4% of those 
on sulfonylureas, and by 66.8% on SGLT2 inhibitors. The increase in the odds of potential 
undertreatment was more than 4.8 times higher in insulin users and more than 3.1 times higher 
in sulfonylureas users. These results are different from those found in the literature, where 
insulin and sulfonylureas are main risk factors of overtreatment in older adults with T2D (75,76). 
There are several factors which might explain this difference: firstly, the glycemic target 
(HbA1c) which is used in this study is different from that reported in the literature (<7.5% vs. 
<7%); secondly, it is also possible to say that there is an influence of the healthcare setting. 
These elderly patients with T2D are being treated in diabetes specialty care institutions, where 
specialists may have more experience and comfort with glucose-lowering medications and 
hence may be more aggressive with their use when glycemic control is inadequate. Finally, 
specialists may give closer focus to diabetes issues during patient visits and offer improved 
access to nonphysician providers and patient education resources. Being continuously 
monitored by the same physician in a diabetes specialty care institution seems to ensure a 
better quality of care in terms of process measures. Specialists were less prone to clinical inertia 
than primary care practitioners, perhaps because specialists can focus closely on diabetes and 
on its related conditions during consultations (74).  
      The care of undertreated older adults with T2D by non-specialist teams might be suboptimal 
and random (8). The reasons for this are unclear but incorporate lack of knowledge and fear of 
inducing hypoglycemia. Additionally, these undertreated older adults with T2D might not 
receive proper treatment regimens with other agents such as metformin, DDP-4 inhibitors, 
SGLT2 inhibitors, and GLP-1 receptor agonists that leave them exposed to long periods of 
hyperglycemia, leading to inadequate glycemic control, and contributing to diabetes 
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complications. Insulin therapy offers the most potent antihyperglycemic effect of all diabetes 
agents and has a unique ability to induce diabetes remission when used to normalize glycemia.   
      As the data used in this study (chapter 2.5) is analogous to the previous one (Chapter 2.4), 
similar constraints were observed. Additionally, the administrative database in the APDP does 
not report other important outcomes such as hypoglycemic episodes, hospitalization, 
emergency rooms’ visits, as well as frailty risk, and death records for the older adults with T2D, 
which limits further analysis for potentially overtreated and undertreated older adults with 
T2D. Finally, as there is no internationally agreed definition for either overtreatment or 
undertreatment. 
Conclusions and Implication for Practice 
      Through the use of different healthcare databases from routine clinical practice, this thesis 
contributed to the examination of the impact of polypharmacy and overtreatment on older 
adults with T2D where the knowledge gap of these two important issues in the population is 
narrow in both RCTs and clinical practice guidelines. Several studies were conducted, and the 
most relevant findings as well as its implications to practice are as follows: 
▪ The global overview of polypharmacy in older adults with T2D has shown that 
polypharmacy can be associated with 62%, 96%, 33%, and 72% odds of  mortality, MI, 
stroke, and hospitalization respectively, compared to those not on polypharmacy. These 
data show the clinical importance for distinguishing the potential harms of multiple 
medicines and asserts the need for further investigations to confirm whether 
polypharmacy can be considered as a marker for prescribing appropriateness.  
▪ The analysis of pharmacy-based data revealed that polypharmacy, potentially serious 
clinically relevant drug-drug interactions, and potentially inappropriate medicines have 
shown to be associated with more 80%, 34% and 57% odds of lower health-related 
quality of life in older adults with T2D, respectively. In spite of providing  evidence that 
supports the need for greater adherence to recommendations for appropriate 
medication use, these findings further advance  that efforts to maximize the quality of 
life of older adults with T2D should be considered as high a priority as preventing 
diabetes complications, namely through managing and screening for geriatric 
syndromes and avoiding hypoglycemia. 
▪ The analysis of APDP administrative-based data has shown that polypharmacy and 
potentially inappropriate medicines can be associated with 2 to 2.5-fold greater odds of 
alteration of glycemic control, and that potentially inappropriate medicines can also be 
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associated with 5.5-fold greater odds of severe kidney function in older adults with T2D. 
These patients are vulnerable and frail with CKD. Management of these patients is often 
complex and lacking specific evidence-based treatment guidelines. Reducing these risk 
factors might be associated with good glycemic control and reducing the progression of 
kidney function. However, further larger RCTs involving older adults with T2D are 
needed to better understand the impact on glycemic control and kidney function in the 
future. 
▪ In a specialized diabetes care institution, that is the APDP, more than 60% of older 
adults with T2D have found to be potentially overtreated, whereas 12% were found 
potentially undertreated. The former patients showed to be more males, pre-obese, 
have higher macrovascular, neuropathy, and diabetic foot, and associated with a higher 
prevalence of severe chronic kidney disease; the latter were more females, obese, have 
a higher prevalence of dyslipidemia, peripheral vascular disease, infections, and diabetic 
foot, and use more insulin compared to those appropriately on target. Personalized 
treatment in older people with T2D is still not common practice. A substantial number 
of older people are overtreated, and a lesser number is undertreated with probable 
harmful consequences. Major clinical guidelines for the treatment of older adults with 
T2D still recommend therapy with a primary objective of reaching set glycemic targets. 
Although guidelines promote individualized glycemic targets for patients based on their 
comorbidities, hypoglycemia, and capacity to carry out the treatment plan, a more 
profound shift is needed. Treatment should be selected to target specific complications 
and inherent risks and not solely HbA1c. Patients at high risk of cardiovascular disease 
may benefit from treatment with drugs that lower this risk. Setting an individualized 
glycemic target without accounting for the types and number of drugs needed to 
achieve it is no longer congruent. If these results have taught us anything, it is that there 
is no single recipe for glycemic management in older adults with T2D. To promote 
personalized care and overcome overuse, it is essential to incorporate the best available 
evidence (balancing harms and benefits) with the clinician’s judgment (individualizing 
the evidence based on a patient’s risk profile, prognosis, and context), as well as the 
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Future Perspectives  
      To optimize polypharmacy and/or overtreatment and undertreatment, a clear 
internationally agreed definition is required. This will give researchers, policymakers, and 
guideline developers a better understanding and a more concrete vision towards proposing a 
management plan. Clinical practice guidelines should also undergo a paradigm shift from the 
focus on single disease management toward multimorbidity and a patient’s individualized 
treatment, with more attention to the data generated from real-world clinical practice. A 
comprehensive geriatric assessment tailoring therapy to the patient's individual needs should 
be placed in the frame of everyday practice since it takes into consideration the high 
heterogeneity in elderly T2D population. Several drug-drug interaction platforms are now 
available. However, most of these platforms produce theoretical interactions rather than 
practical, which are sometimes opposite to guidelines recommendations and may therefore be 
associated with low quality of evidence with the frequent omission of a method of 
administration or dosage form.  
      It is desirable to use more than one platform and compare the results. The quality of 
evidence for these interactions should be assessed carefully. More studies from routine clinical 
practice are needed; relying only on spontaneous reporting to identify patterns of drug-drug 
interactions is not enough. Active pharmacovigilance is required. The presence of explicit 
criteria like STOPP can help healthcare providers and alert them to potential inappropriate 
medicines use, helping to improve prescribing. More studies are needed to conduct a benefit-
risk assessment regarding deprescribing medications in routine clinical practice, with special 
care required in prescribing and monitoring pharmacologic therapies in older adults with T2D. 
      Overtreatment and undertreatment in elderly people with T2D seems a common clinical 
practice despite the recommendations toward deintensification. However, limited studies 
suggest that the benefits of deintensification outweigh the harms. Data from recent RCTs 
showed that cardiovascular, kidney, and mortality outcomes may be improved with the use of 
specific emerging glucose-lowering medicines independently of their glycemic effects. Clinicians 
should be aware that hypoglycemic agents are mostly released after RCTs, thus a multimorbid 
elderly patient with T2D is still underrepresented. Therefore, patient-centered outcomes need 
a paradigm shift from the focus on glycemic control as the main quality indicator, towards 
providing more adequate diabetes care, linking glycemic targets to patients’ preferences, 
reducing complications and burden of polypharmacy, and improving their quality of life. 
Furthermore, avoiding the harm from polypharmacy and overtreatment/undertreatment as 
 
 
Page | 215  
 
well as maximizing the benefits requires a system that regularly monitors and updates patient 
information. The data generation process must, therefore, be established in daily clinical 
practice to produce continual improvement in care, a learning healthcare system that 
generates and applies the best evidence for the collaborative healthcare choices of each 
patient and clinician; one which drives the process of discovery as a natural outgrowth of 
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